Page last updated: 2024-08-24

aripiprazole and Dementia Praecox

aripiprazole has been researched along with Dementia Praecox in 875 studies

Research

Studies (875)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.11)	18.2507
2000's	269 (30.74)	29.6817
2010's	461 (52.69)	24.3611
2020's	144 (16.46)	2.80

Authors

Authors	Studies
Antonio, CB; Barreiro, EJ; Fraga, CA; Grazziottin, LR; Menegatti, R; Neves, G; Noël, F; Rates, SM; Vieira, RO	1
Akunne, HC; Choi, C; Favor, DA; Fay, LK; Fitzgerald, L; Johnson, DS; Nicholls, K; Repine, JT; Serpa, KA; Snyder, BJ; Whetzel, SZ; White, AD; Zhang, L	1
Andreassi, M; Brindisi, M; Brogi, S; Butini, S; Cagnotto, A; Campiani, G; Casagni, A; Franceschini, S; Gemma, S; Gorelli, B; Mikkelsen, JD; Novellino, E; Ros, S; Salmona, M; Sandager-Nielsen, K; Saponara, S; Scheel-Kruger, J; Trotta, F; Weikop, P	1
Alzheimer, C; Banerjee, A; Bouvier, M; Friedland, K; Gmeiner, P; Hübner, H; Huth, T; Möller, D; Müller, CP; Plouffe, B; Skultety, M; Uzuneser, TC	1
Cui, C; He, Y; Jiang, H; Jiang, X; Li, X; Li, Z; Liu, X; Shen, J; Tan, X; Wang, Z; Wu, C; Xie, Y; Xiong, Z; Yang, F; Zhao, Q; Zheng, M; Zhong, F	1
Bojarski, AJ; Dehaen, W; Janousek, J; Juza, R; Karasova, JZ; Kobrlova, T; Korabecny, J; Kubacka, M; Mezeiova, E; Mogilski, S; Musilek, K; Pejchal, J; Petrasek, T; Prchal, L; Randakova, A; Satala, G; Soukup, O; Stark, H; Stefkova-Mazochova, K; Svozil, D; Vlcek, P; Vojtechova, I	1
Boulanger, L; Gleeson, CD; Hedgeman, E; Jariwala-Parikh, K; Lauriello, J; O'Sullivan, AK; Shah, A; Weiden, PJ	1
Bøg, M; de Jong-Laird, AC; Jørgensen, KT; Kabra, MS; Such, P	1
Claxton, A; Du, Y; Nasrallah, HA; Walling, DP; Weiden, PJ; Yagoda, S; Yao, B	1
Fujita, K; Iga, JI; Inada, K; Ishigooka, J; Iwata, N; Kanda, Y; Kikuchi, Y; Kishi, T; Kishimoto, T; Koretsune, S; Nakagome, K; Ohi, K; Ohmori, T; Sekiyama, K; Shichijo, T; Tabuse, H; Terada, H; Tsutsumi, Y	1
Hibino, H; Suzuki, H	1
Jhawar, A; Riddle, MA; Socco, S	1
Guan, N; Li, AN; Li, K; Liu, T; Sun, J; Tan, Y; Uki, M; Wang, G; Wang, L; Wu, B; Xian, M; Xiao, L; Xie, S; Xu, X; Zhang, H; Zhang, K; Zhang, R; Zhang, W; Zhao, Q	1
Bieńkowski, P; Dudek, D; Heitzman, J; Janas-Kozik, M; Rymaszewska, J; Samochowiec, J; Siwek, M; Szulc, A; Wichniak, A; Wolańczyk, T	1
Dragovic, M; Hacking, D; Hulme, D; Parmar, A; Shymko, G; Terina, G; Waters, F	1
Barbui, C; Bartoli, F; Bertolini, F; Callovini, T; Carrà, G; Cavaleri, D; Crocamo, C; D'Agostino, A; Martinotti, G; Ostuzzi, G; Riboldi, I	1
Kam, O; Koola, MM; Lee, G; Reinfeld, S; Russell, G; Weiss, M	1
Kaminska, K; Lech, MA; Lorenc-Koci, E; Rogoz, Z; Wasik, A	1
Baymeeva, NV; Kaleda, VG; Miroshnichenko, II; Platova, AI; Tikhonov, DV	1
Appignanesi, C; Marpepa, B; Orsolini, L; Salvi, V; Volpe, U	1
Kamińska, K; Lech, MA; Lorenc-Koci, E; Rogóż, Z	1
Brissos, S; Taylor, D	1
Augustin, M; Eisner, P; Finner-Prével, M; Gaebler, AJ; Gründer, G; Hendricks, F; Hovancakova, J; Kaleta, P; Keskin, F; Lammertz, S; Lenzen, L; Mathiak, K; Paulzen, M; Röcher, E; Schaffrath, S; Schneider, F; Schwemmer, L; Stöhr, F; Stormanns, E; Winkler, L	1
Gorczyca, P; Kunert, Ł; Rykaczewska-Czerwińska, M; Sobiś, J; Świętochowska, E	1
Chang, CK; Chen, CH; Chen, PY; Chiu, CC; Fang, SC; Huang, MC; Hwang, LL; Lu, ML; Mondelli, V	1
Cho, J; Jeon, SM; Kwon, JW; Lee, DY	1
Bellagamba, S; Orsolini, L; Salvi, V; Volpe, U	1
García Dorado, M; Gutiérrez-Rojas, L; López Rengel, PM; Sánchez-Alonso, S	1
Broberg, BV; Ebdrup, BH; Glenthøj, BY; Lykkesfeldt, J; Myken, AN; Nielsen, MØ; Skjerbæk, MW; Sørensen, ME	1
Chen, CH; Chen, PY; Chiu, CC; Hsieh, TH; Huang, CY; Huang, MC; Liu, YR; Lu, ML	1
Alamome, I; Azorin, JM; Drapier, D; El Hage, W; Fakra, É; Jardri, R; Llorca, PM; Mouchabac, S; Nuss, P; Rabbani, M; Simon, N; Vacheron, MN	1
Byeon, SJ; Chung, SJ; Oh, S	1
Johannesen, CAB; Johnsen, E; Kroken, RA; Larsen, TK; Løberg, EM; Mørkved, N; Rettenbacher, MA; Thimm, JC; Winje, D	1
Arango, C; Leucht, S; Lopez-Morinigo, JD	1
Iwata, N; Kishi, T; Sakuma, K	1
Alamo, C; Almenta Gallego, D; Arques-Egea, S; Fraguas, D; Gómez-Revuelta, M; Hernández Huerta, D; Núñez Arias, D; Oda Plasencia-García, B; Parro Torres, C; Romero-Guillena, SL; Ros Cucurul, E; Sánchez-Lafuente, CG	1
Clerzius, G; Janetzky, W; Oluboka, O; Roy, MA; Schöttle, D; Therrien, F; Wiedemann, K	2
Nawwar, DA; Sayed, RH; Zaki, HF	1
Fujii, Y; Misawa, F; Takeuchi, H	1
Biała, G; Mikulska, J; Orzelska-Górka, J; Wiszniewska, A	1
Anam, A; Gekhman, D; Lynch, S; Mosharraf, N; Soukas, C	1
Cao, L; Liu, J; Wu, J	1
Clement, HW; Conca, A; Eichentopf, L; Faltraco, F; Florio, V; Gründer, G; Grüner, J; Hart, XM; Havemann-Reinecke, U; Hiemke, C; Lense, XM; Molden, E; Paulzen, M; Riemer, TG; Schoretsanitis, G	1
Fitzgerald, HM; Han, X; Ng, M; Patel, R; Rentería, M; Rush, AJ; Sarkar, J; Surendran, S; Thadani, S; Touya, M; Waters, HC; Wee, SN	1
Chen, Q; Deng, W; Du, X; Hao, Q; Hu, X; Li, C; Li, K; Li, L; Li, T; Li, X; Lu, T; Lv, L; Ma, X; Ren, H; Tan, L; Tan, Q; Tang, Y; Wang, C; Wang, L; Wang, Q; Wang, Y; Wu, Y; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, G; Zhang, H; Zhang, Y; Zhao, L	1
Boucher, M; Clerzius, G; Margolese, HC; Therrien, F	1
Guzek, K; Najbar, I; Rożnowska, A; Sadakierska-Chudy, A; Stelmach, A	1
Dorozhenok, IY	1
Huang, Y; Lin, D; Liu, L; Wang, W; Wen, C; Xu, Z; Yuan, Q; Zhang, X	1
Acacio, MC; Dobson, L; Grace, T; Shymko, G; Tadier, S; Waters, F	1
Abdelfattah, AM; Abuelezz, SA; Hendawy, N; Khalil, AMM; Nawishy, SAEK; Negm, EA	1
Akazawa, M; Inada, K; Okada, Y	1
Carvalho, AF; Hsu, CW; Hsu, TW; Liang, CS; Thompson, T; Tsai, TC; Tseng, PT; Yu, CL	1
Asami, T; Fujibayashi, M; Fukushima, T; Furuno, T; Hattori, S; Hishimoto, A; Ishii, C; Ishii, N; Kishida, I; Miyauchi, M; Moritani, T; Noguchi, N; Saeki, T; Saigusa, Y; Shiraishi, Y; Suda, A; Tsujita, N	1
Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y	1
Janetzky, W; Schöttle, D; Therrien, F; Wiedemann, K	1
Harlin, M; Jan, M; Jin, N; Larsen, F; Madera-McDonough, J; Such, P; Watkin, S; Yildirim, M	1
Chen, Z; Duan, M; Fang, M; Gao, J; Li, Q; Li, S; Liao, X; Liu, J; Si, T; Su, Y; Wang, C; Wu, B; Xu, J; Yan, S; Yang, Y; Yao, P; Yu, H; Zhang, C	1
Dudek, D; Heitzman, J; Janas-Kozik, M; Remberk, B; Samochowiec, J; Słopień, A; Wichniak, A	1
Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T	1
Abuelazm, H; Crump, CJ; El-Mallakh, RS; Good, ME	1
Feng, X; Kang, Z; Liao, Y; Lu, T; Lu, Z; Sun, Y; Wang, L; Yan, H; Yue, W; Zhang, D; Zhang, Y	1
Cheng, C; Cui, Y; Gong, Y; Gu, W; Guo, T; Huang, G; Li, Q; Meng, B; Qin, W; Sun, J; Wang, M; Wang, Y; Wu, D; Yang, X; Zhao, S	1
Breen, G; Everall, I; Guo, LK; Huang, HL; Huang, Z; Kang, ZW; Li, J; Li, M; Li, WQ; Li, Y; Liao, YD; Liu, B; Lu, TL; Lu, Z; Lv, LX; Su, Y; Tan, YL; Wang, HX; Wang, LF; Xiao, X; Yan, H; Yang, YF; Yao, Y; Yu, H; Yue, WH; Zhang, D; Zhang, YY	1
Biswas, H; Grover, S; Sahoo, MK	1
Blindheim, A; Gjestad, R; Joa, I; Johnsen, E; Kroken, RA; Løberg, EM; Munk-Jørgensen, P; Reitan, SK; Rettenbacher, M; Stabell, LA	1
Iyo, M; Kanahara, N; Kimura, H; Kogure, M; Koyoshi, S; Nakata, Y; Oiwa, T; Saito, T; Sasaki, T; Yamasaki, F; Yanagisawa, Y; Yoshida, T	1
Bauknecht, P; Baumann, P; Kuzin, M; Schoretsanitis, G	1
Cañete, T; Fernández-Teruel, A; Lavín, V; Oliveras, I; Río-Álamos, C; Sampedro-Viana, D; Sánchez-González, A; Sanna, F; Tapias-Espinosa, C; Tobeña, A; Torrecilla, P	1
Harada, T; Hosokawa, T; Kishi, Y; Miyaji, C; Nomura, A; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Takeda, T; Washida, K; Yada, Y; Yamada, N; Yoshimura, Y	1
Cai, J; Chen, Y; Fang, M; Hu, J; Huang, M; Liu, F; Liu, T; Liu, Z; Long, Y; Meng, H; Song, X; Tang, Y; Wan, C; Wang, X; Wang, Z; Wu, Q; Wu, R; Wu, X; Xiao, J; Xu, X; Xu, Y; Yang, Y; Zhang, R; Zhao, J; Zheng, Y	1
Bai, M; Chen, H; Kang, L; Li, Q; Li, S; Lin, Y; Lu, C; Tang, Z; Xiong, P; Zhang, H	1
Beckham, C; Citrome, L; Harlin, M; Larsen, F; Madera-McDonough, J; Such, P; Yildirim, M; Zhang, Z	1
Brieden, A; Correll, CU; Friede, M; Jahn, H; Janetzky, W; Schöttle, D; Wiedemann, K	1
Munayco Maldonado, GM; Schwartz, TL	1
Brand, BA; Hamers, IMH; Sommer, IE; Willemse, EJM	1
Aguiar, PM; de Melo, DO; de Mendonça Lima, T; Henrique, ICB	1
Cai, S; Cheng, Z; Correll, CU; Deng, H; Han, X; Lu, Z; Wang, C; Xiang, Y; Yang, F; Yang, L; Yu, X; Yuan, Y; Zhao, J	1
Kishi, Y; Kono, T; Minao, N; Mitsui, S; Obayashi, Y; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Takeda, T; Yada, Y; Yamada, N; Yoshimura, B	1
Bulatova, RA; Ezhkova, EV; Ivanets, NN; Titkov, MS; Vinnikova, MA	1
Hibino, H; Inoue, Y; Suzuki, H; Takaya, A	6
Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S	1
Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T	1
Kopciuch, D; Kus, K; Murawiecka, P; Nowakowska, E; Paczkowska, A; Ratajczak, P; Słodzińska, I; Zaprutko, T	1
Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Juncal-Ruiz, M; Pelayo-Terán, JM; Romero-Jiménez, R; Setién Suero, E; Suárez-Pinilla, P; Vázquez-Bourgon, J	1
Shad, MU; Yeager, A	1
Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Sakuma, K	1
Barr, AM; Honer, WG; Kim, DD; Lu, C; Procyshyn, RM; Stewart, SE; White, RF	1
Aloi, M; De Fazio, P; de Filippis, R; Gaetano, R; Magliocco, F; Segura-Garcia, C; Staltari, FA	1
Antoun Reyad, A; Girgis, E; Mishriky, R	1
Economou, M; Kontoangelos, K; Lazaratou, E; Papageorgiou, CC; Yiannopoulou, KG	1
Chen, Q; Coid, J; Deng, W; Guo, W; Hu, X; Li, K; Li, L; Li, T; Li, X; Li, Y; Lu, T; Lv, L; Ma, X; Ren, H; Reynolds, GP; Tan, L; Tan, Q; Tian, Y; Wang, C; Wang, H; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L	1
Copolov, D; Hope, J; Keks, N; McLennan, H; Meadows, G; Schwartz, D	1
Barbui, C; Bartoli, F; Carrà, G; Corbo, M; Crocamo, C; D'Agostino, A; Martinotti, G; Ostinelli, EG; Ostuzzi, G; Tabacchi, T	1
Le, J; Li, Y; Wang, S; Yuan, T	1
Bidollari, I; Cash, E; Claxton, A; Du, Y; Keane, E; Kunovac, J; Walling, DP; Weiden, PJ; Yagoda, S; Yao, B	1
Hamada, T; Hata, T; Kanazawa, T; Katsumata, T; Nakajima, M; Nishihara, M; Yoneda, H	1
Inagaki, A; Iwata, N; Kojima, Y; Niidome, K; Sano, H; Yamada, S	1
Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ	1
Achtyes, ED; Correll, CU; Gibbons, RD; Kane, JM; Marcy, P; Robinson, DG; Schooler, NR	1
Dobson, L; Grace, T; Hacking, D; Jolly, N; Kapi, P; Parmar, A; Shymko, G; Waters, F	1
Lin, Z; Xuan, J	1
Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P	1
Claxton, A; Du, Y; Lauriello, J; Weiden, PJ	1
Fujita, Y; Honma, M; Iyo, M; Kanahara, N; Komatsu, N; Noda, S; Saiga, T; Sasaki, T; Simoyama, T; Suzuki, H; Tadokoro, S; Takase, M; Yamanaka, H; Yanahashi, S	1
Ayesa Arriola, R; Crespo Facorro, B; Gómez Revuelta, M; Ibáñez Alario, M; Juncal Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J	1
Boku, S; Fujiyama, H; Fukuhara, R; Kanno, T; Kawahara, K; Sugawara, H; Takebayashi, M; Tanaka, H	1
Azorin, JM; Simon, N	2
Cohen, D; Coustals, N; Ménard, ML	1
Evins, AE; Kim, SH; Na, E; Noh, S; Park, SJ; Roh, S	1
Chan, GFY; Chung, AKK; Lai, E; Lee, CK; Mak, GKL; Mak, KY; Ng, RMK; Tam, KL; Wong, DTW; Wong, JOY; Wong, MMC; Yeung, TMH	1
Boege, I; Burger, R; Egberts, K; Fekete, S; Gerlach, M; Holtkamp, K; Karwautz, A; Kulpok, C; Mehler-Wex, C; Mitterer, M; Reuter-Dang, SY; Romanos, M; Taurines, R; Wewetzer, C	1
Crnković, D; Karlović, D; Peitl, V; Silić, A	1
Preda, A; Shapiro, BB	1
Davis, JM; Leucht, S	1
Alisauskiene, R; Anda, LG; Bartz-Johannessen, C; Berle, JØ; Bjarke, J; Fathian, F; Fleischhacker, WW; Hugdahl, K; Joa, I; Johnsen, E; Kjelby, E; Kroken, RA; Larsen, TK; Løberg, EM; Reitan, SK; Rettenbacher, M; Sinkeviciute, I; Skrede, S; Stabell, L; Steen, VM; Walla, B	1
Chan, HY; Chen, WJ; Chien, YL; Hsieh, MH; Hwang, TJ; Hwu, HG; Jen, YW; Kuo, CH; Lin, YT; Liu, CC; Liu, CM	1
Inoue, Y; Kubo, K; Shimoda, K; Shinozaki, M; Sugawara, N; Tasaki, M; Yasui-Furukori, N; Yokoyama, S	1
De Berardis, D; Di Giannantonio, M; Fornaro, M; Napoletano, C; Pettorruso, M; Vellante, F; Ventriglio, A	1
Kaur, L; Sinha, VR	1
Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S	1
Baba, H; Inada, K; Kato, M; Katsuki, A; Kikuchi, T; Kikuchi, YS; Kishida, I; Sakurai, H; Suzuki, T; Uchida, H; Watanabe, K; Yasui-Furukori, N	1
Comini, FF; Miola, A; Pavan, C; Pigato, G; Salvati, B; Sambataro, F; Toffanin, T	1
Baandrup, L; Ebdrup, BH	1
Johnsen, E; Kroken, RA; Steen, VM	1
Alvarez-Garcia, R; Baca-García, E; Bello, HJ; Cegla-Schvartzman, F; Migoya-Borja, M; Ovejero, S; Palomar-Ciria, N	1
Aoki, K; Inada, K; Ishigooka, J; Iwashita, S; Kojima, Y; Niidome, K; Yamada, S	1
Hadryś, T; Rymaszewska, J	1
Culej, J; Karlović, D; Matešić, K; Orlović, I; Peitl, V; Rendulić, A; Štefanović, M	1
Barbui, C; Bertolini, F; Bovo, C; Correll, CU; Del Giovane, C; Gastaldon, C; Nosé, M; Ogheri, F; Ostuzzi, G; Papola, D; Purgato, M; Tedeschi, F; Turrini, G	1
Geng, F; Hao, R; Liu, H; Ning, X; Shi, Y; Xia, L; Zhang, K	1
Aronen, ET; Mogk, H; Rättö, H; Saastamoinen, LK; Varimo, E	1
Lysaker, PH; McEvoy, JP; O'Sullivan, AK; Sun, X; Weiden, PJ	1
González-Pinto, A; Olivares, JM; Páramo, M	1
Handayati Harahap, D; Moch Rizal, D; Nurwening Solikhah, E; Raymondalexas Marchira, C	1
Capizzi, M; Gliubizzi, C; Guccione, F; Mangano, S; Marino, A; Nardello, R	1
Artunduaga, JC; Coffey, BJ; Kufert, Y; Mor, M	1
Kyriakopoulos, M; Singappuli, P; Sonuga-Barke, E	1
Bidollari, I; Claxton, A; Du, Y; Kelly, DL	1
Shimoda, K; Shinozaki, M; Sugawara, N; Tasaki, M; Yasui-Furukori, N; Yokoyama, S	1
Mesripour, A; Shahnamnia, S; Taymouri, S; Varshosaz, J	1
Hatano, M; Iwata, N; Kishi, T; Okuya, M; Sakuma, K	1
Díaz-Fernández, S; Fernández-Miranda, JJ; López-Muñoz, F	1
Kamińska, K; Lech, MA; Leśkiewicz, M; Lorenc-Koci, E; Rogóż, Z	1
Bajs JanoviĆ, M; Medved, S; MihaljeviĆ-Peleš, A; Štimac, Z	1
Arias, L; Forbes, A; Harlin, M; Larsen, F; Madera, J; Mustafa, N; Panni, M; Raoufinia, A; Ruiz-White, I; Wang, X; Wang, Y; Yildirim, M	1
Barber, S; Cipriani, A; Corsi, M; Olotu, U	1
Bose, A; Du, Y; Ehrich, E; Potkin, SG; Risinger, R; Silverman, B; Stankovic, S; Zummo, J	1
Citrome, L; Hard, ML; Mills, RJ; Sadler, BM; Turncliff, RZ	1
Estrada, G; Oudovenko, N; San, L; Vieta, E	1
Biagi, E; Brambilla, G; Capuzzi, E; Clerici, M; Colmegna, F; Mascarini, A; Ornaghi, A; Santambrogio, J	1
Baker, RA; Eramo, A; Hertel, P; Ismail, Z; Jin, N; Kane, JM; McQuade, RD; Miguelez, M; Perry, P; Peters-Strickland, T; Sanchez, R	1
Holahan, MR; Tuplin, EW	1
Bahk, WM; Emsley, R; Han, C; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Serretti, A; Wang, SM	1
Baker, RA; Eramo, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nitschky Schmidt, S; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C	1
Gunasekaran, K; Jennings, J; Lone, N; Murthi, S	1
Barde, M; Chaumette, B; Gaillard, R; Gay, O; Masson, M	1
Dawson, J; Dolan, S; Mohan, R; Mohan, T	1
Aleman, A; Knegtering, H; Liemburg, EJ; van Es, F	1
Crespo-Facorro, B; Gomez-Arnau, J; Juncal-Ruiz, M; Martinez-Garcia, O; Neergaard, KD; Ortiz-Garcia de la Foz, V; Ramirez-Bonilla, M; Suarez-Pinilla, P; Tabares-Seisdedos, R	1
Demlova, R; Drazanova, E; Horska, K; Karpisek, M; Kasparek, T; Kotolova, H; Ruda-Kucerova, J	1
Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY; Weiden, PJ	1
Citrome, L; Cutler, AJ; Du, Y; Nasrallah, HA; Risinger, R; Silverman, BL; Zummo, J	1
Ayhan, MG; Eren, İ; Kürkcü, A; Özbek, S; Seven, H	1
Birur, B; Lentowicz, I; Li, L; Rayikanti, R	1
Bishop, JR; Brown, JT; Eum, S; Lee, AM; Schneiderhan, ME	1
Bujor, CE; Nielsen, J; Schjerning, O; Vang, T	1
Fujibayashi, M; Hattori, S; Hirayasu, Y; Ishii, C; Ishii, N; Kishida, I; Miyauchi, M; Moritani, T; Shiraishi, Y; Suda, A; Taguri, M; Tsujita, N	3
Baldelli, S; Bernardi, FF; Bernardini, R; Bravaccio, C; Capuano, A; Cattaneo, D; Cheli, S; Clementi, E; Molteni, M; Pozzi, M; Radice, S; Rafaniello, C; Rossi, F; Sessa, M	1
Kar, SK; Srivastava, A	1
de Haan, L; Schulte, PFJ; Veerman, SRT	1
Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H	1
Du, YH; Li, WW; Lü, LX; Ma, J; Sun, MX; Wang, X; Yang, YF; Zhang, D; Zhang, HX; Zhang, Y; Zhao, JY	1
Baker, RA; Beillat, M; Eramo, A; Ettrup, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nitschky Schmidt, S; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C	1
Baker, RA; Carson, W; Correll, CU; Kohegyi, E; McQuade, R; Nyilas, M; Salzman, PM; Sanchez, R; Zhao, C	1
Hard, M; Risinger, R; Weiden, PJ	1
Aquila, R; Jamal, HH; Nasrallah, HA; Risinger, R; Stanford, AD; Weiden, PJ	1
Emond, B; Joshi, K; Kamstra, R; Lafeuille, MH; Lefebvre, P; Pilon, D; Tandon, N	1
Huh, L; Lee, BJ	1
Chikodzore, L; Elsemary, A; Nagalingam, P; Seshadri, M; Thalitaya, MD	1
Beresford, T; Buchanan, J; Emrick, C; Ronan, PJ; Thumm, EB; Weitzenkamp, D	1
Castle, D; Hope, J; Keks, NA	1
Arnaout, B; Feeley, RJ; Yoon, G	1
Kuang, Q; She, S; Zheng, Y	1
Demlova, R; Drazanova, E; Horska, K; Kasparek, T; Kratka, L; Ruda-Kucerova, J; Starcuk, Z	1
Frampton, JE	2
Cameron, C; Desai, D; Drake, C; Hutton, B; Kotb, A; Weiden, PJ; Zummo, J	1
Bota, RG; Hazen, J; Howard, P; Nguyen, C; Novac, A; Tieu, R	1
Hashimoto, N; Kuksumi, I; Miyamoto, T; Miyazaki, A; Toyomaki, A	1
Deng, S; Hu, J; Qiu, C; Shang, D; Wen, Y; Zhu, X	1
Cuomo, A; Fagiolini, A; Goracci, A	1
Alam, MS; Chiranjeevi, P; Praveen Kumar, KV	1
Sinha, VR	1
Fujita, Y; Nagamine, T; Nakamura, M	1
Chan, CH; Chan, HY; Chen, YC	1
Bramness, JG; Handal, M; Hartz, I; Hjellvik, V; Nesvåg, R; Skurtveit, S	1
Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y	1
Sehgal, SA; Tahir, RA	1
Hu, JQ; Jiang, XJ; Lin, WC; Shang, DW; Shi, L; Wen, YG; Wu, FX; Xiao, B; Zhang, JP; Zhu, HZ	1
Berlin, J; Gopal, S; Kern-Sliwa, J; Kim, E; Mathews, M; Singh, A; Turkoz, I; Wooller, A	1
Bundo, M; Hino, M; Horikoshi, S; Hoshino, H; Iwamoto, K; Kaneko, H; Kanno-Nozaki, K; Kunii, Y; Matsumoto, J; Miura, I; Yabe, H	1
Jung, M; Romanos, M	1
Goldnik, A; Mach, A; Malek, G; Marszalek, D; Pawinski, T; Somogi, A	1
Al-Dhubiab, BE	1
Howes, OD; Kim, E; Kim, S; Kwon, JS; Lee, JS; Seo, S; Shin, S	1
Augusto, M; Greene, M; Sweeney, SM; Touya, M; Waters, H	2
Gao, LJ; Guo, HG; Liang, ZT; Yang, Y; Zhong, XX; Zhu, JC	1
Bukhanovskaya, O; Dobrovolskaya, N; Estrada, G; Montañés, F; Oudovenko, N; Popov, M; San, L; Vieta, E	1
Ballerini, A; Brugnoli, R; Carrus, D; Comparelli, A; De Filippis, S; Del Casale, A; Ducci, G; Francomano, A; Girardi, P; Kotzalidis, GD; Mancinelli, I; Marcellusi, A; Mennini, FS; Pompili, M; Rapinesi, C; Sani, G; Sorice, S; Splendori, F; Trovini, G; Verzura, C	1
Ishigooka, J; Matsumoto, H; Ono, H; Tadori, Y	1
Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P	1
Matsuda, H; Mori, T; Okamoto, K; Ono, S; Ozeki, Y; Sagae, T; Shimoda, K; Someya, T; Sugai, T; Sugawara, N; Suzuki, Y; Yamazaki, M; Yasui-Furukori, N	1
Lorenc-Koci, E; Rogóż, Z; Wąsik, A	1
Aguiar, PM; de Mendonça Lima, T; Ribeiro, ELA; Storpirtis, S; Vieira, MEB	1
Dong, F; Ji, SM; Li, AN; Li, L; Lu, W; Wang, CY; Zhou, TY	1
Hirabayashi, M; Iyo, M; Kanahara, N; Mamada, T; Nishimoto, M	1
Du, Y; Liu, CC; Stanford, AD; Weiden, PJ	1
Frayne, J; Galbally, M; Snellen, M; Watson, SJ	1
Du, Y; Hard, ML; von Moltke, L; Walling, D; Wehr, AY; Weiden, PJ	1
Anastasia, A; D'Urso, G; de Bartolomeis, A; Patti, S; Toscano, E	1
Aquila, R; Claxton, A; Du, Y; Nasrallah, HA; Stanford, AD; Weiden, PJ	1
Barabássy, Á; Daniel, D; Durgam, S; Earley, W; Guo, H; Nasrallah, H; Németh, G; Patel, M; Szatmári, B; Zhong, Y	1
Bolea, B; Davies, S; Ijaz, S; Moran, P; Richards, A; Savović, J; Sullivan, S	1
Broder, MS; Chang, E; Greene, M; Hartry, A; Touya, M; Yan, T	1
Crespo-Facorro, B; Gómez-Revuelta, M; González-Pinto, A; Juncal-Ruiz, M; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Vázquez-Bourgon, J	1
Dias Alves, M; Micoulaud-Franchi, JA; Simon, N; Vion-Dury, J	1
Kumar, A; Mishra, A; Mishra, AK; Singh, H	1
Behling, M; Burudpakdee, C; Greene, M; Krasa, H; Seetasith, A	1
Chhatlani, A; Farheen, SA; Setty, MJ; Tampi, RR	1
Beck, E; Correll, CU; Janetzky, W; Luedecke, D; Schöttle, D; Wiedemann, K	1
Sakamoto, S; Sato, K; So, R; Tsukahara, M; Yoshimura, B; Yoshimura, Y	1
Li, FL; Liang, CS; Yang, FC; Yeh, TC	1
Faden, JB; Lollo, VM	1
Doz, M; Gozlan, G; Lafuma, A; Larroumets, P; Lecardeur, L; Monfort, AS; Ortiz, I	1
Barr, AM; Honer, WG; Kim, DD; Procyshyn, RM; White, RF	1
Ahmed, MS; Ashraf, GM; Barreto, GE; Javed, N; Khalique, A; Khan, SAF; Mir, A; Qing, H; Sehgal, SA; Tahir, RA; Wu, H	1
Belic, A; Bitter, I; Csukly, G; Déri, M; Gabri, E; Kiss, Á; Menus, Á; Monostory, K; Sirok, D; Tóth, K	1
Limandri, BJ	1
Cheng, Y; Jiang, K; Li, Q; Lin, Z; Xuan, J; Zhang, Y; Zhao, J	1
Claxton, A; Du, Y; Miller, BJ; Potkin, SG; Weiden, PJ	1
Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L	1
Correll, CU; Mehtälä, J; Taipale, H; Tanskanen, A; Tiihonen, J; Vattulainen, P	1
Claxton, A; Correll, CU; Du, Y; Stanford, AD; Weiden, PJ	1
Belsham, DD; Hahn, MK; Kanagasundaram, P; Kowalchuk, C	1
Lin, JR; Nakagawasai, O; Nemoto, W; Odaira, T; Onogi, H; Sakuma, W; Srivastava, LK; Takahashi, K; Tan-No, K	1
Aguglia, E; Ballerini, A; Callista, G; Carpiniello, B; Clerici, M; Corrivetti, G; De Fazio, P; De Filippis, S; De Giorgi, S; Fagiolini, A; Favaretto, G; Ferri, E; Gargiulo, G; Giustra, MG; La Barbera, D; Maina, G; Mencacci, C; Montagnani, G; Panariello, A; Pigato, G; Tortorella, A; Vernacotola, L; Vita, A	1
Cai, Q; Connolly, N; El Khoury, AC; Kim, E; Patel, C; Tunceli, O	1
Boland, X; Chhabra, P	1
Kahn, DA	1
Bougie, J; Clerzius, G; Malla, A; Miguelez, M; Mustafa, S; Proulx, J; Rampakakis, E	1
George, CE	1
Rahman, T	1
Achtyes, ED; Correll, CU; Kane, JM; Marcy, P; Robinson, DG; Schooler, NR	1
Brouillette, M; El Khoury, AC; Joshi, K; Smith, D; Song, X	1
Arie, C; Fujii, A; Harada, N; Matsuo, K; Obara, K; Tanaka, Y; Yamaki, F; Yoshio, T	1
Jain, R; Meyer, J; Rege, B; von Moltke, L; Wehr, A; Weiden, PJ	1
Angeletti, G; Brugnoli, R; Cuomo, I; De Filippis, S; Del Casale, A; Ferracuti, S; Giordano, G; Girardi, P; Kotzalidis, GD; Mazzarini, L; Rapinesi, C; Sani, G	1
Downing, L; Kim, DD; Procyshyn, RM`; Tibbo, P	1
Cope, N; Fowler, JC; Knights, J; Makin, A; Peters-Strickland, T; Phiri, P; Rathod, S	1
Hatano, M; Inagaki, R; Kamei, H; Taniguchi, M; Yamada, S	1
Chouinard, G; Peretti, CS	1
Hereta, M; Kamińska, K; Rogóż, Z	1
Huang, A; Loebel, A; Messali, A; Ng-Mak, D; Wang, L	1
Hernandez, R; Lertxundi, U; Medrano, J	1
He, S; Li, HF; Li, Y; Li, YG; Qiao, Y; Shen, YF; Wen, H; Yu, YM; Zhang, L; Zhang, Y	1
Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Valdizan, EM; Vazquez-Barquero, JL	1
Cheung, C; Chua, SE; Collier, DA; Deng, W; Gong, Q; Huang, C; Jiang, L; Li, M; Li, T; Ma, X; McAlonan, GM; Sham, PC; Wang, Q; Wang, Y	1
El-Sayeh, HG; Hunger, H; Khanna, P; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S	1
Furuya, M; Horiguchi, J; Ieda, M; Liaury, K; Miyaoka, T; Takechi, M; Tsuchie, K; Wake, R	1
Wang, YC	1
Li, W; Lv, L; Wang, S; Wang, X; Yang, G; Yang, Y; Zhang, H; Zhao, J	2
Caccia, F; Caloro, M; Cuomo, I; De Filippis, S; De Persis, S; Gentile, G; Girardi, P; Janiri, D; Kotzalidis, GD; Lionetto, L; Piazzi, G; Sciarretta, A; Simmaco, M; Simonetti, A; Telesforo, CL	1
Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J	1
Cichocki, M; Jarmuszkiewicz, Z; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A	1
Baker, RA; Carson, W; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, B; Kane, JM; McQuade, R; Sanchez, R	1
Falkai, P; Schmitt, A	1
Aggarwal, A; Gopalakrishna, G; Lauriello, J	2
Baker, RA; Duca, AR; Eramo, A; Johnson, BR; Kane, JM; McQuade, RD; Peters-Strickland, T; Sanchez, R; Zhao, J	1
An, SK; Chang, JG; Cho, HS; Jung, YC; Kim, CH; Roh, D	1
Tadokoro, S	1
Adams, DH; Baygani, S; Kinon, BJ; Kollack-Walker, S; Millen, BA; Velona, I; Walling, DP	1
Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K	1
Remington, G; Takeuchi, H	1
Tsukarzi, EE	1
Accordini, S; Barbui, C; Cipriani, A; Girlanda, F; Nosè, M; Purgato, M; Tansella, M	1
Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M	1
Jalenques, I; Kernisant, M; Legrand, G; May, R; Richard, B	1
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Tang, CS; Wang, LJ; Yeh, CB	1
Carson, W; Correll, CU; Forbes, RA; Mankoski, R; Marcus, R; McQuade, R; Zhao, J	1
Baker, RA; Bricmont, P; Eramo, A; Kasper, W; Mallikaarjun, S; McQuade, R; Peters-Strickland, T; Potkin, SG; Raoufinia, A; Sanchez, R	1
Barry, SJ; Gaughan, TM; Hunter, R	1
Bricmont, P; Carson, W; Fleischhacker, WW; Forbes, RA; Kane, JM; Mallikaarjun, S; McQuade, R; Sanchez, R	1
Hashiguchi, M; Kunitomi, T; Mochizuki, M	1
Buchanan, RW; Dickerson, FB; Earl, AK; Feldman, S; Fischer, BA; Keller, WR; Kelly, DL; McMahon, RP; Shim, JC; Sullivan, KM; Warfel, D; Wehring, HJ	1
Ishigooka, J; Iwata, N; Nakagome, K; Ohmori, T	1
Datta, SS; Furtado, VA; Kumar, A; Russell, PS; Wright, SD	1
Poncin, YB; Stubbe, DE; Webb, JE; Webb, JR	1
Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L	1
Arnoldy, R; Curtis, J; Samaras, K	1
Au, RW; Chiu, HF; Dickerson, F; Kreyenbuhl, J; Lai, KY; Man, D; Shum, D; Tang, WK; Ungvari, GS; Wang, CY; Xiang, YT; Yu, X; Zhou, FC; Zhou, JJ; Zhou, Y	1
Allain-Veyrac, G; Gaboriau, L; Gérardin, M; Grall-Bronnec, M; Jolliet-Evin, P; Victorri-Vigneau, C	1
Buchanan, RW; Newcomer, JW; Weiden, PJ	1
Bojarski, AJ; Marciniec, K; Partyka, A; Pawlowski, M; Wesolowska, A; Zajdel, P	1
El-Sayeh, HG; Khanna, P; Komossa, K; Leucht, S; Ma, H; Rummel-Kluge, C; Suo, T; Xia, J	1
Aleman, A; Cahn, W; Gijsman, HJ; Hovens, JE; Kahn, RS; Maat, A	1
Aida, SA; Hatim, A; Mohamed, Z; Reynolds, GP; Roffeei, SN; Said, MA; Zainal, NZ	1
Charpeaud, T; Llorca, PM; Samalin, L	1
Dai, G; Zhang, Y	1
Anzai, N; Furukawa, S; Hatsuse, N; Ikebuchi, E; Iwata, K; Kishimoto, T; Matsuda, Y; Sato, S; Watanabe, Y	1
Chen, TT; Huang, WL; Tsai, CH	1
Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A	1
Awad, G; Hassan, M; Hsu, J; Loebel, A; Pikalov, A; Rajagopalan, K	1
Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H	1
Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T	4
Cao, B; Hou, R; Jian, J; Mi, G; Qiu, H; Tang, M; Wang, M	1
Baker, RA; Bentley, TG; Citrome, L; Eramo, A; Gutierrez, B; Hansen, K; Kamat, SA; Ortendahl, J; Sapin, C	1
Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A	1
Danilov, DS	1
Baker, RA; Carson, WH; Eramo, A; Fleischhacker, WW; Jin, N; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R; Walling, D	1
Perry, CM; Shirley, M	1
Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W	1
Bilenberg, N; Correll, CU; Fagerlund, B; Fink-Jensen, A; Gluud, C; Jantzen, P; Jensen, KG; Jeppesen, P; Jepsen, JR; Juul, K; Klauber, DG; Lauritsen, MB; Madsen, S; Nyvang, L; Pagsberg, AK; Paludan, J; Pedersen, J; Rasmussen, S; Rudå, D; Saldeen, EA; Skoog, M; Stenstrøm, AD; Stentebjerg-Olesen, M; Thomsen, PH; Vernal, DL; Werge, TM; Wetterslev, J; Winge, K	1
Pawelczyk, A; Pawelczyk, T; Rabe-Jablonska, J	1
Gentile, S	1
Baker, RA; Carson, WH; Eramo, A; Gara, M; Hertel, P; Jin, N; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R	1
Goyal, P; Kumar, D; Prakash, O; Tripathi, P	1
Du, Y; Ehrich, EW; Hard, M; Risinger, R; Turncliff, R	1
Eifler, S; Englisch, S; Esslinger, C; Kirsch, P; Meyer-Lindenberg, A; Mier, D; Rausch, F; Schirmbeck, F; Zink, M	1
Baker, RA; Carson, WH; Eramo, A; Fleischhacker, WW; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R; Tsai, LF	2
Baker, RA; Duca, AR; Eramo, A; Johnson, BR; Kane, JM; McQuade, RD; Peters-Strickland, T; Sanchez, R; Zhao, C	1
Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A	1
Argyelan, M; Gallego, JA; Ikuta, T; Kane, JM; Karlsgodt, K; Lencz, T; Malhotra, AK; Robinson, DG; Sarpal, DK; Szeszko, PR	1
Stroup, TS	1
Heres, S	1
Chiu, HF; Dong, H; Han, X; Lu, Z; Ungvari, GS; Wang, CY; Wu, YF; Xiang, YT; Yang, FD; Yu, X; Yuan, YB; Zhao, JP	1
Kobayashi, H; Tadori, Y	1
Crespo-Facorro, B; Prieto, C; Sainz, J	1
Damkier, P; Ennis, ZN	1
Fujii, Y; Ishigooka, J; Iwata, N; Iyo, M; Kishimoto, T; Nakamura, J; Nishimura, R; Shimizu, N; Uchimura, N	1
Deng, C; Han, M; Hu, CH; Huang, XF; Pan, B	1
Baker, RA; Eramo, A; Kostic, D; Landsberg, W; Larsen, F; Nylander, AG; Raoufinia, A	1
Cortese, S	1
Gopal, S; Hough, D; Lane, R; Nuamah, I; Savitz, AJ	1
Maneeton, B; Maneeton, N; Srisurapanont, M; Suttajit, S	1
Brugnoli, R; De Filippis, S; Di Sciascio, G; Fagiolini, A; Maina, G	1
Gorczyca, P; Rykaczewska-Czerwińska, M; Sobiś, J; Świętochowska, E	1
Iyo, M; Kanahara, N; Kimura, H; Oda, Y; Takase, M; Watanabe, H	1
Bjelobaba, I; Budimirovic, DB; Kucka, M; Stojilkovic, SS; Tomić, M	1
Audo, I; Faure, C; Letessier, JB; Robert, MP; Zeitz, C	1
Knights, J; Rohatagi, S	1
Fabbri, C; Kato, M; Kinoshita, T; Koshikawa, Y; Nonen, S; Okugawa, G; Sakai, S; Serretti, A; Sunada, N; Takekita, Y; Wakeno, M	3
Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK	1
van der Weide, J; van der Weide, K	1
Hino, M; Horikoshi, S; Kanno-Nozaki, K; Mashiko, H; Miura, I; Niwa, S; Ota, T; Yabe, H	1
Austin, M; Dadlani, N	1
Bian, QT; Chen, JX; Correll, C; Liu, YH; Soares, JC; Su, YA; Wang, SL; Wei, LH; Yang, FD; Zhang, RZ; Zhang, XY	1
Hu, LY; Hung, MB; Hung, YY; Lee, YT; Lu, T	1
Bose, A; Corey, L; Du, Y; Ehrich, EW; Meltzer, HY; Nasrallah, HA; Risinger, R; Silverman, BL; Stankovic, S; Zummo, J	1
Andersen, HS; Baker, RA; Beillat, M; Eramo, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C	1
Falissard, B; Hansen, K; Landsberg, W; Loze, JY; Sapin, C	1
Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M	2
Giannopoulou, A; Kahn, RS	1
Jiang, Y; Ni, W	1
Argyelan, M; Gallego, JA; John, M; Kane, JM; Karlsgodt, KH; Lencz, T; Malhotra, AK; Robinson, DG; Sarpal, DK; Szeszko, PR; Weissman, N	1
Addington, J; Gallego, JA; John, M; Kane, JM; Lencz, T; Malhotra, AK; Robinson, DG; Tohen, M; Yu, J; Zhang, JP	1
Addington, J; Bennett, N; Braga, RJ; Correll, CU; Gallego, JA; Greenberg, J; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Lopez, L; Malhotra, AK; Naraine, M; Petrides, G; Robinson, DG; Sevy, SM; Tohen, M; Zhang, JP	1
Arango, C	1
Addington, J; Burdick, KE; DeRosse, P; Gallego, JA; Goldberg, TE; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Malhotra, AK; Petrides, G; Robinson, DG; Tohen, M; Trampush, JW; Zhang, JP	1
Bereza, BG; Einarson, TR; Goswami, P; Pudas, H; van Impe, K	1
Ai, X; Ding, M; Ding, S; Gu, X; Huang, G; Li, X; Lv, L; Pang, L; Song, X; Zhao, J	1
Caballero, J; Harrington, CA; Thomas, JE	1
Citrome, L	4
Chan, HY; Chen, WJ; Hsieh, MH; Hwang, TJ; Hwu, HG; Kuo, CH; Lin, CF; Liu, CC; Liu, CM; Lo, WM	1
Basri, M; Izadiyan, Z; Lim, CJ; Masoumi, HR; Samiun, WS	1
Bose, A; Citrome, L; Claxton, A; Du, Y; Ehrich, EW; Risinger, R; Silverman, BL; Stankovic, S; Zummo, J	1
Sekiguchi, G; Suzuki, H	1
Fernandez-Egea, E; Mané, A; Mann, L; Mundell, C; Ramos Perdigués, S; Sauras Quecuti, R	1
Cassoli, JS; Guest, PC; Martins-de-Souza, D; Santana, AG	1
Chue, J; Chue, P	1
Cutler, AJ; Durgam, S; Laszlovszky, I; Lu, K; Meltzer, HY; Migliore, R; Németh, G; Ruth, A	1
Adham, N; Fone, KCF; Gyertyán, I; King, MV; Kiss, B; Watson, DJG	1
Lahti, AC	1
Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M	1
Inoue, Y; Kishimoto, T; Murakoshi, A; Takaesu, Y; Takahashi, N	1
Aitchison, KJ; Heald, AH; Lodhi, RJ; Malik, A; Masand, S; McAllister, VD; O'Keane, V; Sherwood, RA; Shivakumar, K; Young, LC	1
Potkin, SG; Preda, A	1
Alfonsi, E; Amodeo, G; Cenci, M; De Filippis, S; Di Lella, M; Fagiolini, A; Farinella, F; Ferraiuolo, F; Fraguas, D; Gutierrez-Rojas, L; Loparco, N; Mignone, ML; Pataracchia, G; Pillai, G; Russo, F; Sanchez-Gistau, V; Spinogatti, F; Toscano, M; Villari, V	1
Stahl, SM	2
Culhane, C; Hope, J; Keks, NA	1
Guo, Q; Li, C; Ouyang, Q; Qiao, Y; Shen, W; Sheng, J; Wen, H; Yang, F; Zhu, S	1
Giermaziak, W; Kus, K; Nowakowska, E; Ratajczak, P	1
Dafreville, C; Mété, D; Paitel, V; Wind, P	1
Baker, RA; Citrome, L; Nagamizu, K; Ota, A; Perry, P; Weiller, E	1
Baymeeva, NV; Burminskiy, DS; Miroshnichenko, II; Morozova, MA; Platova, AI; Potanin, SS	1
Cordes, J; Gründer, G; Heinze, M; Mühlbauer, B; Rüther, E; Schulz, C; Timm, J	1
Huang, WL; Lin, CH; Tsai, YF	1
Crowe, L; Loebel, A; Rajagopalan, K; Squirrell, D; Trueman, D	1
Davis, JM; Furtado, VA; Hosalli, P; Sampson, S	1
Badran, IA; Correll, CU; Curran, RL; DelBello, MP; Pedapati, EV; Peppers, V	1
Ariyawansa, J; De Meulder, M; Remmerie, B; Savitz, A	1
Getova, DP; Topolov, MK	1
Deng, C; Lian, J; Pan, B	1
Chaichan, W; Kittipeerachon, M	1
Bruhn, CH; Fink-Jensen, A; Jakobsen, KD; Nielsen, J; Pagsberg, AK	1
Ishigooka, J; Nishiyama, K; Noda, T; Shima, T; Tadori, Y; Tamaru, N; Yamasaki, Y	1
Eramo, A; Johnson, BR; McQuade, RD; Perry, PP; Peters-Strickland, T; Salzman, PM; Sanchez, R; Zhao, C	1
Bose, A; Du, Y; Ehrich, EW; Nasrallah, HA; Newcomer, JW; Risinger, R; Silverman, BL; Stankovic, S; Zummo, J	1
Serretti, A; Takekita, Y	1
Alonso-Martín, C; Arias-Loste, MT; Crespo, J; Crespo-Facorro, B; Fábrega, E; Martínez-García, O; Morlán-Coarasa, MJ; Ortiz-García de la Foz, V; Romero-Gómez, M	1
Alphs, L; Correll, CU; Kim, E; Mao, L; Starr, HL	1
Aleksic, B; Banno, M; Fujioi, J; Iwamoto, K; Kikuchi, T; Ozaki, N	1
Du, Y; Jamal, HH; Pendergrass, JC; Risinger, R; Silverman, BL; Targum, SD	1
de Leon, J; Li, XB; Tang, YL; Wang, CY; Xiang, YQ; Zheng, W; Zheng, YJ	1
Andrade, C	1
Bergmans, P; Caspi, A; Cherubin, P; Hargarter, L; Keim, S; Lara, E; Pinchuk, I; Schreiner, A; Schuepbach, D; Suleman, S	1
Bervoets, C; Cleymans, S; Morrens, M	1
Baker, RA; Beillat, M; Eramo, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nitschky Schmidt, S; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C	1
Zehtabchi, S	1
Mahapatra, A; Sagar, R; Sharma, P	1
Chen, SF; Shen, YC	1
Kumar C, N; Kumar P B, S; Kumar P T, S; Pandey, RS; Thirthalli, J	1
Loebel, A; Meyer, N; Rajagopalan, K; Wade, S	1
Bastiampillai, T; Cao, CZ; Dhillon, R; Eckert, TG; Tibrewal, P	1
Baker, RA; Bricmont, P; Eramo, A; Hertel, P; Jin, N; Larsen, F; McQuade, RD; Nylander, AG; Peters-Strickland, T; Raoufinia, A; Repella, J	1
Baker, RA; Beillat, M; Eramo, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C; Steen Andersen, H	1
Abe, H; Funahashi, H; Ishida, Y; Naono, H; Naono-Nagatomo, K; Takeda, R; Uchimura, D	1
Atake, K; Beppu, H; Hori, H; Igata, R; Katsuki, A; Konishi, Y; Tominaga, H; Yoshimura, R	1
Dhamija, R; Verma, R	1
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Glikman, J; Krebs, MO; Limosin, F; Millet, B	1
Abbasian, C; Power, P	1
Sikich, L	1
Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR; Zervas, IM	1
Boulton, DW; Kollia, G; Komoroski, B; Kovalick, LJ; Mallikaarjun, S; Reeves, RA; Sharma, A	1
Collins, J; Mervak, B; Valenstein, M	1
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B	1
Berman, RM; Breder, C; Campos, JA; Carson, WH; Kerselaers, W; L'italien, GJ; Marcus, RN; McQuade, RD; Newcomer, JW; Nys, M	1
Nahata, T; Saini, TR	1
Boulton, DW; Carson, WH; Findling, RL; Forbes, RA; Kauffman, RE; Mallikaarjun, S; Nyilas, M; Pikalov, A; Sallee, FR; Shoaf, SE	1
Bachmann, CJ; Heinzel-Gutenbrunner, M; Hiemke, C; Remschmidt, H; Rieger-Gies, A; Theisen, FM	1
Bhattacharjee, J; El-Sayeh, HG	2
Goff, DC	1
Barbero, JD; Benito, N; Cobo Gómez, JV; Coronas, R; Domenech, C; Fuste, G; García-Parés, G; Gómez, JV	1
Ayache, L; Buysschaert, M; Fagnart, O; Feys, JL; Gruson, D; Hermans, MP; Jamart, J; Luts, A; Mertens de Wilmars, S; Misson, A; Oriot, P	1
Bruggeman, R; Postema, R; Schilthuis, M; Schorr, SG; Slooff, CJ; Taxis, K; Van Oven, W	1
Wang, SJ; Yang, TT	1
Carson, WH; Findling, RL; Forbes, RA; Ivanova, S; Iwamoto, T; Jin, N; Marcus, R; McQuade, RD; Nyilas, M; Robb, A	1
Arsura, E; Sethi, NK; Torgovnick, J	1
Choi, JS; Jang, IJ; Kang, DH; Kim, E; Kwon, JS; Shin, SG; Yu, KS	1
Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Kane, JM; Pikalov, A; Whitehead, R	1
Kashima, H; Kikuchi, T; Manki, H; Nakajima, S; Nomura, K; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K	1
Langosch, JM; Schlachetzki, JC	1
Azzoni, A; Raja, M	1
Montero, I; Ruiz, I; Talavera, M	1
Chen, CH; Lu, ML; Shen, WW	1
Chen, CH; Chen, SF; Chen, SJ; Chen, YJ; Lin, CC; Luu, SU; Shen, YC	1
Baardewijk, Mv; Davies, A; L'italien, GJ; Loze, JY; Sennfalt, K; Vardeva, K	1
Baker, RA; Carson, WH; Crandall, DT; Eudicone, JM; L'italien, G; Marcus, RN; McQuade, RD; Meyer, JM; Newcomer, JW; Pikalov, A; Vester-Blokland, E	1
Archibald, D; Carson, WH; Fleischhacker, WW; Marcus, RN; McQuade, RD; Swanink, R	1
Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL	1
Glick, ID; Ivanova, O; Koran, LM; Poyurovsky, M	1
Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS	1
Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R	1
Hanssens, L; Kerselaers, W; L'Italien, G; Loze, JY; Marcus, RN; Pans, M	1
Hauser, D; Ladds, B; Mejia, C; Thomas, P	1
Jong-Yih, L	1
Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY	1
Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD	1
Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR	1
Costentin, J	2
Barnett, AH; Knapp, M; L'Italien, GJ; Loze, JY; Millar, HL; van Baardewijk, M	1
Bashir, M; Keith, S; MacRae, A; Majjiga, C; Murphy, J; Shajahan, P; Taylor, M	1
Caykoylu, A; Ekinci, O; Yilmaz, E	1
Chen, CH; Chen, SF; Shen, YC	2
Breier, A; Kane, JM; Kryzhanovskaya, LA; Osuntokun, O; Stauffer, VL; Watson, SB; Xu, W	1
Ascher-Svanum, H; Ball, T; Conley, R; Liu, L; Stauffer, V	1
Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM	1
Chiesa, A; De Ronchi, D; Mandelli, L; Pae, CU; Serretti, A	2
Bopp, K; Petti, TA; Stern, RG; Tobia, A	1
Chiesa, A; De Ronchi, D; Kim, J; Lee, C; Mandelli, L; Pae, CU; Paik, IH; Serretti, A	1
Accordini, S; Artioli, P; Barale, F; Barbui, C; Beneduce, R; Berardi, D; Bertolazzi, G; Biancosino, B; Bisogno, A; Bivi, R; Bogetto, F; Boso, M; Bozzani, A; Bucolo, P; Casale, M; Cascone, L; Ciammella, L; Cicolini, A; Cipresso, G; Cipriani, A; Colombo, P; Dal Santo, B; De Francesco, M; Di Lorenzo, G; Di Munzio, W; Ducci, G; Erlicher, A; Esposito, E; Ferrannini, L; Ferrato, F; Ferro, A; Fragomeno, N; Frova, M; Gardellin, F; Garzotto, N; Giambartolomei, A; Giupponi, G; Grassi, L; Grazian, N; Grecu, L; Guerrini, G; Laddomada, F; Lazzarin, E; Lintas, C; Malchiodi, F; Malvini, L; Marchiaro, L; Marsilio, A; Mauri, MC; Mautone, A; Menchetti, M; Migliorini, G; Mollica, M; Moretti, D; Mulè, S; Nicholau, S; Nosè, F; Nosè, M; Occhionero, G; Pacilli, AM; Parise, VF; Pecchioli, S; Percudani, M; Piantato, E; Piazza, C; Pontarollo, F; Pycha, R; Quartesan, R; Rillosi, L; Risso, F; Rizzo, R; Rocca, P; Roma, S; Rossattini, M; Rossi, G; Sala, A; Santilli, C; Saraò, G; Sarnicola, A; Sartore, F; Scarone, S; Sciarma, T; Siracusano, A; Strizzolo, S; Tansella, M; Targa, G; Tasser, A; Tomasi, R; Travaglini, R; Veronese, A; Ziero, S	1
Chung, S; Jeon, YW; Jeong, B; Jun, TY; Jung, HY; Kim, CE; Kim, CY; Kim, DH; Kwon, JS; Lee, JN; Lee, MS	1
Kahn, JP; Kerselaers, W; Lissens, J; McQuade, RD; Modell, S; Ryckmans, V; Sanchez, R; Werner, C	1
Bergmann, F; Ebrecht, M; Kungel, M; Modell, S; Nass, A; Spevakné-Göröcs, T; Urban, R; Werner, C; Zacher, A	1
Chiu, NY; Hsu, WY; Kahn, DA; Lee, CI	1
Dziuba, J; Keshavan, M; Lachover, L; Manji, S; Pizzuti, A; Rajarethinam, R	1
Pae, CU	1
Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B	1
Bachmann, CJ; Lehr, D; Preiss, M; Theisen, FM	1
Englisch, S; Inta, D; Weinbrenner, A; Zink, M	1
Kashima, H; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K	2
Bian, QT; Chen, JX; Haile, C; Kosten, TR; Liu, YH; Su, YA; Wang, N; Wang, SL; Yang, FD; Zhang, XY	1
Mace, S; Taylor, D	1
Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Suzuki, T	1
Bates, JA; Guo, Z; Kan, HJ; Kane, JM; Kim, E; Pikalov, A; Whitehead, R	1
de Haan, L; Peters, B	1
Shan, JC; Tseng, MC	1
Pesek, MB	1
El-Sayeh, HG; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S	1
Gagliano, A; Masi, G	1
Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E	1
Fekete, S; Herold, R; Kovacs, A; Osvath, P; Simon, M; Tenyi, T; Voros, V	1
Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV	1
Rocha, FF	1
Stip, E; Tourjman, V	1
Chiesa, A; Gibiino, S; Mandelli, L; Pae, CU; Patkar, AA; Serretti, A	1
Ali, M; Assunção-Talbott, S; Carson, WH; Forbes, RA; Iwamoto, T; Nyilas, M; Pikalov, A; Robb, AS; Whitehead, R	1
Fujita, K; Fukuo, Y; Furukawa, O; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Moriwaki, M; Naitoh, H; Okochi, T	1
Albayrak, Y; Caykoylu, A; Ekinci, O; Kuloglu, M	1
Roxanas, MG	1
Hanatani, T; Ikejiri, Y; Kondo, M; Sumi, N	1
Beck, A; Dembler, T; Dinges, M; Friedel, E; Gallinat, J; Heinz, A; Juckel, G; Sarkar, R; Schlagenhauf, F; Wrase, J; Wüstenberg, T	1
Chen, HK; Shao, CH; Wu, BJ	1
Ebrecht, M; Kungel, M; Messer, T; Modell, S; Schmauss, M; Spevakne-Goeroecs, T; Werner, C	1
Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R	1
Asenbaum, S; Barnas, C; Fischer, P; Mossaheb, N; Spindelegger, C	1
Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S	1
Radics, J	1
Benedetti, AM; Frazee, LA; Leung, JG; Myers, N	1
Cerovecki, A; Dehning, S; Engel, RR; Matz, J; Möller, HJ; Müller, N; Musil, R; Obermeier, M; Opgen-Rhein, M; Riedel, M; Schennach-Wolff, R; Seemüller, F; Severus, E; Spellmann, I	1
Deng, C; Huang, XF; Lian, J; Pai, N	1
Hahn, SW; Ham, BJ; Kang, RH; Lee, HY; Lee, MS; Paik, JW	1
Dewaele, P; Fleischhacker, WW; Heikkinen, ME; Hennicken, D; Kerselaers, W; Landsberg, W; Loze, JY; McQuade, RD; Olié, JP	1
Chiesa, A; Pae, CU; Serretti, A	1
Inada, K; Ishigooka, J; Oshibuchi, H	1
Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS	1
Arand, J; Farger, G; Hiemke, C; Lutz, UC; Wiatr, G; Wildgruber, D	1
Guirguis-Blake, J	1
Hamidin, A; Normala, I	1
Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD	1
Kozumplik, O; Sedić, B; Uzun, S	1
Cohen, J; Gavaudan, G; Lançon, C; Léonetti, G; Magalon, D; Pélissier-Alicot, AL	1
Kibbey, KJ; Nicholson, GC; Roberts, AM	1
Chen, J; Deng, C; Hu, C; Huang, XF	1
Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y	2
Brunetti, L; Patel, MK	1
Chang, CC; Chen, SH; Hwang, PL; Ko, JY; Wei, SY; Yeh, HH	1
Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S	1
Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N	1
Chiesa, A; Mandelli, L; Pae, CU; Serretti, A	1
Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y	1
Hori, H; Nakamura, J; Okamoto, T; Umene-Nakano, W; Yoshimura, R	1
Janicak, PG; Rado, J	1
Kirino, E	2
Carson, W; Cziraky, MJ; Delorenze, G; Niemcryk, SJ; Oliveria, SA; Phillips, S; Quesenberry, CP; Skovron, ML; Tsai, AL; Ulcickas Yood, M; Wells, K; Willey, VJ	1
Girgis, RR; Lieberman, JA; Merrill, DB; Pikalov, A; Vorel, SR; Whitehead, R; You, M	1
Atallah, AN; Melnik, T; Puga, ME; Soares, BG	1
Gen, K; Inoue, Y; Suzuki, H	1
Claes, S; De Hert, M; Martens, GJ; Moons, T; Peuskens, J; Van Loo, KM; Van Schijndel, JE; van Winkel, R	1
Ardizzone, I; Carratelli, TI; Ferrara, M; Marconi, A; Nardecchia, F	1
Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P	1
Bastiampillai, T; Lander, M	1
Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE	1
Case, M; Conley, RR; Hoffmann, VP; Jacobson, JG; Stauffer, VL	1
Ascher-Svanum, H; Faries, DE; Kane, JM; Osuntokun, OO; Peng, X; Stauffer, VL; Stensland, MD	1
Correll, CU	1
Lee, SY; Pae, CU; Park, MH; Patkar, AA	1
Cohn, T; Faulkner, G; Mukundan, A; Remington, G	1
Arakaki, H; Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Ohta, I; Suzuki, T; Uno, T	1
Lee, J; Ng, KW; Swapna, V	1
Kan, HJ; King, D; Knapp, M; Loze, JY; Razzouk, D; Thomas, P; van Baardewijk, M	1
Arends, J; Cohen, D; van Kooten, M	1
Boyer, L; Christophe, L; Cohen, J; Magalon, D; Simon, N	1
Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S	1
Bruno, A; Di Nardo, F; Micò, U; Muscatello, MR; Pandolfo, G; Santoro, V; Scimeca, G; Spina, E; Zoccali, RA	1
Chen, CY; Lin, TY; Shuai, HA; Wang, CC	1
Bobo, WV; Crystal, S; Gerhard, T; Huang, C; Lieberman, JA; Olfson, M	1
Bernagie, C; De Hert, M; Dockx, L; Leucht, S; Peuskens, B; Peuskens, J; Sweers, K; Tack, J; Van de Straete, S; Wampers, M	1
Hashimoto, K; Iyo, M; Kanahara, N; Okamura, N; Sekine, Y; Tadokoro, S	1
Hackett, LP; Ilett, K; Nguyen, T; Teoh, S	1
Aleman, A; Bous, J; Hollander, K; Knegtering, H; Liemburg, E	1
De Risio, A; Gentile, B; Giannarelli, D; Pancheri, A; Simonetti, G; Stefanutto, L	1
Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M	1
Accordini, S; Barbui, C; Cipriani, A; Esposito, E; Girlanda, F; Nosè, M; Purgato, M; Stroup, S; Tansella, M; Veronese, A	1
Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY	1
Breton, C; Delahaye, F; Dickes-Coopman, A; Dutriez-Casteloot, I; Guillemot, J; Laborie, C; Lesage, J; Lukaszewski, MA; Mayeur, S; Montel, V; Vieau, D	1
Howes, OD; Jang, IJ; Jeong, JM; Kapur, S; Kim, E; Kwon, JS; Lee, JS; Shin, SG; Yu, KS	1
Andel, R; Becker, MA; Boaz, TL; Chandler, K; Desmarais, SL; Howe, A; Van Dorn, RA	1
Kasahara, M; Murashima, A; Nakajima, K; Nakamura, T; Sugibayashi, R; Watanabe, N; Watanabe, O	1
Chiu, NY; Hsu, WY; Lee, BS; Liao, YC; Lin, TW	1
Eriksson, J; Kasteng, F; Lindgren, P; Sennfält, K	1
Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N	1
Sokolski, KN	1
Hou, YC; Lai, CH	1
Basu, R; Brar, JS; Chang, CC; Ganguli, R; Garbut, R	1
Bous, J; de Boer, MK; Hamamura, T; Knegtering, H; Sytema, S; van der Moolen, AE; Wiersma, D; Wilffert, B	1
Fukui, N; Ono, S; Sawamura, K; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J	1
Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS	1
Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C	1
Bowden-Jones, H; Kitchenham, N; Smith, N	1
de Arce Cordón, R; Eding, E; Marques-Teixeira, J; Milanova, V; Rancans, E; Schreiner, A	1
Biswas, J; Gandhi, RA; George, RJ; Nair, AG	1
Belgamwar, RB; El-Sayeh, HG	2
Chou, J; Chung, MT; Lin, CH; Ma, H	1
Camacho, LR; Celso, F; Da Rosa, KM; Da Silva, TG; Dos Santos, Bde J; Freitas, TM; Monteiro, JD; Pereira, P; Picada, JN; Pontes, VM; Vieira, LR	1
Faludi, G; Fejes, L; Inczédy-Farkas, G; Kassai-Farkas, A; Lazáry, J; Makkos, Z	1
Weiden, PJ	1
Cho, HY; Fang, ZH; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Phuong, VT; Seo, MK	1
Bervoets, C; Constant, E; de Patoul, A; Delatte, B; Gillain, B; Halkin, V; Kok, F; Loze, JY; Peuskens, J; Touquet, G; Vansteelandt, K	1
Diaz-Atienza, F; Gurpegui, M; Gutiérrez-Rojas, L; Jurado, D; Martínez-Ortega, JM	1
Lai, CH	1
Chang, KY; Wu, YF	1
Bastiampillai, T; Dhillon, R; Goh, T	1
Ikeda, R; Katagiri, N; Mizumura, S; Mizuno, M; Nemoto, T; Shiraga, N; Tohgi, N; Tsujino, N; Yamaguchi, T	1
Fleischhacker, WW; Han, C; Lee, SJ; Masand, PS; Pae, CU; Park, MH; Patkar, AA	1
Chen, CK; Lin, SK; Liu, YL	1
Endo, T; Fukui, N; Ono, S; Shindo, M; Someya, T; Sugai, T; Suzuki, Y	1
Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Mori, A; Niwa, S; Numata, Y; Takeuchi, S; Yang, Q	1
Brotzge, K; El-Mallakh, RS; Manshadi, M	1
Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Tomita, M; Umene-Nakano, W; Yoshimura, R	1
Berkowitz, RL; Docherty, JP; Ni, Q; Parks, JJ; Patel, U	1
Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K	1
Croxtall, JD	1
Goto, S; Terao, T; Tomita, M; Uchimura, N	1
Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C	1
Jindal, KC; Munjal, V; Singh, GP	1
Ahlbrand, R; Bronson, SL; Grainger, M; Horn, P; McNamara, RK; Richtand, NM; Tambyraja, R	1
Hashimoto, N; Ito, K; Koyama, T; Kusumi, I; Matsuda, N	1
Doey, T	1
Han, C; Jeong, HG; Joe, SH; Ko, YH; Lee, HY; Lee, MS	1
Johnsen, E; Kroken, RA	1
Chang, LR; Huang, WL	1
Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Umene-Nakano, W; Yoshimura, R	1
Dunn, G; French, P; Hutton, P; Morrison, AP; Taylor, PJ; Yung, AR	1
Anandarajan, T; Bastiampillai, T; Dhillon, R; Tibrewal, P	1
Mari, Jde J; Moreira, HC; Nunes, LV; Nunes, SO; Razzouk, D	1
Kikuchi, T; Tadori, Y	1
Carson, WH; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Sanchez, R	1
Abdallah, CG; Hong, X; Huang, H; Huang, Q; Jiang, L; Liang, C; Liu, Y; Wan, X; Wang, J; Wu, R; Xu, C; Zhang, J	1
Fleischhacker, WW; Uchida, H	1
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Liang, HY; Tang, CS; Wang, LJ; Wu, YY; Yeh, CB	1
Alvir, JM; Berger, A; Edelsberg, J; Mychaskiw, MA; Oster, G; Sanders, KN	1
Moteshafi, H; Stip, E	1
Azorin, JM; Gasquet, I; Gierski, F; Leguay, D; Lemogne, C; Limosin, F; Raucher-Chéné, D; Rouillon, F; Schuster, JP	1
Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K	1
Borba, CP; Copeland, P; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC	1
Chaumartin, N; Lachaux, B; Monville, M	1
Bervoets, C; Constant, E; de Patoul, A; Halkin, V; Kok, F; Morrens, M; Peuskens, J; Pitsi, D; Sabbe, B; Vansteelandt, K	1
Kato, M; Kinoshita, T; Nishida, K; Okugawa, G; Sakai, S; Suwa, A; Takekita, Y; Wakeno, M	1
Arakaki, H; Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Ohta, I; Suzuki, T	1
Landowski, J; Wichowicz, H; Wilkowska, A	1
Hiranyatheb, T; Ittasakul, P; Ketter, TA; Srivastava, S	1
Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA	1
Chang, HC; Chang, LR; Huang, WL; Liu, CM; Tsai, YF	1
Bouvard, S; Ciumas, C; d'Amato, T; Daléry, J; Lerond, J; Lothe, A; Poulet, E; Ryvlin, P; Saoud, M	1
Chen, L; Zhou, Z; Zhu, H	1
Bienroth, M; Curtis, V; Debenham, M; George, M; Gonzalez, D; Jones, S; Pitsi, D	1
Ananjit, S; Badiah, Y; Bulgiba, A; Habil, MH; Hairi, NN; Haslina, MY; Hatim, A; Mahmud, B; Ramli, MA; Said, MA; Sapini, Y; Shah, M; Zafidah, W	1
Okamoto, Y; Sato, G; Yamashita, H; Yamawaki, S; Yoshimura, S	1
Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M	1
Leung, JG; Nelson, S	1
Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL	1
Goa, KL; McGavin, JK	1
Goodnick, PJ; Jerry, JM	1
Ali, MW; Carson, WH; Casey, DE; Ingenito, GG; Jody, D; Liebeskind, A; Saha, AR	1
Bailey, KP	1
Keck, PE; McElroy, SL	1
Buckley, PF	2
Bowles, TM; Levin, GM	1
Crismon, ML; DeLeon, A; Miller, AL	1
Kutscher, EC	1
Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E	1
Gasperoni, TL; Grady, MA; Kirkpatrick, P	1
Woods, SW	1
Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J	1
Carlsson, A; Grunder, G; Wong, DF	1
Kaplan, D; Koliatsos, V; Lindsey, RL; Sandson, NB; Walters, JK	1
Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A	1
Carson, WH; Ingenito, GG; Pigott, TA; Saha, AR; Stock, EG; Torbeyns, AF	1
Tamminga, CA	1
Winans, E	1
Carlsson, A; Carlsson, ML; Nilsson, M	1
Buckley, PF; Glazer, W; Sebastian, CS	1
DeQuardo, JR	1
Green, B	1
Lieberman, JA	1
Duggal, HS	1
El-Sayeh, HG; Morganti, C	2
Buchanan, RW; Buckley, PF; Chiles, JA; Conley, RR; Crismon, ML; Ereshefsky, L; Essock, SM; Finnerty, M; Hall, CS; Marder, SR; McEvoy, JP; Miller, A; Miller, DD; Rush, AJ; Saeed, SA; Schooler, NR; Shon, SP; Stroup, S; Tarin-Godoy, B	1
Crismon, ML; DeLeon, A; Patel, NC	1
Perry, CM; Swainston Harrison, T	1
Kasper, S; Winkler, D	1
Fear, C	1
Shayegan, DK; Stahl, SM	1
Chakraborty, N; Johnston, T	1
Tsai, SJ	1
Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Reddy, H	1
Lambert, M; Naber, D	1
Archibald, D; Carson, WH; Gharbia, NA; Jody, D; Marcus, R; McQuade, RD; Stock, E; Vanveggel, S	1
Bark, N; Citrome, L; Josiassen, R; Mallikaarjun, S; Salazar, DE	1
Bolonna, AA; Kerwin, RW	1
Cousins, DA; Young, AH	1
Burns, T; Dursun, S; Fahy, T; Frangou, S; Gray, R; Haddad, PM; Hunter, R; Taylor, DM; Travis, MJ; Young, AH	1
Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A	1
Launer, M	1
Kinghorn, WA; McEvoy, JP	1
Bartholomä, A; Gregor, A; Hein, J; Heinz, A; Juckel, G	1
Bridler, R	1
Alfers, J; Beresford, HF; Beresford, TP; Clapp, L; Martin, B; Wiberg, JL	1
Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA	1
Ostroff, R; Wahl, R	1
Been, A; de Bruijn, C; Vergouwen, AC	1
Hiemke, C; Kirschbaum, KM; Malevani, J; Mobascher, A; Müller, MJ; Saria, A; Zernig, G	1
Church, CO; Fugate, SE; Stevens, DL	1
Fleischhacker, WW	1
Annable, L; Beauclair, L; Chouinard, G; Kolivakis, TT; Margolese, HC; Miller, R	1
Hirose, T; Kikuchi, T	1
Folnegović-Smalc, V; Kozumplik, O; Mimica, N; Uzun, S	1
Odiyoor, M; Salmoiraghi, A	1
Duggal, V; Glick, ID; Hodulik, C	1
Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J	1
Borba, CP; Cather, C; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Kunkel, L; Louie, PM; Nguyen, DD	1
Bork, B; Christensen, A; Christensen, AF; Christensen, M; Nielsen, CT; Poulsen, J	1
Crandall, DT; Iwamoto, T; Kostic, D; Marcus, RN; McQuade, RD; Nyilas, M; Pans, M; Riera, LC; Stock, EG; Tandon, R	1
Raja, M	1
Baciu, D; Walther, S	1
Ebrecht, M; Göröcs, T; Gründer, G; Kungel, M; Modell, S	1
Harms, E; Kropp, S; Luebbe, G; Ziegenbein, M	1
Kantrowitz, JT; Srihari, VH; Tek, C	2
Kim, YK; Lee, BH; Park, SH	1
Clarke, LA; Kaushik, S; Lindenmayer, JP	1
Duggal, HS; Mendhekar, DN	1
Strawn, JR	1
Bahta, E; Levine, S; Manas, K; Reddymasu, S; Slay, LE	1
Bourin, M	1
Gaszner, P	1
Tsai, JF	1
Egger, C; Geretsegger, C; Muehlbacher, M; Nickel, M; Rauscher, A; Stuppaeck, C	1
Adams, CE; El-Sayeh, HG; Morganti, C	1
Crossman, AM; Lindenmayer, JP	1
Alla, L; Sabaratnam, M; Shastri, M	1
Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG	1
De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M	3
Gründer, G; Paulzen, M	1
Carson, WH; Cutler, AJ; Hardy, SA; Marcus, RN; McQuade, RD; O'Donnell, A	1
Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E	1
Fernald, DS; Hovens, JE; Loonen, AJ; van Dellen, RT	1
Kang, SG; Kim, L; Lee, HJ; Lee, MS; Park, JS	1
Harborne, GC; Karunakaran, K; Tungaraza, TE	1
Chrzanowski, WK; Marcus, RN; McQuade, RD; Nyilas, M; Torbeyns, A	1
Correll, CU; Frederickson, AM; Kane, JM; Manu, P	1
Kovács, G; Kovács, L	1
Andrezina, R; Carson, WH; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E	1
Dimopoulos, NP; Kararizou, EG; Katsa, AN; Katsanou, MN; Mitropoulos, PA; Mitsonis, CI; Tsakiris, FE	1
Chen, R; Johnson, JL; Jordan, S; Kambayashi, J; Kikuchi, T; Kitagawa, H; McQuade, R; Regardie, K; Tadori, Y	1
Hirose, T; Kameya, T; Kikuchi, T; Mamiya, N; Taguchi, M; Yamada, S	1
Padala, KP; Padala, PR; Sadiq, HJ	1
Abu-Tair, F; Bergemann, N; Kopitz, J	1
Chavez, B; Poveda, RA	1
Kropp, S; Wittmann, G; Ziegenbein, M	1
De Oliveira, IR; Juruena, MF	1
Cassano, GB; Fagiolini, A; Lattanzi, L; Monteleone, P; Niolu, C; Sacchetti, E; Siracusano, A; Vita, A	1
Liskow, BI; Moeller, KE; Shireman, TI	1
Arlien-Soborg, P; Kondziella, D	1
Oosterhuis, M; Tenback, D; Van De Kraats, G	1
Engel, JA; Fejgin, K; Klamer, D; Pålsson, E; Safonov, S; Svensson, L; Wass, C	1
Auby, P; Marcus, RN; McQuade, RD; Oren, DA; Sack, DA; Tran-Johnson, TK	1
Pinninti, NR; Sanghadia, M	1
Keller Ashton, A	1
Thomas, P	1
Limosin, F	1
Lamberti, JS; Olsen, D; Spurling, RD; Tang, W; Tu, X	1
Freeman, B; Gorman, JM; Levy, W	1
Chen, YY; Hung, GC	2
Boulton, DW; Citrome, L; Macher, JP; Mallikaarjun, S; Salazar, DE	1
Crandall, DT; Gutierrez-Esteinou, R; Lau, GS; Marcus, RN; Marder, SR; Pikalov, A; Pultz, JA; West, B	1
Chen, CH; Chen, SJ; Lin, CC; Shen, YC	1
Citrome, LL; Crandall, DT; Currier, GW; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL	1
Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL	1
Fan, XW; Luo, JW; Zeng, DZ	1
Banki, CM; Beuzen, JN; Hanssens, L; Herman, E; Kerwin, R; L'Italien, G; Lublin, H; McQuade, RD; Millet, B; Pans, M	1
Bienroth, M; Jones, M; Millar, H; Ratna, L; Sullivan, G; Taylor, D	1
Feldman, JJ; Rosenberg, J; Salzman, C	1
Cuffel, BJ; Loebel, AD; Mullins, CD; Naradzay, J; Obeidat, NA	1
Carson, WH; Daniel, DG; Marcus, RN; McEvoy, JP; McQuade, RD	1
Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM	1
Bourgeois, JA; Kahn, D	1
Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W	1
Forbes, RA; Kikuchi, T; Kitagawa, H; McQuade, RD; Stark, A; Tadori, Y	1
Adelbrecht, C; Allain, H; Bernardo, M; Janssen, F; Laughton, J; Lublin, H; Maier, W; Millar, H; Pans, M; Salokangas, RK; Smeraldi, E; Werner, C; Wolf, J	1
Wooten, J	1
Kessler, RM	1
Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH	1
Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM	1
Chiclana, C; Gonzalez, R; Lopez-Garcia, P	1
Burchardt, C; Hiemke, C; Kirschbaum, KM; Malevani, J; Mobascher, A; Müller, MJ; Piel, M	1
Chen, CH; Huang, MC; Lu, ML	2
Loebel, A; Siu, C; Warrington, L; Yang, R; Zimbroff, D	1
Allen, MH; Nordstrom, K	1
Carson, WH; Casey, DE; Kan, HJ; L'Italien, GJ; Marcus, RN	1
Atkinson, J; Fischetti, C; Jones, S; Sparshatt, A; Taylor, D	1
Chou, YH; Su, TP; Yang, KC	1
Keating, GM; Sanford, M	2
Bushe, CJ; Leonard, BE	1
Rosenheck, RA	1
Hettema, JM; Ross, DE	1
Lee, C; Lee, CU; Lim, HK; Pae, CU	1
Thone, J	1
Eudicone, JM; Kim, E; Miller, DD; Pikalov, A	1
Chou, SY; Chung, PC; Su, JA; Tsang, HY	1
Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ	1
Gonidakis, F; Papadimitriou, G; Ploubidis, D	1
Desseilles, M; Mathot, F	1
Gray, R; Jones, M	1
Bashir, M; Macrae, A; Shajahan, P; Taylor, M	1
Hughes, D; Morcos, M	1
Hazra, M; Mamo, DC; Remington, G	1
Poyurovsky, M; Weizman, A; Weizman, R	1
Sanford, M; Scott, LJ	1
Andersen, SE; Johansson, M; Manniche, C	1
Bianchi, F; Di Lorenzo, G; Leo, R; Razzini, C; Romeo, F; Siracusano, A; Tesauro, M; Zanasi, M	1
Ahn, YM; Chang, JS; Kang, UG; Kim, SH; Kim, YS; Lee, KY; Park, HJ	1
Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD	1
Boy, C; Bröcheler, A; Fellows, C; Gründer, G; Hellmann, S; Hiemke, C; Janouschek, H; Kirschbaum, KM; Rösch, F; Schaefer, WM; Spreckelmeyer, KM; Vernaleken, I; Veselinovic, T	1
Abi-Dargham, A; Alvarez, B; Bae, SA; Frankle, WG; Gil, R; Gonzales, R; Hackett, E; Kegeles, LS; Kim, JH; Laruelle, M; Slifstein, M; Xu, X	1
Hanssens, L; L'Italien, G; Loze, JY; Marcus, RN; Pans, M; Taylor, D	1
Blonde, L; Gutterman, EM; Hanssens, L; Kan, HJ; Kim, MS; L'Italien, GJ; McQuade, RD	1
Campanella, LM; Lartey, R; Shih, R	1
Strange, PG	1
Hwang, MY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS	1
Kelly, DL; Shim, JC; You, YS	1
Cañive, JM; Davis, JT; Edgar, JC; Lewine, JD; Miller, GA; Torres, F; Tuason, VB	1
Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP	1
Fourie, J; Ozdemir, V; Ozdener, F	1
Biziere, K; Bramer, S; Dannals, RF; Dogan, AS; Gründer, G; Ravert, H; Stephane, M; Suri, A; Wong, DF; Yokoi, F	1

Reviews

158 review(s) available for aripiprazole and Dementia Praecox

Article	Year
Aripiprazole in young people with early psychosis: a systematic review and meta-analysis of weight gain. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2022, Volume: 30, Issue:1 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Weight Gain	2022
Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC psychiatry, 2022, 05-28, Volume: 22, Issue:1 Topics: Adult; Aripiprazole; Delphi Technique; Dopamine; Dopamine Agonists; Female; Humans; Pregnancy; Schizophrenia	2022
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs. Pharmacopsychiatry, 2022, Volume: 55, Issue:5 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Humans; Lurasidone Hydrochloride; Molindone; Olanzapine; Paliperidone Palmitate; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Systematic Reviews as Topic	2022
Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis. Pharmacopsychiatry, 2022, Volume: 55, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Administration Schedule; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Schizophrenia	2022
Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice. International journal of psychiatry in clinical practice, 2023, Volume: 27, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dopamine; Humans; Psychiatry; Schizophrenia	2023
New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. International journal of molecular sciences, 2022, Sep-13, Volume: 23, Issue:18 Topics: Antipsychotic Agents; Aripiprazole; Depression; Humans; Lurasidone Hydrochloride; Psychotropic Drugs; Schizophrenia	2022
Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China. Frontiers in public health, 2022, Volume: 10 Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Humans; Lurasidone Hydrochloride; Olanzapine; Risperidone; Schizophrenia	2022
Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis. Psychopharmacology, 2022, Volume: 239, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Humans; Reference Values; Schizophrenia	2022
Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms. Pharmacological reports : PR, 2023, Volume: 75, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Drug-Related Side Effects and Adverse Reactions; Humans; Polymorphism, Genetic; Schizophrenia	2023
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia. BMJ mental health, 2023, Volume: 26, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Haloperidol; Humans; Mania; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia	2023
Narrative review of the advances in the pharmacotherapeutic management of juvenile-onset schizophrenia. Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:9 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Humans; Lurasidone Hydrochloride; Quetiapine Fumarate; Schizophrenia; Young Adult	2023
Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review. International journal of psychiatry in clinical practice, 2023, Volume: 27, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Schizophrenia	2023
Differentiating the third generation of antipsychotics: a focus on lumateperone's similarities and differences. International clinical psychopharmacology, 2024, Jan-01, Volume: 39, Issue:1 Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Schizophrenia; Weight Gain	2024
Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders. Current psychiatry reports, 2023, Volume: 25, Issue:11 Topics: Aged; Antipsychotic Agents; Aripiprazole; Estrogens; Female; Humans; Hyperprolactinemia; Male; Raloxifene Hydrochloride; Schizophrenia	2023
Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Cost of Illness; Cost-Benefit Analysis; Humans; Models, Economic; Research Design; Schizophrenia	2020
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. The American journal of psychiatry, 2020, 04-01, Volume: 177, Issue:4 Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes	2020
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology, 2020, Volume: 237, Issue:5 Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Network Meta-Analysis; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain	2020
Clozapine-Associated Obsessive-Compulsive Symptoms and Their Management: A Systematic Review and Analysis of 107 Reported Cases. Psychotherapy and psychosomatics, 2020, Volume: 89, Issue:3 Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Obsessive-Compulsive Disorder; Schizophrenia	2020
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials. International clinical psychopharmacology, 2020, Volume: 35, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome	2020
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS drugs, 2020, Volume: 34, Issue:5 Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Thiophenes	2020
Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Expert opinion on drug metabolism & toxicology, 2020, Volume: 16, Issue:12 Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Models, Theoretical; Polypharmacy; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Schizophrenia	2020
Aripiprazole in Children and Adolescents. Journal of child and adolescent psychopharmacology, 2021, Volume: 31, Issue:1 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Drug-Related Side Effects and Adverse Reactions; Humans; Off-Label Use; Schizophrenia; Tourette Syndrome; Weight Gain	2021
A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert opinion on drug safety, 2020, Volume: 19, Issue:12 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Administration Schedule; Humans; Medication Adherence; Prolactin; Schizophrenia	2020
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis. Drug and alcohol dependence, 2021, 02-01, Volume: 219 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network Meta-Analysis; Olanzapine; Patient Dropouts; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia	2021
Amisulpride - is it as all other medicines or is it different? An update. Psychiatria polska, 2020, Oct-31, Volume: 54, Issue:5 Topics: Administration, Oral; Amisulpride; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Neurosecretory Systems; Olanzapine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology	2020
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. The American journal of psychiatry, 2021, 05-01, Volume: 178, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Patient Acceptance of Health Care; Phenothiazines; Psychotic Disorders; Risperidone; Schizophrenia; Secondary Prevention	2021
Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. CNS spectrums, 2022, Volume: 27, Issue:5 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Humans; Mental Health; Olanzapine; Prolactin; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia	2022
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. The Cochrane database of systematic reviews, 2017, 03-23, Volume: 3 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain	2017
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. Advances in therapy, 2017, Volume: 34, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections; Male; Middle Aged; Recurrence; Schizophrenia	2017
Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. International clinical psychopharmacology, 2017, Volume: 32, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Humans; Injections, Intramuscular; Paliperidone Palmitate; Schizophrenia; Treatment Outcome	2017
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review. Drugs, 2017, Volume: 77, Issue:13 Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Drug Therapy, Combination; Humans; Meta-Analysis as Topic; Psychotic Disorders; Quality of Life; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology	2017
Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2018, Volume: 26, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes	2018
Aripiprazole Lauroxil: A Review in Schizophrenia. Drugs, 2017, Volume: 77, Issue:18 Topics: Antipsychotic Agents; Aripiprazole; Humans; Injections, Intramuscular; Recurrence; Schizophrenia	2017
Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. Current medical research and opinion, 2018, Volume: 34, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Bayes Theorem; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Network Meta-Analysis; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain	2018
Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. Journal of affective disorders, 2018, 03-01, Volume: 228 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Breast Feeding; Female; Humans; Infant; Lactation; Peripartum Period; Pregnancy; Pregnancy Complications; Prospective Studies; Psychotropic Drugs; Retrospective Studies; Schizophrenia	2018
Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. European journal of clinical pharmacology, 2018, Volume: 74, Issue:10 Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Cholesterol; Glucose Metabolism Disorders; Humans; Lipid Metabolism; Schizophrenia; Treatment Outcome; Weight Gain	2018
Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC psychiatry, 2018, 09-03, Volume: 18, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Polypharmacy; Prospective Studies; Schizophrenia; Systematic Reviews as Topic	2018
Aripiprazole: An FDA Approved Bioactive Compound to Treat Schizophrenia- A Mini Review. Current drug discovery technologies, 2020, Volume: 17, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Drug Approval; Humans; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome; United States; United States Food and Drug Administration	2020
Use of cariprazine in psychiatric disorders: A systematic review. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2018, Volume: 30, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder; Humans; Piperazines; Risperidone; Schizophrenia	2018
[Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact]. L'Encephale, 2018, Volume: 44, Issue:6 Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Psychotic Disorders; Schizophrenia	2018
[Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France]. L'Encephale, 2018, Volume: 44, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; France; Humans; Paliperidone Palmitate; Quality of Life; Schizophrenia; Schizophrenic Psychology	2018
Brexpiprazole: A Review in Schizophrenia. Drugs, 2019, Volume: 79, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Approval; Humans; Japan; Quinolones; Schizophrenia; Serotonin Receptor Agonists; Thiophenes; United States	2019
Aripiprazole with digital ingestion tracking (Abilify MyCite). The Medical letter on drugs and therapeutics, 2019, Jan-28, Volume: 61, Issue:1564 Topics: Antipsychotic Agents; Aripiprazole; Biosensing Techniques; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder, Major; Gastrointestinal Absorption; Humans; Schizophrenia; Signal Processing, Computer-Assisted	2019
Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. CNS spectrums, 2020, Volume: 25, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Humans; Injections; Nanoparticles; Schizophrenia	2020
Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review. Clinical drug investigation, 2019, Volume: 39, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Delayed-Action Preparations; Humans; Injections, Intramuscular; Male; Recurrence; Schizophrenia	2019
Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2013, Feb-28, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles	2013
Long-acting injectable aripiprazole: how might it fit in our tool box? Clinical schizophrenia & related psychoses, 2013,Summer, Volume: 7, Issue:2 Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Humans; Injections; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; United States	2013
[Aripiprazole as "dopamine sensitivity stabilizer"]. Nihon rinsho. Japanese journal of clinical medicine, 2013, Volume: 71, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine; Schizophrenia	2013
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology, 2013, Volume: 228, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Piperazines; Practice Guidelines as Topic; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology	2013
[Efficacy of aripiprazole (amdoal) in the long-term treatment of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Follow-Up Studies; Humans; Piperazines; Quinolones; Schizophrenia; Time Factors; Treatment Outcome	2013
Long-acting injectable aripiprazole (Abilify Maintena) for schizophrenia. The Medical letter on drugs and therapeutics, 2013, Apr-29, Volume: 55, Issue:1415 Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Injections; Piperazines; Quinolones; Schizophrenia; Time Factors	2013
Schizophrenia. BMJ clinical evidence, 2012, Jun-28, Volume: 2012 Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Risperidone; Schizophrenia; Treatment Outcome	2012
Atypical antipsychotics for psychosis in adolescents. The Cochrane database of systematic reviews, 2013, Oct-15, Issue:10 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Molindone; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia	2013
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. The Journal of clinical psychiatry, 2013, Volume: 74, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Drug Substitution; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Lipids; Olanzapine; Patient Outcome Assessment; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology	2013
Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents? Future medicinal chemistry, 2014, Volume: 6, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Humans; Isoquinolines; Piperazines; Protein Binding; Quinolines; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Sulfonamides	2014
Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2014, Jan-02, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia	2014
[Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?]. L'Encephale, 2014, Volume: 40, Issue:1 Topics: Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Hostility; Humans; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2014
Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs, 2014, Volume: 74, Issue:10 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia	2014
A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. Expert opinion on drug safety, 2014, Volume: 13, Issue:12 Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Postpartum Period; Pregnancy; Psychotic Disorders; Quinolones; Schizophrenia	2014
[In vitro pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2014, Volume: 144, Issue:6 Topics: Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Cricetulus; Depression; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Synaptic Transmission	2014
Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic & clinical pharmacology & toxicology, 2015, Volume: 116, Issue:4 Topics: Abnormalities, Drug-Induced; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Olanzapine; Pregnancy; Pregnancy Complications; Quetiapine Fumarate; Risperidone; Schizophrenia	2015
Initiation of aripiprazole once-monthly in patients with schizophrenia. Current medical research and opinion, 2015, Volume: 31, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomedical Research; Delayed-Action Preparations; Drug Administration Schedule; Drug Monitoring; Drug Substitution; Female; Humans; Injections; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2015
Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. Journal of psychiatric research, 2015, Volume: 62 Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Humans; Randomized Controlled Trials as Topic; Schizophrenia	2015
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. International journal of psychiatry in medicine, 2015, Volume: 49, Issue:1 Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Fluoxetine; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology	2015
The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis. Current neuropharmacology, 2015, Volume: 13, Issue:5 Topics: Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Aripiprazole; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Incidence; Lurasidone Hydrochloride; Schizophrenia	2015
Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert review of clinical pharmacology, 2016, Volume: 9, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Injections; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome	2016
Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia. Proteomics. Clinical applications, 2016, Volume: 10, Issue:4 Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Chlorpromazine; Clozapine; Disease Models, Animal; Gene Expression Regulation; Glycolysis; Humans; Mitochondrial Proteins; Nerve Tissue Proteins; Oxidative Phosphorylation; Proteome; Proteomics; Schizophrenia; Treatment Outcome	2016
A review of aripiprazole long-acting injection. Current medical research and opinion, 2016, Volume: 32, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Hospitalization; Humans; Paliperidone Palmitate; Quality of Life; Schizophrenia	2016
Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Administration Schedule; Drug Partial Agonism; Humans; Injections, Intramuscular; Randomized Controlled Trials as Topic; Receptors, Dopamine D2; Schizophrenia	2016
Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents. Clinical schizophrenia & related psychoses, 2016,spring, Volume: 10, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Psychotic Disorders; Schizophrenia; United States	2016
Risperidone (depot) for schizophrenia. The Cochrane database of systematic reviews, 2016, Apr-14, Volume: 4 Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delayed-Action Preparations; Humans; Olanzapine; Patient Dropouts; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia	2016
Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole. Folia medica, 2016, 03-01, Volume: 58, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Dopamine; Humans; Schizophrenia; Schizophrenic Psychology	2016
Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia: Meta-Analysis of Randomized Controlled Trials. Journal of clinical psychopharmacology, 2016, Volume: 36, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Drug Synergism; Humans; Randomized Controlled Trials as Topic; Schizophrenia	2016
Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions. The Journal of clinical psychiatry, 2016, Volume: 77, Issue:9 Topics: Anti-Obesity Agents; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Fructose; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Schizophrenia; Topiramate	2016
Aripiprazole vs. Placebo or Haloperidol for Schizophrenia. American family physician, 2016, Dec-01, Volume: 94, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Haloperidol; Humans; Schizophrenia; Treatment Outcome	2016
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next? CNS spectrums, 2016, Volume: 21, Issue:S1 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Paliperidone Palmitate; Piperazines; Quinolones; Schizophrenia; Tetrabenazine; Thiophenes; Valine	2016
[Present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. L'Encephale, 2008, Volume: 34, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Administration Schedule; Follow-Up Studies; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome	2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 4 Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure	2008
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature]. L'Encephale, 2008, Volume: 34, Issue:2 Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome	2008
Aripiprazole versus typical antipsychotic drugs for schizophrenia. The Cochrane database of systematic reviews, 2008, Jul-16, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia	2008
The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Schizophrenia research, 2008, Volume: 105, Issue:1-3 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2008
Clinical trials with a new atypical antipsychotic (Aripiprazole): gender specific information analysis. Women & health, 2008, Volume: 47, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sex Distribution; Treatment Outcome; United States; United States Food and Drug Administration	2008
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophrenia research, 2008, Volume: 106, Issue:2-3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol; Cholesterol, HDL; Endpoint Determination; Female; Humans; Lipoproteins; Male; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome; Triglycerides	2008
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evidence-Based Medicine; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult	2009
[A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole]. L'Encephale, 2009, Volume: 35, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Brain; Humans; Neurons; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Synaptic Transmission	2009
A review of the safety and tolerability of aripiprazole. Expert opinion on drug safety, 2009, Volume: 8, Issue:3 Topics: Animals; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia	2009
Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS drugs, 2009, Volume: 23, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia	2009
[A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists]. Annales pharmaceutiques francaises, 2009, Volume: 67, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Design; Dyskinesia, Drug-Induced; History, 20th Century; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia	2009
Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia	2009
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:7 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2010
Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clinical therapeutics, 2010, Volume: 32 Suppl 1 Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Nausea; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain; Young Adult	2010
Olanzapine versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2010, Mar-17, Issue:3 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles	2010
[Action of amygdala dopamine and effect of antipsychotics]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2010, Volume: 30, Issue:2 Topics: Amygdala; Animals; Antipsychotic Agents; Aripiprazole; Catecholamines; Conditioning, Classical; Dopamine; Fear; Haloperidol; Humans; Piperazines; Quinolones; Rats; Schizophrenia; Schizophrenic Psychology; Stress, Psychological	2010
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia research, 2010, Volume: 123, Issue:2-3 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain	2010
Aripiprazole for late-life schizophrenia. Clinical interventions in aging, 2010, Sep-07, Volume: 5 Topics: Aged; Aging; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia	2010
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. Sao Paulo medical journal = Revista paulista de medicina, 2010, Volume: 128, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Isoxazoles; Meta-Analysis as Topic; Paliperidone Palmitate; Piperazines; Placebos; Pyrimidines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Review Literature as Topic; Risperidone; Schizophrenia; Treatment Outcome	2010
Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Psychopharmacology bulletin, 2010, Volume: 43, Issue:2 Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Evidence-Based Medicine; Female; Humans; Male; Multicenter Studies as Topic; Olanzapine; Patient Selection; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2010
Switching and combining antipsychotics. CNS spectrums, 2010, Volume: 15, Issue:4 Suppl 6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Decision Making; Female; Humans; Olanzapine; Piperazines; Polypharmacy; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Weight Gain	2010
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Dibenzothiazepines; Drug Substitution; Fasting; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia; Weight Gain	2010
Risperidone versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2011, Jan-19, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles	2011
Aripiprazole versus placebo for schizophrenia. The Cochrane database of systematic reviews, 2011, Aug-10, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Humans; Patient Dropouts; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia	2011
Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert review of neurotherapeutics, 2011, Volume: 11, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones; Schizophrenia	2011
Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. Journal of clinical pharmacy and therapeutics, 2012, Volume: 37, Issue:3 Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sex Characteristics; Treatment Outcome; Young Adult	2012
Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS drugs, 2012, Feb-01, Volume: 26, Issue:2 Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemia; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Weight Gain	2012
Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review. Journal of affective disorders, 2012, Volume: 138 Suppl Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia	2012
Is rational antipsychotic polytherapy feasible? A selective review. Current psychiatry reports, 2012, Volume: 14, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Haloperidol; Humans; Piperazines; Prolactin; Quinolones; Schizophrenia	2012
Efficacy and safety of aripiprazole in child and adolescent patients. European child & adolescent psychiatry, 2012, Volume: 21, Issue:7 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Bipolar Disorder; Child; Humans; Piperazines; Quinolones; Schizophrenia	2012
Aripiprazole vs placebo for schizophrenia. Schizophrenia bulletin, 2012, Volume: 38, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia	2012
Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. Journal of sex & marital therapy, 2012, Volume: 38, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Male; Piperazines; Psychotic Disorders; Purines; Quinolones; Schizophrenia; Schizophrenic Psychology; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Vasodilator Agents	2012
[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2012, Volume: 32, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Cells, Cultured; Colforsin; Dopamine D2 Receptor Antagonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia	2012
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. The international journal of neuropsychopharmacology, 2014, Volume: 17, Issue:7 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clozapine; Humans; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quinolones; Schizophrenia	2014
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert opinion on drug safety, 2012, Volume: 11, Issue:5 Topics: Adult; Affective Disorders, Psychotic; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Hypercholesterolemia; Incidence; Pharmacovigilance; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles	2012
Torticollis after low-dose aripiprazole administration in a Thai schizophrenia patient. Asian journal of psychiatry, 2012, Volume: 5, Issue:4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Torticollis; Young Adult	2012
Aripiprazole. CNS drugs, 2002, Volume: 16, Issue:11 Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Cognition; Humans; Meta-Analysis as Topic; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome	2002
Aripiprazole: profile on efficacy and safety. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:12 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain; Cardiovascular System; Clinical Trials as Topic; Digestive System; Dyskinesia, Drug-Induced; Humans; Mental Disorders; Piperazines; Quinolones; Schizophrenia	2002
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert opinion on investigational drugs, 2003, Volume: 12, Issue:4 Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia	2003
Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic. Drugs of today (Barcelona, Spain : 1998), 2003, Volume: 39, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome	2003
Aripiprazole: a new atypical antipsychotic drug. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Humans; Piperazines; Quinolones; Schizophrenia	2003
Aripiprazole: quite possibly a new type of antipsychotic. South Dakota journal of medicine, 2003, Volume: 56, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia	2003
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research, 2003, Jun-01, Volume: 61, Issue:2-3 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology	2003
Chlorpromazine equivalent doses for the newer atypical antipsychotics. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles	2003
Mechanism of new antipsychotic medications: occupancy is not just antagonism. Archives of general psychiatry, 2003, Volume: 60, Issue:10 Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Prolactin; Putamen; Quinolones; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed	2003
Schizophrenia: from dopamine to glutamate and back. Current medicinal chemistry, 2004, Volume: 11, Issue:3 Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Mice; Piperazines; Piperidines; Quinolones; Schizophrenia	2004
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Current medicinal chemistry, 2004, Volume: 11, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Piperazines; Polypharmacy; Quetiapine Fumarate; Quinolones; Research Design; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome	2004
Focus on aripiprazole. Current medical research and opinion, 2004, Volume: 20, Issue:2 Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia	2004
Dopamine partial agonists: a new class of antipsychotic. CNS drugs, 2004, Volume: 18, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine; Dopamine Agonists; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin; Treatment Outcome	2004
Aripiprazole for schizophrenia. The Cochrane database of systematic reviews, 2004, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia	2004
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:4 Topics: Algorithms; Ambulatory Care; Ambulatory Care Facilities; Antipsychotic Agents; Aripiprazole; Clozapine; Decision Trees; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; Schizophrenic Psychology; Texas; Thiazoles; Treatment Outcome	2004
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical therapeutics, 2004, Volume: 26, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia	2004
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs, 2004, Volume: 64, Issue:15 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Metabolic Clearance Rate; Piperazines; Psychotic Disorders; Quinolones; Receptors, Neurotransmitter; Schizophrenia; Tissue Distribution; Treatment Outcome	2004
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase III as Topic; Haloperidol; Humans; Meta-Analysis as Topic; Piperazines; Quinolones; Risperidone; Schizophrenia; Time Factors	2004
Partial agonism and schizophrenia. The British journal of psychiatry : the journal of mental science, 2005, Volume: 186 Topics: Antipsychotic Agents; Aripiprazole; Binding Sites; Brain; Dopamine; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia	2005
Second-generation antipsychotic medications in the treatment of mood disorders: focus on aripiprazole. Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Humans; Mood Disorders; Piperazines; Quinolones; Schizophrenia	2005
Partial dopamine agonists in schizophrenia. Hospital medicine (London, England : 1998), 2005, Volume: 66, Issue:5 Topics: Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2005
Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert review of neurotherapeutics, 2005, Volume: 5, Issue:3 Topics: Animals; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Schizophrenia	2005
Aripiprazole. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:12 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology	2005
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2005, Volume: 50, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Incidence; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles	2005
Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. The journal of medical investigation : JMI, 2005, Volume: 52 Suppl Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Molecular Structure; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia	2005
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome	2005
Aripiprazole for schizophrenia. The Cochrane database of systematic reviews, 2006, Apr-19, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia	2006
Aripiprazole for schizophrenia. Systematic review. The British journal of psychiatry : the journal of mental science, 2006, Volume: 189 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Patient Compliance; Piperazines; Prolactin; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia; Treatment Outcome	2006
[The antipsychotic drug aripiprazole (ABILIFY)]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2006, Volume: 128, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia	2006
Treatment of psychosis: 30 years of progress. Journal of clinical pharmacy and therapeutics, 2006, Volume: 31, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles	2006
The stable patient with schizophrenia--from antipsychotic effectiveness to adherence. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2007, Volume: 17 Suppl 2 Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Metabolic Syndrome; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology	2007
[The use of atypical antipsychotics in the long-term care of schizophrenia]. L'Encephale, 2006, Volume: 32 Pt 3 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors	2006
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophrenia research, 2007, Volume: 95, Issue:1-3 Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Haloperidol; Humans; Longitudinal Studies; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Schizophrenic Psychology; Survival Analysis; Treatment Outcome	2007
Metabolic effects of the atypical antipsychotics. Southern medical journal, 2007, Volume: 100, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles	2007
Managing the acutely agitated and psychotic patient. CNS spectrums, 2007, Volume: 12, Issue:10 Suppl 1 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Emergencies; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles	2007
Aripiprazole: in adolescents with schizophrenia. Paediatric drugs, 2007, Volume: 9, Issue:6 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia	2007
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines; Quinolones; Schizophrenia	2007
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:12 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome	2007
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Sleep Stages; Thiazoles; Treatment Outcome	2008
Aripiprazole versus typicals for schizophrenia. The Cochrane database of systematic reviews, 2008, Jan-23, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia	2008
Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS drugs, 2008, Volume: 22, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Injections, Intramuscular; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia	2008
Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends in pharmacological sciences, 2008, Volume: 29, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Inverse Agonism; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Signal Transduction	2008
Aripiprazole in adolescents with schizophrenia: profile report. CNS drugs, 2008, Volume: 22, Issue:6 Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia	2008
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS drugs, 2002, Volume: 16, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles	2002
Aripiprazole (Otsuka Pharmaceutical Co). Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:1 Topics: Animals; Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Dopamine Antagonists; Humans; Piperazines; Quinolones; Schizophrenia; Technology, Pharmaceutical	2002

Trials

211 trial(s) available for aripiprazole and Dementia Praecox

Article	Year
Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. BMC psychiatry, 2021, 10-08, Volume: 21, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Patient Reported Outcome Measures; Quality of Life; Schizophrenia; Treatment Outcome	2021
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study. Psychiatry and clinical neurosciences, 2022, Volume: 76, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Japan; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Piperazines; Piperidines; Remission Induction; Schizophrenia; Social Interaction; Treatment Outcome	2022
Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study. Psychopharmacology, 2022, Volume: 239, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Humans; Schizophrenia; Treatment Outcome	2022
Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial. Schizophrenia research, 2022, Volume: 246 Topics: Adverse Childhood Experiences; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Prospective Studies; Risperidone; Schizophrenia	2022
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial. Current neuropharmacology, 2023, Volume: 21, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia; Treatment Outcome	2023
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs, 2023, Volume: 37, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Delayed-Action Preparations; Female; Humans; Injections; Male; Middle Aged; Schizophrenia	2023
Efficacy of transcutaneous electrical acupoint stimulation for patients with first-episode schizophrenia: An 8-week, preliminary, randomized controlled trial. Psychiatry research, 2023, Volume: 325 Topics: Acupuncture Points; Antipsychotic Agents; Aripiprazole; Humans; Schizophrenia; Transcutaneous Electric Nerve Stimulation	2023
Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial. BMC psychiatry, 2023, 06-29, Volume: 23, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia	2023
Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial. BMC medicine, 2023, 07-19, Volume: 21, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Risperidone; Schizophrenia; Treatment Outcome	2023
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study. The Journal of clinical psychiatry, 2023, 09-04, Volume: 84, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Humans; Schizophrenia	2023
An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. Journal of psychopharmacology (Oxford, England), 2019, Volume: 33, Issue:10 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Risperidone; Schizophrenia; Young Adult	2019
[Aripiprazole and quetiapine in the treatment of patients with 'dual diagnosis' of schizophrenia and drug addiction]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2019, Volume: 119, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Dibenzothiazepines; Humans; Male; Psychiatric Status Rating Scales; Quetiapine Fumarate; Schizophrenia; Substance-Related Disorders; Treatment Outcome	2019
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. The international journal of neuropsychopharmacology, 2020, 04-23, Volume: 23, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult	2020
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial. The Journal of clinical psychiatry, 2020, 03-24, Volume: 81, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Triglycerides	2020
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study. The Journal of clinical psychiatry, 2020, 05-19, Volume: 81, Issue:3 Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Hospitalization; Humans; Injections, Intramuscular; Middle Aged; Paliperidone Palmitate; Patient Discharge; Schizophrenia; Young Adult	2020
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. CNS drugs, 2020, Volume: 34, Issue:9 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Treatment Outcome	2020
Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. JAMA psychiatry, 2020, 12-01, Volume: 77, Issue:12 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Follow-Up Studies; Hospitalization; Humans; Injections; Male; Outcome Assessment, Health Care; Schizophrenia; Time Factors; Young Adult	2020
Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study. The Journal of clinical psychiatry, 2020, 08-18, Volume: 81, Issue:5 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Time Factors; Treatment Outcome; Young Adult	2020
The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. International clinical psychopharmacology, 2020, Volume: 35, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Humans; Male; Middle Aged; Psychoses, Substance-Induced; Schizophrenia; Young Adult	2020
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2020, Volume: 39 Topics: Adult; Antipsychotic Agents; Aripiprazole; Energy Metabolism; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Time Factors; Weight Gain; Young Adult	2020
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. The lancet. Psychiatry, 2020, Volume: 7, Issue:11 Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Norway; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Treatment Outcome; Weight Gain; Young Adult	2020
Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? BMC psychiatry, 2020, 11-23, Volume: 20, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Biomarkers; Humans; Prolactin; Schizophrenia	2020
Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Schizophrenia research, 2017, Volume: 190 Topics: Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2017
Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. BMC psychiatry, 2017, 04-04, Volume: 17, Issue:1 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clinical Protocols; Humans; Injections, Intramuscular; Loxapine; Male; Middle Aged; Psychomotor Agitation; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult	2017
Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Humans; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia	2017
Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study. Progress in neuro-psychopharmacology & biological psychiatry, 2017, 10-03, Volume: 79, Issue:Pt B Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Emotions; Female; Humans; Interview, Psychological; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Problem Solving; Risperidone; Schizophrenia; Schizophrenic Psychology; Single-Blind Method; Social Perception; Treatment Outcome	2017
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology, 2017, Volume: 234, Issue:17 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Young Adult	2017
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. CNS drugs, 2017, Volume: 31, Issue:7 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections; Male; Middle Aged; Models, Biological; Psychotic Disorders; Schizophrenia	2017
Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. CNS spectrums, 2018, Volume: 23, Issue:4 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Schizophrenia	2018
Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, Volume: 56, Issue:9 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia	2017
A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Outcome Assessment, Health Care; Schizophrenia	2017
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol; Delayed-Action Preparations; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Injections, Intramuscular; Male; Middle Aged; Outpatients; Prolactin; Schizophrenia; Triglycerides; Weight Gain; Young Adult	2017
Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cocaine-Related Disorders; Comorbidity; Craving; Diagnosis, Dual (Psychiatry); Dopamine Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Perphenazine; Schizophrenia	2017
Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. Drug research, 2018, Volume: 68, Issue:7 Topics: Antipsychotic Agents; Aripiprazole; Estradiol; Female; Humans; Middle Aged; Prolactin; Prospective Studies; Retrospective Studies; Risperidone; Schizophrenia; Testosterone	2018
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA. Journal of comparative effectiveness research, 2018, Volume: 7, Issue:7 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administration Schedule; Drug Costs; Female; Humans; Injections, Intramuscular; Male; Markov Chains; Middle Aged; Paliperidone Palmitate; Piperazines; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Young Adult	2018
PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2018, Volume: 28, Issue:6 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Injections, Intramuscular; Loxapine; Male; Middle Aged; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Single-Blind Method; Treatment Outcome; Young Adult	2018
Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan. Psychiatry and clinical neurosciences, 2018, Volume: 72, Issue:9 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Schizophrenia; Treatment Outcome	2018
Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. CNS spectrums, 2019, Volume: 24, Issue:4 Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Injections; Long Term Adverse Effects; Male; Middle Aged; Schizophrenia	2019
Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia. Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:5 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Schizophrenia; Treatment Outcome	2018
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS spectrums, 2019, Volume: 24, Issue:4 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Drug Tolerance; Female; Humans; Long Term Adverse Effects; Male; Middle Aged; Schizophrenia	2019
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophrenia research, 2019, Volume: 204 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Young Adult	2019
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. The international journal of neuropsychopharmacology, 2018, 12-01, Volume: 21, Issue:12 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Male; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Young Adult	2018
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC psychiatry, 2018, 11-14, Volume: 18, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Prospective Studies; Schizophrenia; Treatment Outcome; Young Adult	2018
Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. Psychiatry research, 2019, Volume: 274 Topics: Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Social Behavior; Time Factors; Treatment Outcome; Young Adult	2019
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC psychiatry, 2019, 04-16, Volume: 19, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Canada; Cohort Studies; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Weight Gain; Young Adult	2019
Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. The Journal of clinical psychiatry, 2019, 04-23, Volume: 80, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cohort Studies; Decision Making, Shared; Delayed-Action Preparations; Early Medical Intervention; Female; Humans; Injections; Male; Patient Acceptance of Health Care; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; United States; Young Adult	2019
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis. BMJ open, 2019, 06-27, Volume: 9, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Biosensing Techniques; Cloud Computing; Humans; Medical Informatics Applications; Medication Adherence; Mobile Applications; Multicenter Studies as Topic; Olanzapine; Pragmatic Clinical Trials as Topic; Psychiatry; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Tablets; United Kingdom	2019
Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult	2013
Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy, 2013, Volume: 33, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Hospitals, University; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Young Adult	2013
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia. Human psychopharmacology, 2013, Volume: 28, Issue:3 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sex Factors; Young Adult	2013
Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International clinical psychopharmacology, 2013, Volume: 28, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Humans; Incidence; Injections, Intramuscular; Maintenance Chemotherapy; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sleep Initiation and Maintenance Disorders; Weight Gain; Young Adult	2013
Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of medical economics, 2013, Volume: 16, Issue:7 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Community Mental Health Services; Cross-Over Studies; Delayed-Action Preparations; Female; Hospitalization; Humans; Injections, Intramuscular; Male; North America; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index; Standard of Care	2013
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC psychiatry, 2013, May-22, Volume: 13 Topics: Adolescent; Adult; Aged; Amino Acids; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Standard of Care; Treatment Outcome; Young Adult	2013
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Disease-Free Survival; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Italy; Kaplan-Meier Estimate; Linear Models; Multivariate Analysis; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome	2013
Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Chemistry, Pharmaceutical; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors; Treatment Outcome	2013
Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, Volume: 52, Issue:7 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Humans; Piperazines; Placebos; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Sensitivity and Specificity; Time Factors; Treatment Outcome	2013
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Current medical research and opinion, 2013, Volume: 29, Issue:10 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Risk Factors; Schizophrenia; Sex Factors; Time Factors	2013
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophrenia research, 2013, Volume: 150, Issue:1 Topics: Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors	2013
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC psychiatry, 2013, Aug-22, Volume: 13 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Protocols; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Research Design; Schizophrenia	2013
Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia. BMC psychiatry, 2013, Oct-03, Volume: 13 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Protocols; Female; Humans; Japan; Longitudinal Studies; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Remission Induction; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Treatment Outcome	2013
Predictive value of prospective memory for remission in first-episode schizophrenia. Perspectives in psychiatric care, 2014, Volume: 50, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Memory, Episodic; Olanzapine; Piperazines; Prognosis; Quinolones; Remission Induction; Risperidone; Schizophrenia; Treatment Outcome; Young Adult	2014
Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Dopamine Antagonists; Drug Monitoring; Emotional Intelligence; Female; Humans; Male; Memory, Short-Term; Middle Aged; Netherlands; Patient Dropouts; Reaction Time; Recognition, Psychology; Risperidone; Schizophrenia; Social Behavior Disorders; Young Adult	2014
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. Human psychopharmacology, 2014, Volume: 29, Issue:1 Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Follow-Up Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Receptors, Adrenergic, alpha-2; Schizophrenia; Thiazoles; Weight Gain; Weight Loss	2014
Efﬁcacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Human psychopharmacology, 2012, Volume: 27, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult	2012
Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia. Psychiatry and clinical neurosciences, 2014, Volume: 68, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Synergism; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Behavior; Young Adult	2014
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophrenia research, 2014, Volume: 153, Issue:1-3 Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult	2014
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. BMC psychiatry, 2014, Feb-23, Volume: 14 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Olanzapine; Outpatients; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome	2014
Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia. Human psychopharmacology, 2014, Volume: 29, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome	2014
[The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014, Volume: 114, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Obesity; Piperazines; Quinolones; Schizophrenia; Withholding Treatment	2014
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. The British journal of psychiatry : the journal of mental science, 2014, Volume: 205, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Young Adult	2014
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. Schizophrenia research, 2014, Volume: 157, Issue:1-3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hyperprolactinemia; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Weight Gain	2014
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. BMC psychiatry, 2014, Jul-11, Volume: 14 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Patient Selection; Piperazines; Psychotic Disorders; Quality of Life; Quetiapine Fumarate; Quinolones; Sample Size; Schizophrenia	2014
Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry, 2014, Volume: 75, Issue:11 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Placebos; Quinolones; Schizophrenia; Treatment Outcome	2014
Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophrenia research, 2014, Volume: 159, Issue:2-3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Biological Availability; Buttocks; Delayed-Action Preparations; Deltoid Muscle; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult	2014
Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia research, 2014, Volume: 159, Issue:2-3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Interpersonal Relations; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Self Care; Social Behavior; Treatment Outcome	2014
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia. Clinical schizophrenia & related psychoses, 2015, Volume: 8, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome	2015
Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA psychiatry, 2015, Volume: 72, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cerebral Cortex; Connectome; Corpus Striatum; Drug Monitoring; Episode of Care; Female; Humans; Magnetic Resonance Imaging; Male; Neural Pathways; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Treatment Outcome	2015
The Chinese First-Episode Schizophrenia Trial: background and study design. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, 2014, Volume: 24, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Quinolones; Research Design; Risperidone; Schizophrenia; Treatment Outcome	2014
Schizophrenia gene expression profile reverted to normal levels by antipsychotics. The international journal of neuropsychopharmacology, 2014, Oct-31, Volume: 18, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Longitudinal Studies; Male; Olanzapine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Transcriptome; Treatment Outcome	2014
Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophrenia research, 2015, Volume: 161, Issue:2-3 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Asian People; Double-Blind Method; Drug Administration Schedule; Female; Humans; Injections; Japan; Kaplan-Meier Estimate; Malaysia; Male; Philippines; Psychiatric Status Rating Scales; Schizophrenia; Taiwan; Treatment Outcome; Weight Gain	2015
Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, Volume: 54, Issue:2 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Europe; Female; Headache; Humans; India; Male; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Severity of Illness Index; Treatment Outcome; United States; Weight Gain	2015
Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical schizophrenia & related psychoses, 2015,Summer, Volume: 9, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Medication Adherence; Patient Outcome Assessment; Patient Satisfaction; Schizophrenia	2015
Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacological reports : PR, 2015, Volume: 67, Issue:2 Topics: Anti-Inflammatory Agents; Aripiprazole; Body Weight; C-Reactive Protein; Chronic Disease; Cytokines; Female; Humans; Insulin; Male; Middle Aged; Schizophrenia	2015
Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment. Journal of pharmacokinetics and pharmacodynamics, 2015, Volume: 42, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Male; Medication Adherence; Middle Aged; Models, Biological; Schizophrenia; Young Adult	2015
HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haplotypes; Humans; Isoindoles; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Treatment Outcome	2015
Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology, 2015, Volume: 58 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; Risperidone; Schizophrenia; Treatment Outcome; Young Adult	2015
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. European archives of psychiatry and clinical neuroscience, 2015, Volume: 265, Issue:7 Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Drug Partial Agonism; Female; Humans; Isoindoles; Male; Middle Aged; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Young Adult	2015
A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. The Journal of clinical psychiatry, 2015, Volume: 76, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Schizophrenia; Treatment Outcome	2015
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia research, 2015, Volume: 168, Issue:1-2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Least-Squares Analysis; Male; Paliperidone Palmitate; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Single-Blind Method; Treatment Outcome	2015
Defining the minimal clinically important difference (MCID) of the Heinrichs-carpenter quality of life scale (QLS). International journal of methods in psychiatric research, 2016, Volume: 25, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Minimal Clinically Important Difference; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia	2016
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta psychiatrica Scandinavica, 2016, Volume: 133, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Schizophrenia; Treatment Outcome	2016
Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. The American journal of psychiatry, 2016, Volume: 173, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Connectome; Corpus Striatum; Female; Humans; Magnetic Resonance Imaging; Male; Prognosis; Reproducibility of Results; Risperidone; Schizophrenia; Treatment Outcome	2016
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophrenia bulletin, 2015, Volume: 41, Issue:6 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Risperidone; Schizophrenia; Young Adult	2015
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophrenia bulletin, 2015, Volume: 41, Issue:6 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Remission Induction; Risperidone; Schizophrenia; Young Adult	2015
Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial. PloS one, 2015, Volume: 10, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Etoposide; Female; Humans; Hyperprolactinemia; Lipoproteins, HDL; Male; Mitoxantrone; Prednisone; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides; Vincristine	2015
Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Treatment Outcome	2015
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International clinical psychopharmacology, 2016, Volume: 31, Issue:2 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Asia; Disease Progression; Europe; Female; Hostility; Humans; Injections, Intramuscular; Male; Middle Aged; Psychiatric Status Rating Scales; Psychomotor Agitation; Recurrence; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; United States; Young Adult	2016
Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. Neuropsychobiology, 2015, Volume: 72, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Female; Humans; Isoindoles; Japan; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Single Nucleotide; Precision Medicine; Psychiatric Status Rating Scales; Receptors, Serotonin; Schizophrenia; Thiazoles; Treatment Outcome	2015
Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. The Journal of clinical psychiatry, 2015, Volume: 76, Issue:12 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Schizophrenia	2015
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. International clinical psychopharmacology, 2016, Volume: 31, Issue:4 Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Weight Gain	2016
Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial. Schizophrenia research, 2016, Volume: 176, Issue:2-3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Comparative Effectiveness Research; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Treatment Outcome; Young Adult	2016
[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2016, Volume: 36, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult	2016
Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. The Journal of clinical psychiatry, 2016, Volume: 77, Issue:11 Topics: Acute Disease; Adolescent; Adult; Aged; Aripiprazole; Blood Glucose; Body Weight; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Injections, Intramuscular; Lipids; Lipoproteins; Male; Middle Aged; Prolactin; Risk; Schizophrenia; Schizophrenic Psychology; Young Adult	2016
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology, 2016, Volume: 233, Issue:23-24 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Middle Aged; Non-alcoholic Fatty Liver Disease; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult	2016
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. CNS spectrums, 2016, Volume: 21, Issue:6 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Delayed-Action Preparations; Female; Haloperidol; Humans; Hyperprolactinemia; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Perphenazine; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome	2016
Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study. Pharmacopsychiatry, 2017, Volume: 50, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Male; Prolactin; Schizophrenia; Sexual Dysfunction, Physiological	2017
Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. Schizophrenia research, 2017, Volume: 179 Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Sex Factors; Young Adult	2017
Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1. Therapeutic drug monitoring, 2017, Volume: 39, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nomograms; Piperazines; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Young Adult	2017
Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. The international journal of neuropsychopharmacology, 2017, 01-01, Volume: 20, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Employment; Female; Humans; Male; Paliperidone Palmitate; Patient Satisfaction; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome	2017
Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. The international journal of neuropsychopharmacology, 2017, 04-01, Volume: 20, Issue:4 Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Area Under Curve; Aripiprazole; Buttocks; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Middle Aged; Schizophrenia; Shoulder; Young Adult	2017
Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. International clinical psychopharmacology, 2017, Volume: 32, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Prolactin; Quality of Life; Schizophrenia; Sexual Dysfunction, Physiological; Young Adult	2017
Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clinical pharmacokinetics, 2008, Volume: 47, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Biological Availability; Biotransformation; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult	2008
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:7 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides	2008
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. The American journal of psychiatry, 2008, Volume: 165, Issue:11 Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2008
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008, Volume: 18, Issue:12 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult	2008
A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:5 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index	2008
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting. Psychiatria Danubina, 2008, Volume: 20, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Humans; Intensive Care Units; Male; Middle Aged; Piperazines; Psychiatric Department, Hospital; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome	2008
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Dec-12, Volume: 32, Issue:8 Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sulpiride; Young Adult	2008
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biological psychiatry, 2009, Mar-15, Volume: 65, Issue:6 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Double-Blind Method; Electrocardiography; Female; Glucose; Humans; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Schizophrenia	2009
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:6 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Dopamine Antagonists; Double-Blind Method; Female; Hospitalization; Humans; Lorazepam; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; Triglycerides; United States; Young Adult	2008
Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:12 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult	2008
Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia research, 2009, Volume: 107, Issue:1 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Female; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult	2009
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophrenia research, 2009, Volume: 107, Issue:2-3 Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult	2009
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC psychiatry, 2008, Dec-22, Volume: 8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Olanzapine; Patient Satisfaction; Piperazines; Prolactin; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sexual Behavior; Treatment Outcome	2008
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. CNS spectrums, 2009, Volume: 14, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome	2009
UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). European archives of psychiatry and clinical neuroscience, 2009, Volume: 259, Issue:4 Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Coronary Disease; Cost of Illness; Costs and Cost Analysis; Diabetes Mellitus; Female; Follow-Up Studies; Health Resources; Health Services; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia; United Kingdom; Young Adult	2009
Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Progress in neuro-psychopharmacology & biological psychiatry, 2009, Apr-30, Volume: 33, Issue:3 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Female; Genotype; Glycine; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Polymorphism, Restriction Fragment Length; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D3; Retrospective Studies; Schizophrenia; Serine; Time Factors; Treatment Outcome	2009
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:4 Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires	2009
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients. Journal of psychiatric practice, 2009, Volume: 15, Issue:2 Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome	2009
HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology, 2009, Volume: 205, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Receptor, Serotonin, 5-HT2A; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Statistics, Nonparametric; Young Adult	2009
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phobic Disorders; Piperazines; Prospective Studies; Psychometrics; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Time Factors; Treatment Outcome	2009
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2009, Volume: 19, Issue:8 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult	2009
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials, 2009, May-15, Volume: 10 Topics: Antipsychotic Agents; Aripiprazole; Clinical Protocols; Clozapine; Drug Resistance; Drug Therapy, Combination; Government Regulation; Haloperidol; Humans; Italy; Piperazines; Prospective Studies; Quinolones; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2009
A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International clinical psychopharmacology, 2009, Volume: 24, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Severity of Illness Index	2009
Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry, 2009, Volume: 42, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Health Status; Humans; Male; Middle Aged; Outpatients; Patient Satisfaction; Piperazines; Prolactin; Quality of Life; Quinolones; Risperidone; Schizophrenia; Sexuality; Treatment Outcome	2009
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; C-Reactive Protein; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Triglycerides	2009
Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Time Factors; Treatment Failure	2009
Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Therapeutic drug monitoring, 2009, Volume: 31, Issue:5 Topics: Antimanic Agents; Aripiprazole; Carbamazepine; Drug Interactions; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia	2009
Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Applied health economics and health policy, 2009, Volume: 7, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2009
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:10 Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Headache; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Treatment Outcome	2009
Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. Clinical drug investigation, 2010, Volume: 30, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome	2010
Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data. Journal of child and adolescent psychopharmacology, 2010, Volume: 20, Issue:1 Topics: Administration, Oral; Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hostility; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Syndrome; Time Factors; Treatment Outcome	2010
Clinical use of aripiprazole in patients with schizophrenia: a real-life setting results from the German Postmarketing Surveillance Study. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:2 Pt 2 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Germany; Humans; Male; Nausea; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Sleep Initiation and Maintenance Disorders; Vomiting	2010
Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry, 2010, Volume: 43, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Attention; Cognition; Humans; Inpatients; Memory; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Reaction Time; Schizophrenia; Time Factors; Treatment Outcome	2010
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. The international journal of neuropsychopharmacology, 2010, Volume: 13, Issue:8 Topics: Adolescent; Adult; Aged; Aripiprazole; Body Mass Index; Body Weight; Chemotherapy, Adjuvant; Cholesterol; Clozapine; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult	2010
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clinical neuropharmacology, 2010, Volume: 33, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult	2010
Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophrenia research, 2010, Volume: 120, Issue:1-3 Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Social Behavior Disorders; Young Adult	2010
Aripiprazole versus haloperidol treatment in early-stage schizophrenia. Journal of psychiatric research, 2011, Volume: 45, Issue:6 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome; Young Adult	2011
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jan-15, Volume: 35, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Attention; Benzodiazepines; Chronic Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Substitution; Executive Function; Female; Humans; Isoindoles; Longitudinal Studies; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Single-Blind Method; Thiazoles; Time Factors; Verbal Learning	2011
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Thiazoles; Time Factors; Triglycerides; Weight Gain	2010
Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study. Current medical research and opinion, 2011, Volume: 27, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Quality of Life; Quinolones; Residence Characteristics; Schizophrenia; Standard of Care; Surveys and Questionnaires; Treatment Outcome	2011
Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophrenia research, 2011, Volume: 127, Issue:1-3 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Double-Blind Method; Drug Interactions; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors	2011
Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological	2011
An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry, 2011, Volume: 44, Issue:3 Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Mood Disorders; Personal Satisfaction; Pilot Projects; Piperazines; Pleasure; Quinolones; Risperidone; Schizophrenia	2011
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Schizophrenia	2011
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. Contemporary clinical trials, 2011, Volume: 32, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Italy; Logistic Models; Olanzapine; Patient Selection; Piperazines; Proportional Hazards Models; Quinolones; Research Design; Schizophrenia; Time Factors	2011
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Risperidone; Schizophrenia	2012
Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clinical schizophrenia & related psychoses, 2011, Volume: 5, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Drug Substitution; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Overweight; Piperazines; Quinolones; Schizophrenia; Weight Loss	2011
A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study). Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:4 Topics: Adult; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Sexual Dysfunctions, Psychological; Young Adult	2011
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). The American journal of psychiatry, 2011, Volume: 168, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dibenzothiazepines; Diet, Reducing; Drug Substitution; Exercise; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides	2011
Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European archives of psychiatry and clinical neuroscience, 2012, Volume: 262, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Secondary Prevention; Time Factors	2012
A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia. European psychiatry : the journal of the Association of European Psychiatrists, 2012, Volume: 27, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Piperazines; Prospective Studies; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome	2012
Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome	2011
Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:1 Topics: Acute Disease; Adult; Alleles; Antipsychotic Agents; Aripiprazole; Female; Genetic Carrier Screening; Genotype; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Schizophrenia; Taq Polymerase; Treatment Outcome; Young Adult	2012
Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Human psychopharmacology, 2012, Volume: 27, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain-Derived Neurotrophic Factor; Case-Control Studies; Chromatography, High Pressure Liquid; Enzyme-Linked Immunosorbent Assay; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Young Adult	2012
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:9 Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss	2012
Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India. International journal of psychiatry in clinical practice, 2013, Volume: 17, Issue:1 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; India; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult	2013
Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic drug monitoring, 2012, Volume: 34, Issue:2 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Basal Ganglia Diseases; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Japan; Male; Mass Spectrometry; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Young Adult	2012
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:5 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Proportional Hazards Models; Quinolones; Schizophrenia; Secondary Prevention	2012
Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: comparison of first-episode to recurrent psychosis. Early intervention in psychiatry, 2013, Volume: 7, Issue:1 Topics: Adolescent; Adolescent Behavior; Adult; Aripiprazole; Child; Female; Humans; Male; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology	2013
Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. Human psychopharmacology, 2012, Volume: 27, Issue:5 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult	2012
Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta psychiatrica Scandinavica, 2013, Volume: 127, Issue:3 Topics: Absorptiometry, Photon; Adult; Antipsychotic Agents; Aripiprazole; Body Composition; Clozapine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose; Glucose Tolerance Test; Humans; Lipoproteins, LDL; Magnetic Resonance Spectroscopy; Male; Piperazines; Quinolones; Schizophrenia	2013
Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study. CNS drugs, 2012, Volume: 26, Issue:11 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Memory; Middle Aged; Piperazines; Prospective Studies; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Semantics; Treatment Outcome; Verbal Learning; Young Adult	2012
A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Progress in neuro-psychopharmacology & biological psychiatry, 2013, Jan-10, Volume: 40 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Japan; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome	2013
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. The Journal of clinical psychiatry, 2013, Volume: 74, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Therapeutic Equipoise; Triglycerides; United States	2013
The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. Hiroshima journal of medical sciences, 2012, Volume: 61, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia	2012
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:9 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome	2002
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology, 2003, Volume: 166, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2003
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry, 2003, Volume: 60, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hospitalization; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2003
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:4 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Long-Term Care; Male; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2003
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:9 Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome	2003
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. The Journal of clinical psychiatry, 2004, Volume: 65 Suppl 18 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Hyperlipidemias; Incidence; Lipids; Male; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome; Weight Gain	2004
Aripiprazole in schizophrenia with cocaine dependence: a pilot study. Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:4 Topics: Adult; Alcoholism; Antipsychotic Agents; Aripiprazole; Cocaine-Related Disorders; Diagnosis, Dual (Psychiatry); Humans; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Schizophrenia	2005
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta psychiatrica Scandinavica, 2006, Volume: 113, Issue:2 Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Clozapine; Community Mental Health Centers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides	2006
Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta psychiatrica Scandinavica, 2006, Volume: 113, Issue:2 Topics: Activities of Daily Living; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Body Mass Index; Denmark; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Schizophrenia; Treatment Outcome	2006
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophrenia research, 2006, Volume: 84, Issue:1 Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Primary Health Care; Prospective Studies; Psychiatry; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome	2006
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Progress in neuro-psychopharmacology & biological psychiatry, 2006, Volume: 30, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Schizophrenia; Time Factors	2006
[Clinical observations with aripiprazole in schizophrenia]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2006, Volume: 8, Issue:1 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Single-Blind Method; Treatment Outcome	2006
The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS spectrums, 2006, Volume: 11, Issue:9 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia	2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology, 2006, Volume: 188, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Blood Glucose; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Withholding Treatment	2006
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology, 2006, Volume: 189, Issue:2 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Triglycerides	2006
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Current medical research and opinion, 2006, Volume: 22, Issue:11 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Treatment Outcome	2006
Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Mar-30, Volume: 31, Issue:2 Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outpatients; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Schizophrenia; Time Factors	2007
Clozapine augmented with aripiprazole in 5 patients with schizophrenia. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome	2006
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:1 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome	2007
Pharmacokinetics of aripiprazole and concomitant carbamazepine. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:3 Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Carbamazepine; Drug Antagonism; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia	2007
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:5 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Severity of Illness Index; Treatment Outcome	2007
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of psychiatric practice, 2007, Volume: 13, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia	2007
[Clinical observation on effect of Jieyu Anshen Decoction combined with aripiprazole in treating chronic schizophrenia]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Phytotherapy; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2007
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. European psychiatry : the journal of the Association of European Psychiatrists, 2007, Volume: 22, Issue:7 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Blood Glucose; Community Mental Health Services; Female; Humans; Lipoproteins; Male; Middle Aged; Patient Care; Piperazines; Prolactin; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Weight Gain	2007
Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Humans; Pilot Projects; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2007
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of psychiatric research, 2007, Volume: 41, Issue:11 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia	2007
A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Current medical research and opinion, 2007, Volume: 23, Issue:10 Topics: Antipsychotic Agents; Aripiprazole; Europe; Humans; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Surveys and Questionnaires; Treatment Outcome	2007
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. The American journal of psychiatry, 2007, Volume: 164, Issue:9 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Dopamine Antagonists; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Placebos; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome	2007
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. The American journal of psychiatry, 2007, Volume: 164, Issue:9 Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Basal Ganglia Diseases; Carbon Radioisotopes; Caudate Nucleus; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Putamen; Pyridines; Pyrimidinones; Quinolones; Raclopride; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome	2007
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. International clinical psychopharmacology, 2007, Volume: 22, Issue:6 Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Aripiprazole; Blood Glucose; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Electrocardiography; Fasting; Humans; Lipids; Nausea; Piperazines; Prolactin; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Weight Loss	2007
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires	2008
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Self Concept; Social Adjustment	2008
Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:5 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Choice Behavior; Community Mental Health Services; Consumer Behavior; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy; Female; Humans; Male; Middle Aged; Piperazines; Quality of Life; Quinolones; Schizophrenia; Surveys and Questionnaires	2008
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:5 Topics: Adult; Algorithms; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Humans; Hypertension; Incidence; Male; Piperazines; Prevalence; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia	2008
Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. Psychopharmacology bulletin, 1998, Volume: 34, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Electroencephalography; Humans; Male; Piperazines; Quinolones; Schizophrenia	1998

Other Studies

506 other study(ies) available for aripiprazole and Dementia Praecox

Article	Year
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorganic & medicinal chemistry, 2010, Mar-01, Volume: 18, Issue:5 Topics: Administration, Oral; Animals; Antipsychotic Agents; Cell Line; Humans; Ligands; Male; Mice; Piperazines; Pyrazoles; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia	2010
Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder. Bioorganic & medicinal chemistry letters, 2011, May-01, Volume: 21, Issue:9 Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Drug Discovery; Haplorhini; Male; Molecular Structure; Naphthyridines; Piperazine; Piperazines; Rats; Receptors, Dopamine D2; Schizophrenia; Structure-Activity Relationship	2011
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. Journal of medicinal chemistry, 2014, Nov-26, Volume: 57, Issue:22 Topics: Amides; Animals; Antipsychotic Agents; Behavior, Animal; Dizocilpine Maleate; Dopamine Antagonists; Drug Evaluation, Preclinical; Female; Kinetics; Ligands; Male; Mice; Prefrontal Cortex; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Schizophrenia; Serotonin Receptor Agonists; Structure-Activity Relationship	2014
Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure. Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7 Topics: Animals; Antipsychotic Agents; beta-Arrestins; Dopamine Agonists; Drug Discovery; GTP-Binding Proteins; Humans; Male; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia	2017
Automated design and optimization of multitarget schizophrenia drug candidates by deep learning. European journal of medicinal chemistry, 2020, Oct-15, Volume: 204 Topics: Animals; Automation; Deep Learning; Drug Discovery; Mice; Molecular Targeted Therapy; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia	2020
Novel D European journal of medicinal chemistry, 2022, Mar-15, Volume: 232 Topics: Animals; Antipsychotic Agents; Piperazines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia	2022
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. CNS drugs, 2021, Volume: 35, Issue:10 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cohort Studies; Delayed-Action Preparations; Drug Costs; Female; Humans; Injections; Longitudinal Studies; Male; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Schizophrenia; Treatment Outcome; Young Adult	2021
A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia. The primary care companion for CNS disorders, 2021, Sep-30, Volume: 23, Issue:5 Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Cohort Studies; Humans; Schizophrenia	2021
Comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2022, Volume: 22, Issue:1 Topics: Aged; Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Risperidone; Schizophrenia	2022
The use of carbamazepine to expedite the metabolism of a long-acting aripiprazole injection. Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Carbamazepine; Delayed-Action Preparations; Female; Fluphenazine; Humans; Schizophrenia	2022
The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders. Psychiatria polska, 2021, Oct-31, Volume: 55, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Poland; Receptors, Dopamine D3; Schizophrenia	2021
Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study. Psychiatry research, 2022, Volume: 309 Topics: Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Prospective Studies; Schizophrenia	2022
Case series on aripiprazole and dopamine supersensitivity psychosis. International clinical psychopharmacology, 2022, 05-01, Volume: 37, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Humans; Psychotic Disorders; Schizophrenia	2022
Repeated co-treatment with mirtazapine and aripiprazole reversed the schizophrenia-like behaviors and increased the brain-derived neurotrophic factor mRNA expression in the adult Sprague-Dawley rats exposed to glutathione deficit during early postnatal br Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2021, Volume: 72, Issue:5 Topics: Animals; Aripiprazole; Brain; Brain-Derived Neurotrophic Factor; Glutathione; Male; Mirtazapine; Rats; Rats, Sprague-Dawley; RNA, Messenger; Schizophrenia	2021
[Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Monitoring; Humans; Piperazines; Quinolones; Schizophrenia; Young Adult	2022
Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports, 2022, Volume: 42, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Male; Schizophrenia	2022
N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia. International journal of molecular sciences, 2022, Feb-15, Volume: 23, Issue:4 Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Disease Models, Animal; Female; Hippocampus; Prefrontal Cortex; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Social Behavior	2022
Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections? CNS drugs, 2022, Volume: 36, Issue:4 Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections; Schizophrenia	2022
The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia. British journal of clinical pharmacology, 2022, Volume: 88, Issue:7 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cytochrome P-450 CYP3A; Humans; Quetiapine Fumarate; Schizophrenia; Vitamin D	2022
The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. Endokrynologia Polska, 2022, Volume: 73, Issue:1 Topics: Acute-Phase Proteins; Aripiprazole; Body Composition; Body Mass Index; Cytokines; Female; Humans; Leptin; Male; Schizophrenia	2022
Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome. Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Orexins; Prospective Studies; Schizophrenia	2022
Comparison of prediction methods for treatment continuation of antipsychotics in children and adolescents with schizophrenia. Evidence-based mental health, 2022, Volume: 25, Issue:e1 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Humans; Machine Learning; Risperidone; Schizophrenia	2022
A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy. Asian journal of psychiatry, 2022, Volume: 72 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Quinolones; Schizophrenia; Schizophrenia, Treatment-Resistant; Thiophenes; Young Adult	2022
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain. CNS drugs, 2022, Volume: 36, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Recurrence; Retrospective Studies; Schizophrenia; Spain	2022
Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis. The international journal of neuropsychopharmacology, 2022, 08-16, Volume: 25, Issue:8 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Ascorbic Acid; Female; Humans; Psychotic Disorders; Schizophrenia; Young Adult	2022
The relationship of antipsychotic treatment with reduced brown adipose tissue activity in patients with schizophrenia. Psychoneuroendocrinology, 2022, Volume: 142 Topics: Adipose Tissue, Brown; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Metabolic Syndrome; Schizophrenia; Thermogenesis	2022
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:9 Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia	2022
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies. European psychiatry : the journal of the Association of European Psychiatrists, 2022, Jul-20, Volume: 65, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Canada; Clinical Studies as Topic; Female; Humans; Male; Middle Aged; Schizophrenia; Treatment Outcome	2022
Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. Inflammopharmacology, 2022, Volume: 30, Issue:5 Topics: Animals; Antipsychotic Agents; Aripiprazole; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamates; Humans; Imidazoles; Indoles; Ketamine; Male; Neuregulin-1; Parvalbumins; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Receptor, ErbB-4; RNA, Messenger; Schizophrenia; Signal Transduction; Sucrose; TOR Serine-Threonine Kinases	2022
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan. The Journal of clinical psychiatry, 2022, 08-03, Volume: 83, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Japan; Paliperidone Palmitate; Risperidone; Schizophrenia; Tardive Dyskinesia	2022
Aripiprazole: examining the clinical implications of D2 affinity. International clinical psychopharmacology, 2023, 03-01, Volume: 38, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Risperidone; Schizophrenia	2023
Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study. Current medical research and opinion, 2023, Volume: 39, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Humans; Patient Acceptance of Health Care; Retrospective Studies; Schizophrenia	2023
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study. BMC psychiatry, 2022, 12-08, Volume: 22, Issue:1 Topics: Aripiprazole; Canada; Humans; Prospective Studies; Schizophrenia; Substance-Related Disorders	2022
[Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:12 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Recurrence; Schizophrenia	2022
Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. Journal of molecular neuroscience : MN, 2023, Volume: 73, Issue:1 Topics: Aripiprazole; East Asian People; Gene Frequency; Genotype; Glycogen Synthase Kinase 3 beta; Haplotypes; Humans; Linkage Disequilibrium; Polymorphism, Single Nucleotide; Schizophrenia	2023
Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole. Schizophrenia research, 2023, Volume: 251 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections; Psychotic Disorders; Schizophrenia	2023
Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences, 2023, Mar-01, Volume: 316 Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Hedgehog Proteins; Male; Rats; Rats, Wistar; Schizophrenia	2023
Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. Schizophrenia research, 2023, Volume: 252 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Japan; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia	2023
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry, 2023, 03-03, Volume: 23, Issue:1 Topics: Acceptance and Commitment Therapy; Antipsychotic Agents; Aripiprazole; Autonomic Nervous System; Humans; Schizophrenia	2023
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. Psychiatry research, 2023, Volume: 322 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones; Recurrence; Schizophrenia	2023
BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study). BMC psychiatry, 2023, 03-14, Volume: 23, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Female; Humans; Male; Schizophrenia; Treatment Outcome	2023
Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China. Chinese medical journal, 2023, 05-05, Volume: 136, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; China; Humans; Risperidone; Schizophrenia; Treatment Outcome	2023
Polish Psychiatric Association diagnostic and therapeutic management guidelines for patients with early-onset schizophrenia. Psychiatria polska, 2022, Aug-31, Volume: 56, Issue:4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Humans; Poland; Psychotic Disorders; Schizophrenia	2022
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. Asian journal of psychiatry, 2023, Volume: 84 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Humans; Olanzapine; Risperidone; Schizophrenia; Weight Gain	2023
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation. Psychiatry and clinical neurosciences, 2023, Volume: 77, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Lipids; Olanzapine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Treatment Outcome	2023
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study). BMC psychiatry, 2023, 05-31, Volume: 23, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Canada; Delayed-Action Preparations; Female; Humans; Male; Patient Acuity; Schizophrenia	2023
Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis. Military Medical Research, 2023, 06-02, Volume: 10, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Multiomics; Olanzapine; Phospholipases; Precision Medicine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia	2023
Safety Profile of Aripiprazole During Pregnancy and Lactation: Report of 2 Cases. Turk psikiyatri dergisi = Turkish journal of psychiatry, 2023,Summer, Volume: 34, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Lactation; Pregnancy; Schizophrenia	2023
Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice. Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:10 Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Psychotic Disorders; Retrospective Studies; Schizophrenia	2023
Atypical antipsychotics attenuate MK801-induced social withdrawal and hyperlocomotion in the RHA rat model of schizophrenia-relevant features. Psychopharmacology, 2023, Volume: 240, Issue:9 Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dizocilpine Maleate; Male; Rats; Schizophrenia; Social Isolation	2023
Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting. Psychopharmacology, 2023, Volume: 240, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Hospitals; Humans; Olanzapine; Patient Discharge; Piperazines; Quinolones; Retrospective Studies; Schizophrenia	2023
Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. Neuroscience letters, 2023, 08-24, Volume: 812 Topics: Animals; Aripiprazole; Brain-Derived Neurotrophic Factor; Cognition; Hippocampus; Mice; Nerve Growth Factor; Schizophrenia	2023
Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly. Schizophrenia research, 2023, Volume: 260 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Piperazines; Schizophrenia	2023
Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole. Psychopharmacology, 2020, Volume: 237, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Humans; Male; Middle Aged; Olanzapine; Schizophrenia; Treatment Outcome; Young Adult	2020
The effect of aripiprazole once-monthly 300 mg in maintenance therapy for schizophrenia. Asian journal of psychiatry, 2020, Volume: 47 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Schizophrenia; Secondary Prevention; Treatment Outcome	2020
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy. Clinical therapeutics, 2020, Volume: 42, Issue:1 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Thiophenes; United States	2020
Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions. Pharmacology, biochemistry, and behavior, 2020, Volume: 189 Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Cognition; Disease Models, Animal; Female; Male; Methylazoxymethanol Acetate; Morris Water Maze Test; Neurotoxins; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Schizophrenia; Spatial Memory; Tobacco Smoke Pollution; Treatment Outcome	2020
Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series. The primary care companion for CNS disorders, 2020, Jan-30, Volume: 22, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Psychotic Disorders; Retrospective Studies; Schizophrenia	2020
Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study. International journal of psychiatry in clinical practice, 2020, Volume: 24, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Delayed-Action Preparations; Executive Function; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Prospective Studies; Schizophrenia	2020
Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome. Psychopharmacology bulletin, 2020, 03-12, Volume: 50, Issue:1 Topics: Adolescent; Aripiprazole; Child; DiGeorge Syndrome; Hallucinations; Humans; Male; Psychotic Disorders; Schizophrenia	2020
Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: findings from the STAR Network Depot Study. International clinical psychopharmacology, 2020, Volume: 35, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Paliperidone Palmitate; Practice Patterns, Physicians'; Schizophrenia; Schizophrenic Psychology; Young Adult	2020
Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia. Journal of clinical pharmacology, 2020, Volume: 60, Issue:10 Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Humans; Male; Olanzapine; Paliperidone Palmitate; Schizophrenia; Vitamin A; Vitamin D; Vitamin E; Vitamins; Young Adult	2020
The 12-year trend report of antipsychotic usage in a nationwide claims database derived from four million people in Japan. Journal of psychiatric research, 2020, Volume: 127 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Humans; Japan; Schizophrenia	2020
Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan. Advances in therapy, 2020, Volume: 37, Issue:7 Topics: Administration, Oral; Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Drug Administration Routes; Drug Administration Schedule; Female; Humans; Injections; Japan; Male; Medication Adherence; Middle Aged; Schizophrenia; Sex Factors	2020
Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone). Early intervention in psychiatry, 2021, Volume: 15, Issue:4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Weight Gain	2021
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China. Expert review of pharmacoeconomics & outcomes research, 2020, Volume: 20, Issue:5 Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; China; Computer Simulation; Cost-Benefit Analysis; Drug Delivery Systems; Humans; Medication Adherence; Olanzapine; Quality-Adjusted Life Years; Recurrence; Schizophrenia; Tablets	2020
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis. Journal of analytical toxicology, 2020, Dec-12, Volume: 44, Issue:8 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Humans; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Substance Abuse Detection; Suicide; Sulpiride; Tandem Mass Spectrometry; Thiazoles	2020
Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report. Psychiatry and clinical neurosciences, 2020, Volume: 74, Issue:12 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes	2020
Effects of various antipsychotics on driving-related cognitive performance in adults with schizophrenia. Journal of psychiatric research, 2020, Volume: 131 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cognition; Cross-Sectional Studies; Haloperidol; Humans; Schizophrenia	2020
Consensus statements on the clinical usage and characteristics of aripiprazole for Hong Kong. Internal medicine journal, 2020, Volume: 50 Suppl 3 Topics: Antipsychotic Agents; Aripiprazole; Consensus; Hong Kong; Humans; Schizophrenia	2020
Therapeutic drug monitoring of children and adolescents treated with aripiprazole: observational results from routine patient care. Journal of neural transmission (Vienna, Austria : 1996), 2020, Volume: 127, Issue:12 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Drug Monitoring; Female; Humans; Male; Patient Care; Schizophrenia	2020
Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia. Human psychopharmacology, 2021, Volume: 36, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Hospitalization; Humans; Injections; Schizophrenia	2021
What is the "best intro"-explanatory versus pragmatic antipsychotic drug trials. The lancet. Psychiatry, 2020, Volume: 7, Issue:12 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia	2020
Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia. Therapeutic drug monitoring, 2021, 08-01, Volume: 43, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Prolactin; Schizophrenia	2021
Case of aripiprazole long-acting-related akathisia successfully managed with carvedilol: A case report. Psychiatry and clinical neurosciences, 2021, Volume: 75, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Carvedilol; Humans; Psychomotor Agitation; Schizophrenia	2021
Long Acting Polycaprolactone Based Parenteral Formulation of Aripiprazole Targeting Behavioural and Biochemical Deficit in Schizophrenia. Journal of pharmaceutical sciences, 2021, Volume: 110, Issue:5 Topics: Animals; Aripiprazole; Delayed-Action Preparations; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Particle Size; Polyesters; Rats; Schizophrenia	2021
Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry, 2021, Volume: 54, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Consensus; Humans; Japan; Quetiapine Fumarate; Schizophrenia	2021
Long-Acting Aripiprazole in the Management of Violence in Treatment Nonadherent Schizophrenia. The primary care companion for CNS disorders, 2021, Jan-14, Volume: 23, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Schizophrenia; Violence	2021
Pragmatic antipsychotics trial-caution in interpretation. The lancet. Psychiatry, 2021, Volume: 8, Issue:2 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia	2021
Pragmatic antipsychotics trial-caution in interpretation - Authors' reply. The lancet. Psychiatry, 2021, Volume: 8, Issue:2 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia	2021
Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. International clinical psychopharmacology, 2021, 03-01, Volume: 36, Issue:2 Topics: Aripiprazole; Delayed-Action Preparations; Hospitalization; Humans; Injections; Schizophrenia; Spain; Time Factors	2021
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study. Human psychopharmacology, 2021, Volume: 36, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Humans; Japan; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome	2021
Long acting aripiprazole influences cognitive functions in recent onset schizophrenia. Psychopharmacology, 2021, Volume: 238, Issue:6 Topics: Adolescent; Adult; Alleles; Aripiprazole; Attention; Catechol O-Methyltransferase; Cognition; Executive Function; Female; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Genetic; Schizophrenia; Young Adult	2021
Cognitive improvement function of aripiprazole in adolescents with first-episode and repeated-episode schizophrenia. Asian journal of psychiatry, 2021, Volume: 58 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Cognition; Humans; Risperidone; Schizophrenia; Treatment Outcome	2021
Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study. Journal of child and adolescent psychopharmacology, 2021, Volume: 31, Issue:6 Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Duration of Therapy; Female; Finland; Humans; Infant; Infant, Newborn; Male; Off-Label Use; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia	2021
Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. BMC psychiatry, 2021, 03-24, Volume: 21, Issue:1 Topics: Adult; Aripiprazole; Diabetes Mellitus, Type 2; Humans; Quality of Life; Schizophrenia	2021
Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. European psychiatry : the journal of the Association of European Psychiatrists, 2021, 04-12, Volume: 64, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Retrospective Studies; Schizophrenia	2021
The role of aripiprazole in improvement of penile erection in schizophrenia patients with erectile dysfunction. Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina, 2021, 08-01, Volume: 18, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Erectile Dysfunction; Humans; Male; Penile Erection; Schizophrenia	2021
Resolution of enuresis with aripiprazole in children with psychiatric disorders: two case reports. Journal of medical case reports, 2021, Apr-21, Volume: 15, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Child; Female; Humans; Male; Nocturnal Enuresis; Schizophrenia	2021
Catatonic Symptoms Successfully Treated with Olanzapine in an Adolescent with Schizophrenia. Journal of child and adolescent psychopharmacology, 2021, Volume: 31, Issue:4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Male; Olanzapine; Schizophrenia	2021
Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. Psychiatry research, 2021, Volume: 302 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Male; Paliperidone Palmitate; Prolactin; Prospective Studies; Schizophrenia	2021
Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacology reports, 2021, Volume: 41, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Female; Genetic Diseases, Inborn; Humans; Hyperprolactinemia; Lactation Disorders; Male; Paliperidone Palmitate; Prolactin; Risperidone; Schizophrenia; Testosterone	2021
Pharmaceutical development and technology, 2021, Volume: 26, Issue:8 Topics: Administration, Intranasal; Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Humans; Male; Mice; Motor Activity; Nanogels; Nanoparticle Drug Delivery System; Particle Size; Schizophrenia; Spectroscopy, Fourier Transform Infrared	2021
Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review. Neuropsychopharmacology reports, 2021, Volume: 41, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Schizophrenia	2021
Adherence, Tolerability and Effective Doses of Aripiprazole Once-monthly in the Long-term Treatment of Patients with Severe Schizophrenia. Current pharmaceutical design, 2021, Volume: 27, Issue:39 Topics: Antipsychotic Agents; Aripiprazole; Humans; Prospective Studies; Schizophrenia; Treatment Outcome	2021
Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague-Dawley rats exposed to glutathione deficit during early postnatal development of the brain. Pharmacological reports : PR, 2021, Volume: 73, Issue:6 Topics: Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Escitalopram; Glutathione; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Schizophrenia; Selective Serotonin Reuptake Inhibitors	2021
Add-on Oxytocin in the Treatment of Postpartum Acute Schizophrenia: A Case Report. Journal of psychiatric practice, 2021, 07-28, Volume: 27, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Oxytocin; Postpartum Period; Schizophrenia; Young Adult	2021
An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Current medical research and opinion, 2021, Volume: 37, Issue:11 Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Schizophrenia	2021
Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Injections, Intramuscular; Models, Theoretical; Schizophrenia	2017
Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Current neuropharmacology, 2017, Nov-14, Volume: 15, Issue:8 Topics: Animals; Antipsychotic Agents; Aripiprazole; Humans; PubMed; Schizophrenia	2017
Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophrenia research, 2018, Volume: 192 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; International Cooperation; Longitudinal Studies; Male; Middle Aged; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Young Adult	2018
Aripiprazole-induced hypersensitivity pneumonitis. BMJ case reports, 2017, May-09, Volume: 2017 Topics: Adult; Alveolitis, Extrinsic Allergic; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Female; Humans; Lung Diseases, Interstitial; Schizophrenia; Tomography, X-Ray Computed	2017
[Switching from antipsychotics to aripiprazole and risk of agitation]. L'Encephale, 2018, Volume: 44, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Psychomotor Agitation; Risk; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult	2018
Aripiprazole and impulse-control disorders in high-risk patients. Asian journal of psychiatry, 2017, Volume: 27 Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Humans; Male; Middle Aged; Risk; Schizophrenia	2017
Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats. Neuropharmacology, 2017, Sep-01, Volume: 123 Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Cytokines; Disease Models, Animal; Ghrelin; Glucagon-Like Peptide 1; Leptin; Male; Metabolic Syndrome; Poly I-C; Random Allocation; Rats, Wistar; Schizophrenia	2017
Aripiprazole-induced Asymptomatic Hypertension: A Case Report. Psychopharmacology bulletin, 2017, 05-15, Volume: 47, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Blood Pressure; Female; Humans; Hypertension; Middle Aged; Schizophrenia	2017
Combined Antipsychotics and Electroconvulsive Therapy in an Acutely Psychotic Patient with Treatment-resistant Schizophrenia. Psychopharmacology bulletin, 2017, 05-15, Volume: 47, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Combined Modality Therapy; Drug Therapy, Combination; Electroconvulsive Therapy; Female; Hospitalization; Humans; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome	2017
Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report. BMC psychiatry, 2017, 07-03, Volume: 17, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections; Male; Middle Aged; Pharmacogenetics; Psychotic Disorders; Schizophrenia	2017
Antipsychotic-associated psoriatic rash - a case report. BMC psychiatry, 2017, 07-04, Volume: 17, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Psoriasis; Quetiapine Fumarate; Schizophrenia; Young Adult	2017
Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia. Schizophrenia research, 2018, Volume: 193 Topics: Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Autonomic Nervous System Diseases; Benzodiazepines; Cross-Sectional Studies; Electrocardiography; Female; Heart Rate; Humans; Japan; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia	2018
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. The pharmacogenomics journal, 2018, 05-22, Volume: 18, Issue:3 Topics: Adolescent; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Child; Child, Preschool; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Humans; Male; Neoplasm Proteins; Olanzapine; Pediatrics; Polymorphism, Genetic; Quetiapine Fumarate; Risperidone; Schizophrenia; Young Adult	2018
Attributions to new onset catatonic symptoms, late in the course of chronic schizophrenia. Asian journal of psychiatry, 2017, Volume: 30 Topics: Amlodipine; Antihypertensive Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; GABA Modulators; Humans; Hydrochlorothiazide; Lorazepam; Male; Middle Aged; Schizophrenia; Telmisartan; Time	2017
Reduced insomnia following short-term administration of suvorexant during aripiprazole once-monthly treatment in a patient with schizophrenia. Asian journal of psychiatry, 2017, Volume: 28 Topics: Adult; Antipsychotic Agents; Aripiprazole; Azepines; Female; Humans; Schizophrenia; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles	2017
[Analysis of early response to the antipsychotic treatment and related factors in acute schizophrenia patients]. Zhonghua yi xue za zhi, 2017, Aug-15, Volume: 97, Issue:31 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Retrospective Studies; Schizophrenia; Treatment Outcome	2017
Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study. PloS one, 2017, Volume: 12, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Therapy, Combination; Employment; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Schizophrenia	2017
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. Clinical therapeutics, 2017, Volume: 39, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost Savings; Delayed-Action Preparations; Female; Health Care Costs; Hospitalization; Humans; Injections; Long-Term Care; Male; Medicaid; Medication Adherence; Middle Aged; Olanzapine; Paliperidone Palmitate; Practice Patterns, Physicians'; Risperidone; Schizophrenia; United States; Young Adult	2017
[Efficacy of low-Dose Aripiprazole to Treat Clozapine-Associated Tardive Dystonia in a Patient with Schizophrenia]. Turk psikiyatri dergisi = Turkish journal of psychiatry, 2017,Fall, Volume: 28, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Diagnosis, Differential; Female; Humans; Middle Aged; Schizophrenia; Tardive Dyskinesia	2017
Study on the prescribing patterns of antipsychotic medication in a rural England Community Mental Health Team. Psychiatria Danubina, 2017, Volume: 29, Issue:Suppl 3 Topics: Adult; Antipsychotic Agents; Aripiprazole; England; Humans; Mental Health; Practice Patterns, Physicians'; Risperidone; Rural Population; Schizophrenia	2017
Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:6 Topics: Aged; Alcoholism; Antipsychotic Agents; Aripiprazole; Clozapine; Comorbidity; Drug Substitution; Humans; Male; Schizophrenia	2017
Aripiprazole-induced tardive dyskinesia in patients with schizophrenia: A case report of twins. Schizophrenia research, 2018, Volume: 197 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Schizophrenia; Tardive Dyskinesia; Twins, Monozygotic	2018
Poly(I:C) model of schizophrenia in rats induces sex-dependent functional brain changes detected by MRI that are not reversed by aripiprazole treatment. Brain research bulletin, 2018, Volume: 137 Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Cerebrovascular Circulation; Disease Models, Animal; Female; Magnetic Resonance Imaging; Male; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Rats, Wistar; Schizophrenia; Sex Characteristics	2018
Associations of ABCB1 gene polymorphisms with aripiprazole-induced autonomic nervous system dysfunction in schizophrenia. Schizophrenia research, 2018, Volume: 197 Topics: Adult; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; Autonomic Nervous System; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Polymorphism, Genetic; Schizophrenia	2018
Weight gain changes in patients with aripiprazole monotherapy compared with aripiprazole-antidepressant polypharmacy in an outpatient sample. Journal of psychopharmacology (Oxford, England), 2018, Volume: 32, Issue:4 Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Body Mass Index; Cohort Studies; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mood Disorders; Outpatients; Polypharmacy; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Weight Gain	2018
Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia. Schizophrenia research, 2018, Volume: 197 Topics: Adult; Anticipation, Psychological; Antipsychotic Agents; Aripiprazole; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Piperidines; Prefrontal Cortex; Reward; Schizophrenia; Ventral Striatum	2018
Rhabdomyolysis and elevated liver enzymes after rapid correction of hyponatremia due to pneumonia and concurrent use of aripiprazole: A case report. The Australian and New Zealand journal of psychiatry, 2018, Volume: 52, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyponatremia; Liver; Male; Middle Aged; Pneumonia; Rhabdomyolysis; Schizophrenia	2018
Aripiprazole-induced transient myopia: A rare entity. Indian journal of ophthalmology, 2018, Volume: 66, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Microscopy, Acoustic; Myopia; Refraction, Ocular; Schizophrenia; Slit Lamp Microscopy; Young Adult	2018
Enhancement of In Vivo Efficacy and Oral Bioavailability of Aripiprazole with Solid Lipid Nanoparticles. AAPS PharmSciTech, 2018, Volume: 19, Issue:3 Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Biological Availability; Drug Carriers; Male; Mice; Nanoparticles; Particle Size; Rats; Rats, Wistar; Schizophrenia; Surface-Active Agents; Triglycerides	2018
Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2018, Volume: 10, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Biomarkers; Humans; Male; Middle Aged; Paliperidone Palmitate; Prolactin; Schizophrenia; Treatment Outcome	2018
Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study. International clinical psychopharmacology, 2018, Volume: 33, Issue:3 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Cohort Studies; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Psychotic Disorders; Schizophrenia; Taiwan; Tardive Dyskinesia	2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents. European psychiatry : the journal of the Association of European Psychiatrists, 2018, Volume: 49 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Comorbidity; Depressive Disorder, Major; Female; Humans; Incidence; Infant; Male; Mental Disorders; Norway; Olanzapine; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia	2018
Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. International clinical psychopharmacology, 2018, Volume: 33, Issue:3 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Hospitals, Psychiatric; Humans; Middle Aged; Psychotic Disorders; Retrospective Studies; Risperidone; Schizophrenia; Survival Analysis; Young Adult	2018
Pharmacoinformatics and Molecular Docking Studies Reveal Potential Novel Compounds Against Schizophrenia by Target SYN II. Combinatorial chemistry & high throughput screening, 2018, Volume: 21, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Computational Biology; Drug Discovery; Humans; Models, Molecular; Molecular Docking Simulation; Schizophrenia; Synapsins	2018
Factors related to the continuation of aripiprazole once-monthly treatment at 1 year. Asian journal of psychiatry, 2018, Volume: 31 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cohort Studies; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Patient Compliance; Retrospective Studies; Schizophrenia; Treatment Outcome; Withholding Treatment	2018
Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International clinical psychopharmacology, 2018, Volume: 33, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Paliperidone Palmitate; Reproducibility of Results; Schizophrenia; Treatment Outcome	2018
DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study. Journal of psychiatric research, 2018, Volume: 100 Topics: Adult; Aripiprazole; CpG Islands; DNA Methylation; Dopamine D2 Receptor Antagonists; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Protein Serine-Threonine Kinases; Schizophrenia	2018
Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, 2018, Volume: 46, Issue:2 Topics: Aripiprazole; Bipolar Disorder; Drug Monitoring; Drug Packaging; Humans; Medication Adherence; Schizophrenia; Signal Processing, Computer-Assisted	2018
SIMULTANEOUS ASSAY OF ARIPIPRAZOLE AND ITS ACTIVE METABOLITE IN SERUM BY HPLC. Acta poloniae pharmaceutica, 2017, Volume: 74, Issue:2 Topics: Acetonitriles; Activation, Metabolic; Antipsychotic Agents; Aripiprazole; Buffers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Compounding; Drug Monitoring; Humans; Hydrogen-Ion Concentration; Phosphoric Acids; Piperazines; Quinolones; Schizophrenia; Solvents; Water	2017
Changes in length of hospital stay and number of hospitalization before and after the administration of three second-generation antipsychotics long-acting injections in patients with schizophrenia: Mirror-image study. Asian journal of psychiatry, 2018, Volume: 34 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Hospitalization; Humans; Length of Stay; Male; Paliperidone Palmitate; Risperidone; Schizophrenia; Treatment Outcome	2018
Aripiprazole Nanocrystal Impregnated Buccoadhesive Films for Schizophrenia. Journal of nanoscience and nanotechnology, 2017, Volume: 17, Issue:4 Topics: Animals; Antipsychotic Agents; Aripiprazole; Chitosan; Drug Delivery Systems; Drug Liberation; Mouth Mucosa; Nanoparticles; Rabbits; Schizophrenia	2017
The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [ Translational psychiatry, 2018, 04-24, Volume: 8, Issue:1 Topics: Adult; Aripiprazole; Cognition; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Female; Humans; Male; Memory, Short-Term; Positron-Emission Tomography; Prospective Studies; Raclopride; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Schizophrenic Psychology	2018
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA. Journal of comparative effectiveness research, 2018, Volume: 7, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Budgets; Cost-Benefit Analysis; Delayed-Action Preparations; Dibenzocycloheptenes; Drug Administration Schedule; Drug Costs; Health Care Costs; Heterocyclic Compounds, 4 or More Rings; Hospitalization; Humans; Injections, Intramuscular; Injections, Subcutaneous; Medication Adherence; Paliperidone Palmitate; Piperazines; Schizophrenia	2018
[Aripiprazole for drug-induced sexual dysfunction in schizophrenic males]. Zhonghua nan ke xue = National journal of andrology, 2017, Volume: 23, Issue:7 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Prolactin; Risperidone; Schizophrenia; Sexual Behavior; Sexual Dysfunction, Physiological; Sulpiride; Testosterone; Treatment Outcome	2017
Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Human psychopharmacology, 2018, Volume: 33, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult	2018
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. International clinical psychopharmacology, 2018, Volume: 33, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain	2018
High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. BMC psychiatry, 2018, 06-08, Volume: 18, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Mass Index; Cholesterol, HDL; Correlation of Data; Female; Humans; Japan; Male; Middle Aged; Olanzapine; Overweight; Prevalence; Risperidone; Schizophrenia; Surveys and Questionnaires; Waist Circumference	2018
Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. Pharmacological reports : PR, 2018, Volume: 70, Issue:4 Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Disease Models, Animal; Dizocilpine Maleate; Drug Synergism; Drug Therapy, Combination; Hyperkinesis; Male; Memory Disorders; Mianserin; Mice; Mirtazapine; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology	2018
[Using the cumulative odds Logit model to explore the application of the questionnaire derived from PANSS]. Yao xue xue bao = Acta pharmaceutica Sinica, 2016, Volume: 51, Issue:10 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Logistic Models; Olanzapine; Risperidone; Schizophrenia; Surveys and Questionnaires	2016
Combination therapy of electroconvulsive therapy and aripiprazole for dopamine supersensitivity psychosis. Schizophrenia research, 2018, Volume: 202 Topics: Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Electroconvulsive Therapy; Humans; Male; Middle Aged; Psychoses, Substance-Induced; Schizophrenia	2018
Aripiprazole and pregnancy: A retrospective, multicentre study. Journal of affective disorders, 2018, 10-01, Volume: 238 Topics: Adult; Antipsychotic Agents; Aripiprazole; Australia; Bipolar Disorder; Birth Weight; Female; Humans; Hypertension; Infant, Newborn; Maternal Exposure; Mental Disorders; Pregnancy; Pregnancy Complications; Retrospective Studies; Schizophrenia	2018
Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia. BMC psychiatry, 2018, 07-17, Volume: 18, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; Autonomic Nervous System; Cross-Sectional Studies; Female; Heart Rate; Humans; Male; Middle Aged; Olanzapine; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Risperidone; Schizophrenia	2018
Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors. Experimental and clinical psychopharmacology, 2018, Volume: 26, Issue:5 Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Antipsychotic Agents; Aripiprazole; Atrial Fibrillation; Drug Substitution; Electric Countershock; Electrocardiography; Humans; Male; Psychiatric Status Rating Scales; Risk Factors; Schizophrenia; Treatment Outcome	2018
Comparisons of the effects of second-generation antipsychotics long-acting injections on treatment retention according to severity of patient condition. Asian journal of psychiatry, 2018, Volume: 37 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections; Japan; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia; Severity of Illness Index	2018
Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data. Advances in therapy, 2018, Volume: 35, Issue:10 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cohort Studies; Delayed-Action Preparations; Drug Administration Routes; Female; Humans; Insurance Claim Review; Male; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; United States	2018
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies. Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:6 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Clozapine; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Young Adult	2018
Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers. Current medical research and opinion, 2019, Volume: 35, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Community Health Centers; Female; Humans; Male; Medication Adherence; Middle Aged; Schizophrenia; Young Adult	2019
Treatment Continuation of 3 Second-Generation Antipsychotic Long-Acting Injections, and Oral Paliperidone in Patients With Schizophrenia for 2 Years. Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:6 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Cohort Studies; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Injections; Male; Middle Aged; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia; Treatment Outcome	2018
Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. Psychopharmacology, 2019, Volume: 236, Issue:2 Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Predictive Value of Tests; Retrospective Studies; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome	2019
Mortality rate is associated with aripiprazole once-monthly and oral asenapine administration. Asian journal of psychiatry, 2019, Volume: 39 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Male; Middle Aged; Retrospective Studies; Schizophrenia; Suicide	2019
Combined typical and atypical long-acting injectable antipsychotics in treatment-resistant schizophrenia: Two cases. Psychiatry and clinical neurosciences, 2019, Volume: 73, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Flupenthixol; Humans; Male; Middle Aged; Paliperidone Palmitate; Schizophrenia; Treatment Outcome	2019
A Case Report of the Oral Ingestion of Aripiprazole Long-Acting Injectable. The primary care companion for CNS disorders, 2018, Nov-08, Volume: 20, Issue:6 Topics: Administration, Oral; Adult; Aripiprazole; Delayed-Action Preparations; Female; Hallucinations; Humans; Injections; Medication Adherence; Schizophrenia	2018
Clozapine-induced obsessive–compulsive symptoms: mechanisms and treatment Journal of psychiatry & neuroscience : JPN, 2019, 01-01, Volume: 44, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Schizophrenia	2019
Pharmacoinformatics and molecular docking reveal potential drug candidates against Schizophrenia to target TAAR6. Journal of cellular physiology, 2019, Volume: 234, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Cell Cycle Proteins; Computational Biology; Drug Design; Humans; Molecular Docking Simulation; Protein Conformation; Receptors, G-Protein-Coupled; Schizophrenia	2019
Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. European archives of psychiatry and clinical neuroscience, 2020, Volume: 270, Issue:1 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Female; Humans; Male; Middle Aged; Schizophrenia; Young Adult	2020
Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents. Journal of psychosocial nursing and mental health services, 2019, Feb-01, Volume: 57, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Dopamine D2 Receptor Antagonists; Humans; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin Antagonists; Thiophenes	2019
Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China. Journal of medical economics, 2019, Volume: 22, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; China; Cost-Benefit Analysis; Drug Compounding; Health Resources; Humans; Medication Adherence; Models, Econometric; Olanzapine; Quality-Adjusted Life Years; Recurrence; Schizophrenia	2019
Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. Schizophrenia research, 2019, Volume: 208 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Substitution; Female; Humans; Injections; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Prospective Studies; Schizophrenia	2019
Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients. Irish journal of medical science, 2019, Volume: 188, Issue:4 Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cytochrome P-450 CYP2D6; Female; Humans; Hyperprolactinemia; Male; Phenotype; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Young Adult	2019
Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA psychiatry, 2019, 05-01, Volume: 76, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Readmission; Polypharmacy; Schizophrenia; Treatment Outcome	2019
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons. Psychoneuroendocrinology, 2019, Volume: 104 Topics: Animals; Antipsychotic Agents; Aripiprazole; Cell Line; Clozapine; Energy Metabolism; Hypothalamus; Inflammation; Insulin; Insulin Resistance; MAP Kinase Signaling System; Neurons; Olanzapine; Phosphorylation; Rats; Schizophrenia; Signal Transduction	2019
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice. Neuropharmacology, 2019, 05-15, Volume: 150 Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperidol; Hippocampus; Methylazoxymethanol Acetate; Mice; Motor Activity; Pregnancy; Prenatal Exposure Delayed Effects; Prepulse Inhibition; Risperidone; Schizophrenia	2019
Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice. Psychiatry research, 2019, Volume: 272 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Italy; Male; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Treatment Outcome	2019
Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in therapy, 2019, Volume: 36, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Utilization Review; Female; Humans; Injections; Male; Medicaid; Paliperidone Palmitate; Patient Selection; Practice Patterns, Physicians'; Schizophrenia; United States	2019
Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report. Journal of psychiatric practice, 2019, Volume: 25, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Humans; Male; Olanzapine; Schizophrenia; Weight Loss	2019
Commentary: Aripiprazole: The Second Wave of the Second-generation Antipsychotics. Journal of psychiatric practice, 2019, Volume: 25, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agents; History, 21st Century; Humans; Mental Disorders; Psychotic Disorders; Schizophrenia	2019
Should a Psychiatrist Prescribe a Nanodrug to Help Parents Monitor a Teen's Adherence? AMA journal of ethics, 2019, 04-01, Volume: 21, Issue:4 Topics: Adolescent; Adolescent Psychiatry; Adult; Antipsychotic Agents; Aripiprazole; Biological Monitoring; Humans; Male; Medication Adherence; Middle Aged; Nanocapsules; Parents; Physicians; Schizophrenia; Surveys and Questionnaires	2019
Should Trackable Pill Technologies Be Used to Facilitate Adherence Among Patients Without Insight? AMA journal of ethics, 2019, 04-01, Volume: 21, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Biological Monitoring; Humans; Male; Medication Adherence; Nanocapsules; Nanomedicine; Practice Guidelines as Topic; Schizophrenia; Surveys and Questionnaires	2019
Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. Journal of medical economics, 2019, Volume: 22, Issue:11 Topics: Administration, Oral; Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Comorbidity; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Insurance Claim Review; Kaplan-Meier Estimate; Longitudinal Studies; Male; Medicaid; Medication Adherence; Middle Aged; Paliperidone Palmitate; Proportional Hazards Models; Racial Groups; Retrospective Studies; Risperidone; Schizophrenia; Sex Factors; United States	2019
Inhibition of Recombinant Human Acetylcholinesterase Activity by Antipsychotics. Pharmacology, 2019, Volume: 104, Issue:1-2 Topics: Acetylcholinesterase; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Enzyme Assays; GPI-Linked Proteins; HEK293 Cells; Humans; Inhibitory Concentration 50; Recombinant Proteins; Schizophrenia	2019
Management of sexual adverse effects induced by atypical antipsychotic medication Journal of psychiatry & neuroscience : JPN, 2019, 07-01, Volume: 44, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological	2019
Factors That Affect Continuation of Antipsychotic Long-Acting Injections. Biological & pharmaceutical bulletin, 2019, Volume: 42, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Risperidone; Schizophrenia	2019
Aripiprazole Combined with Lamotrigine in the Treatment of a Treatment-Resistant Schizophrenic Patient with Tardive Dyskinesia and Supersensitivity Psychosis. Psychotherapy and psychosomatics, 2019, Volume: 88, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; Humans; Lamotrigine; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Treatment Outcome	2019
Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats. Pharmacological reports : PR, 2019, Volume: 71, Issue:5 Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Dizocilpine Maleate; Drug Therapy, Combination; Male; Motor Activity; Rats, Sprague-Dawley; Schizophrenia; Social Behavior	2019
Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics. The American journal of managed care, 2019, Volume: 25, Issue:14 Suppl Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Female; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia	2019
The impact of the ambiguous definition of "month" on pharmacotherapy. Medical hypotheses, 2019, Volume: 129 Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Therapy; Humans; Medication Adherence; Models, Theoretical; Paliperidone Palmitate; Schizophrenia; Software; Spain; Time	2019
Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China. Acta pharmacologica Sinica, 2019, Volume: 40, Issue:12 Topics: Adult; Antipsychotic Agents; Aripiprazole; China; Female; Humans; Male; Middle Aged; Models, Biological; Olanzapine; Prospective Studies; Risperidone; Schizophrenia; Young Adult	2019
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment. Psychological medicine, 2013, Volume: 43, Issue:11 Topics: Adolescent; Adult; Anisotropy; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Brain Mapping; Case-Control Studies; Dibenzothiazepines; Diffusion Tensor Imaging; Female; Frontal Lobe; Gyrus Cinguli; Haloperidol; Humans; Image Processing, Computer-Assisted; Male; Nerve Fibers, Myelinated; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome; Young Adult	2013
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia. Asian journal of psychiatry, 2013, Volume: 6, Issue:2 Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia; Inhibition, Psychological; Locomotion; Male; Neuropsychological Tests; Piperazines; Quinolones; Rats; Rats, Gunn; Reflex, Startle; Risperidone; Schizophrenia; Social Behavior; Treatment Outcome	2013
Dose-related reversible hypotension during aripiprazole treatment. The Journal of neuropsychiatry and clinical neurosciences, 2013,Winter, Volume: 25, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Hypotension; Male; Piperazines; Quinolones; Schizophrenia; Young Adult	2013
Association of estrogen receptor alpha gene polymorphism with age at onset, general psychopathology symptoms, and therapeutic effect of schizophrenia. Behavioral and brain functions : BBF, 2013, Mar-15, Volume: 9 Topics: Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Asian People; Data Interpretation, Statistical; Diagnostic and Statistical Manual of Mental Disorders; DNA; Estrogen Receptor alpha; Female; Genotype; Haplotypes; Humans; Kaplan-Meier Estimate; Male; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2013
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period. Pharmacological reports : PR, 2013, Volume: 65, Issue:1 Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Cognition Disorders; Depression; Disease Models, Animal; Drug Administration Schedule; Female; Male; Maze Learning; Memory Disorders; Olanzapine; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological; Time Factors	2013
Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease. European archives of psychiatry and clinical neuroscience, 2013, Volume: 263, Issue:4 Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Biomarkers; Disease Progression; Histone Deacetylase Inhibitors; Humans; Piperazines; Quinolones; Schizophrenia	2013
Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. The Australian and New Zealand journal of psychiatry, 2014, Volume: 48, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Humans; Inpatients; Male; Middle Aged; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Republic of Korea; Schizophrenia	2014
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of medical economics, 2013, Volume: 16, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States	2013
A case report of partial bowel obstruction after aripiprazole addition to clozapine in a young male with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Defecation; Drug Substitution; Drug Therapy, Combination; Humans; Intestinal Obstruction; Lamotrigine; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Treatment Outcome; Triazines	2013
Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia. Nordic journal of psychiatry, 2014, Volume: 68, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brief Psychiatric Rating Scale; Child; Cognition; Female; Humans; Male; Neuropsychological Tests; Piperazines; Prospective Studies; Psychotic Disorders; Quality of Life; Quinolones; Schizophrenia; Taiwan; Treatment Outcome; Young Adult	2014
Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia. British journal of clinical pharmacology, 2014, Volume: 77, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quinolones; Schizophrenia	2014
Aspirin as an adjunctive treatment for childhood onset schizophrenia. Journal of child and adolescent psychopharmacology, 2013, Volume: 23, Issue:8 Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aripiprazole; Aspirin; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia	2013
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. CNS spectrums, 2014, Volume: 19, Issue:4 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Humans; Hypochondriasis; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Paliperidone Palmitate; Prevalence; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride	2014
The effects of antipsychotic switching on diabetes in chronic schizophrenia. Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Weight Loss	2014
Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addictive behaviors, 2014, Volume: 39, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Female; Gambling; Humans; Male; Middle Aged; Piperazines; Quinolones; Risk Factors; Schizophrenia; Young Adult	2014
Combination of escitalopram and aripiprazole causes significant improvement of negative symptoms of simple schizophrenia. Psychiatry and clinical neurosciences, 2014, Volume: 68, Issue:7 Topics: Aripiprazole; Citalopram; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2014
Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic drug monitoring, 2014, Volume: 36, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Schizophrenia; Young Adult	2014
Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Human psychopharmacology, 2014, Volume: 29, Issue:2 Topics: Adult; Alkaline Phosphatase; Antipsychotic Agents; Aripiprazole; Bone Density; Chlorpromazine; Clozapine; Dibenzothiazepines; Estrogens; Female; Humans; Male; Middle Aged; Osteoporosis; Perphenazine; Piperazines; Prolactin; Prospective Studies; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sulpiride	2014
Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia. Therapeutic drug monitoring, 2014, Volume: 36, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia	2014
Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of medical economics, 2014, Volume: 17, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Humans; Injections, Intramuscular; Isoxazoles; Paliperidone Palmitate; Palmitates; Piperazines; Quinolones; Schizophrenia; United States	2014
Effects of antipsychotic drugs on insight in schizophrenia. Psychiatry research, 2014, Aug-15, Volume: 218, Issue:1-2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles	2014
Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole. Journal of psychiatric practice, 2014, Volume: 20, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Hypertriglyceridemia; Liver; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Transaminases; Treatment Outcome	2014
Association of microRNA137 gene polymorphisms with age at onset and positive symptoms of schizophrenia in a Han Chinese population. International journal of psychiatry in medicine, 2014, Volume: 47, Issue:2 Topics: Adult; Age of Onset; Aripiprazole; China; Female; Genetic Predisposition to Disease; Genotype; Humans; Male; MicroRNAs; Phenotype; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2014
High doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine. The Australian and New Zealand journal of psychiatry, 2015, Volume: 49, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia	2015
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia. Journal of psychiatry & neuroscience : JPN, 2015, Volume: 40, Issue:2 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Mapping; Clozapine; Executive Function; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Obsessive Behavior; Olanzapine; Piperazines; Prefrontal Cortex; Psychiatric Status Rating Scales; Psychomotor Performance; Quinolones; Schizophrenia; Sulpiride	2015
Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of medical economics, 2015, Volume: 18, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; North America; Retrospective Studies; Schizophrenia; Socioeconomic Factors	2015
What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia? The Journal of clinical psychiatry, 2014, Volume: 75, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia	2014
Long-acting injectable antipsychotics: an underutilized treatment option. The Journal of clinical psychiatry, 2014, Volume: 75, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia	2014
Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain. Psychiatry research, 2015, Feb-28, Volume: 225, Issue:3 Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebral Cortex; Female; Haloperidol; Hippocampus; Neuregulin-1; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, ErbB-4; Schizophrenia; Signal Transduction; Time Factors; Up-Regulation	2015
Here/In this issue and there/abstract thinking: trials in child psychiatry: and now … be more pragmatic, please! Journal of the American Academy of Child and Adolescent Psychiatry, 2015, Volume: 54, Issue:2 Topics: Adolescent; Aripiprazole; Bipolar Disorder; Child; Child Psychiatry; Child Rearing; Cognitive Behavioral Therapy; Humans; Paliperidone Palmitate; Periodicals as Topic; Pragmatic Clinical Trials as Topic; Schizophrenia	2015
Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Drug Substitution; Humans; Italy; Piperazines; Quinolones; Schizophrenia	2015
Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Partial Agonism; Female; Humans; Male; Middle Aged; Psychoses, Substance-Induced; Retrospective Studies; Schizophrenia; Young Adult	2015
Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Scientific reports, 2015, Mar-10, Volume: 5 Topics: Animals; Aripiprazole; Calcium Signaling; Dopamine; Female; Humans; Hyperprolactinemia; Lactotrophs; Paliperidone Palmitate; Prolactin; Rats; Schizophrenia; Signal Transduction	2015
Aripiprazole-induced chorioretinopathy: multimodal imaging and electrophysiological features. Documenta ophthalmologica. Advances in ophthalmology, 2015, Volume: 131, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Coloring Agents; Dark Adaptation; Electrooculography; Electroretinography; Female; Fluorescein Angiography; Humans; Indocyanine Green; Middle Aged; Multimodal Imaging; Piperazines; Quinolones; Retina; Retinal Diseases; Retinal Pigment Epithelium; Schizophrenia; Tomography, Optical Coherence; Visual Acuity	2015
The Influence of the CYP3A422 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:3* Topics: Adolescent; Adult; Alleles; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Genotype; Haloperidol; Heterozygote; Humans; Male; Middle Aged; Pimozide; Polymorphism, Single Nucleotide; Retrospective Studies; Risperidone; Schizophrenia; Young Adult	2015
Influence of -141C Ins/Del Polymorphism in DRD2 Gene on Clinical Symptoms and Plasma Homovanillic Acid Levels in the Treatment of Schizophrenia With Aripiprazole. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Homovanillic Acid; Humans; INDEL Mutation; Male; Methoxyhydroxyphenylglycol; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology	2015
Bethanechol and Aripiprazole for the management of refractory urinary incontinence in a patient on Clozapine. The Australian and New Zealand journal of psychiatry, 2016, Volume: 50, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Bethanechol; Clozapine; Female; Humans; Middle Aged; Schizophrenia; Urinary Incontinence	2016
Using aripiprazole to treat new-onset hyperprolactinemia-related delusion of pregnancy. The Australian and New Zealand journal of psychiatry, 2015, Volume: 49, Issue:10 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Hyperprolactinemia; Risperidone; Schizophrenia	2015
The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert review of neurotherapeutics, 2015, Volume: 15, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Randomized Controlled Trials as Topic; Schizophrenia	2015
Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:9 Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cohort Studies; Drug Costs; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Patient Acceptance of Health Care; Retrospective Studies; Schizophrenia	2015
Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophrenia bulletin, 2015, Volume: 41, Issue:6 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Genetic Loci; Humans; Male; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Psychotic Disorders; Randomized Controlled Trials as Topic; Receptors, Dopamine D2; Risk; Risperidone; Schizophrenia; Young Adult	2015
First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards). Schizophrenia bulletin, 2015, Volume: 41, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Risperidone; Schizophrenia	2015
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. Journal of medical economics, 2016, Volume: 19, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Finland; Humans; Male; Olanzapine; Paliperidone Palmitate; Risperidone; Schizophrenia	2016
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. International journal of clinical practice, 2015, Volume: 69, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Thiophenes	2015
Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design. International journal of nanomedicine, 2015, Volume: 10 Topics: Antipsychotic Agents; Aripiprazole; Capsules; Chemistry, Pharmaceutical; Emulsions; Nanomedicine; Schizophrenia	2015
Two long-acting injectable antipsychotics for schizophrenia. The Medical letter on drugs and therapeutics, 2015, Nov-09, Volume: 57, Issue:1481 Topics: Antipsychotic Agents; Aripiprazole; Double-Blind Method; Humans; Injections; Paliperidone Palmitate; Schizophrenia; United States; United States Food and Drug Administration	2015
Influence of aripiprazole once monthly on clinical symptoms and cognitive function in two schizophrenia patients: Preliminary results. Psychiatry and clinical neurosciences, 2016, Volume: 70, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Delayed-Action Preparations; Drug Administration Schedule; Humans; Male; Middle Aged; Schizophrenia; Schizophrenic Psychology	2016
An observational study of clozapine induced sedation and its pharmacological management. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2016, Volume: 26, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Humans; Hypnotics and Sedatives; Prospective Studies; Schizophrenia; Sleep; Treatment Outcome	2016
The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2016, Volume: 26, Issue:2 Topics: Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Association Learning; Developmental Disabilities; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Exploratory Behavior; Interpersonal Relations; Locomotion; Male; Memory Disorders; Phencyclidine; Piperazines; Rats; Recognition, Psychology; Schizophrenia	2016
Making Progress Toward Individualized Medicine in the Treatment of Psychosis. The American journal of psychiatry, 2016, Volume: 173, Issue:1 Topics: Aripiprazole; Corpus Striatum; Ether-A-Go-Go Potassium Channels; Female; Humans; Male; Risperidone; Schizophrenia	2016
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. The journal of mental health policy and economics, 2015, Volume: 18, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Computer Simulation; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections, Intramuscular; Markov Chains; Models, Economic; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; State Medicine; United Kingdom	2015
Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: A prospective observational study. Psychiatry research, 2016, Feb-28, Volume: 236 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Female; Humans; Male; Middle Aged; Prospective Studies; Schizophrenia; Time Factors; Treatment Outcome; Withholding Treatment; Young Adult	2016
Editorial. The journal of mental health policy and economics, 2015, Volume: 18, Issue:4 Topics: Antidepressive Agents; Anxiety Disorders; Aripiprazole; Cost-Benefit Analysis; Cross-Cultural Comparison; Delayed-Action Preparations; Depressive Disorder; Drug Costs; Humans; Injections, Intramuscular; Insurance Coverage; Insurance, Pharmaceutical Services; Schizophrenia	2015
Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study. Schizophrenia research, 2016, Volume: 170, Issue:2-3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Bipolar Disorder; Bone Remodeling; Estrogens; Female; Follow-Up Studies; Humans; Male; Middle Aged; PAX5 Transcription Factor; Prolactin; Prospective Studies; Psychotic Disorders; Schizophrenia; Sensitivity and Specificity; Testosterone; Young Adult	2016
Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. Expert opinion on drug safety, 2016, Volume: 15, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Consensus; Delayed-Action Preparations; Humans; Italy; Psychiatry; Schizophrenia; Spain	2016
Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS spectrums, 2016, Volume: 21, Issue:1 Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Thiophenes	2016
Aripiprazole long-acting injection: promising but more evidence needed. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2016, Volume: 24, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Injections, Intramuscular; Schizophrenia; Weight Gain	2016
Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Psychiatry research, 2016, Mar-30, Volume: 237 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Estradiol; Female; Humans; Hyperprolactinemia; Middle Aged; Paliperidone Palmitate; Prolactin; Risperidone; Schizophrenia; Treatment Outcome; Young Adult	2016
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol. Pharmacological reports : PR, 2016, Volume: 68, Issue:2 Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Disease Models, Animal; Ethanol; Female; Male; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological	2016
[Aripiprazole, gambling disorder and compulsive sexuality]. L'Encephale, 2016, Volume: 42, Issue:3 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Compulsive Behavior; Gambling; Humans; Male; Schizoid Personality Disorder; Schizophrenia; Sexual Behavior; Sexual Dysfunctions, Psychological; Sulpiride	2016
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:11 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Depression; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Prolactin; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult	2015
Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study. Clinical trials (London, England), 2016, Volume: 13, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Studies as Topic; Flupenthixol; Haloperidol; Humans; Olanzapine; Patient-Centered Care; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Research Design; Schizophrenia	2016
Aripiprazole relieves catatonia but worsens hallucination in a patient with catatonic schizophrenia. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2016, Volume: 8, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Delusions; Hallucinations; Humans; Male; Schizophrenia; Schizophrenia, Catatonic	2016
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. PharmacoEconomics, 2016, Volume: 34, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Financing, Personal; Humans; Lurasidone Hydrochloride; Markov Chains; Quality-Adjusted Life Years; Recurrence; Schizophrenia; Scotland; Wales	2016
Aripiprazole for the Treatment of Antipsychotic-Induced Hyperprolactinemia in an Adolescent Boy. Journal of child and adolescent psychopharmacology, 2016, Volume: 26, Issue:5 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Hyperprolactinemia; Male; Prolactin; Quinolones; Schizophrenia	2016
Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. Clinical pharmacology in drug development, 2016, Volume: 5, Issue:6 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Specimen Collection; Capillaries; Female; Fingers; Half-Life; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Schizophrenia; Veins; Young Adult	2016
Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats. Pharmacological reports : PR, 2016, Volume: 68, Issue:5 Topics: Animals; Antipsychotic Agents; Aripiprazole; Autoradiography; Benzodiazepines; Female; Male; Nucleus Accumbens; Olanzapine; Prefrontal Cortex; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia	2016
Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole. Journal of clinical psychopharmacology, 2016, Volume: 36, Issue:5 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Child, Preschool; Databases, Factual; Denmark; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Neurodevelopmental Disorders; Obsessive-Compulsive Disorder; Psychotic Disorders; Schizophrenia; Tourette Syndrome	2016
Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS spectrums, 2016, Volume: 21, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Prospective Studies; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2016
Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Evidence-based mental health, 2016, Volume: 19, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Humans; Schizophrenia; Treatment Outcome	2016
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study. Psychopharmacology, 2017, Volume: 234, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Substitution; Female; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Patient Satisfaction; Prospective Studies; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome	2017
Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium. Journal of medical ethics, 2017, Volume: 43, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Belgium; Benzodiazepines; Cross-Sectional Studies; Drug Industry; Drug Prescriptions; Drug Utilization Review; Female; Humans; Male; Middle Aged; Olanzapine; Practice Patterns, Physicians'; Quetiapine Fumarate; Risperidone; Schizophrenia	2017
Aripiprazole induced Impulse Control Disorders: Where do we stand? Asian journal of psychiatry, 2016, Volume: 23 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Young Adult	2016
5-HT1A C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Depression; Female; Humans; Male; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Young Adult	2017
A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia. Current neuropharmacology, 2017, Nov-14, Volume: 15, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Single-Blind Method; Statistics, Nonparametric; Treatment Outcome; Young Adult	2017
Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis. Current medical research and opinion, 2017, Volume: 33, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Insurance Claim Review; Lurasidone Hydrochloride; Male; Medicaid; Medication Adherence; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; United States	2017
Aripiprazole and Impulse-Control Disorders: A Recent FDA Warning and a Case Report. The primary care companion for CNS disorders, 2017, Jan-12, Volume: 19, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Humans; Male; Schizophrenia; United States; United States Food and Drug Administration	2017
Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series. Asian journal of psychiatry, 2017, Volume: 25 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Japan; Male; Middle Aged; Prolactin; Schizophrenia; Treatment Outcome	2017
Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia. International journal of molecular sciences, 2017, Mar-06, Volume: 18, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Brain-Derived Neurotrophic Factor; Cognition; Executive Function; Female; Homovanillic Acid; Humans; Male; Memory, Short-Term; Methoxyhydroxyphenylglycol; Middle Aged; Schizophrenia	2017
Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy. Diabetes care, 2008, Volume: 31, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Child; Diabetic Ketoacidosis; Humans; Male; Piperazines; Quinolones; Schizophrenia	2008
A case of aripiprazole and tardive dyskinesia. Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Schizophrenia; Young Adult	2009
The safety of the electroconvulsive therapy-aripiprazole combination: four case reports. The journal of ECT, 2008, Volume: 24, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Inpatients; Middle Aged; Piperazines; Quinolones; Safety; Schizophrenia	2008
Case report of aripiprazole usage during pregnancy. Archives of women's mental health, 2008, Volume: 11, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Infant, Newborn; Maternal Behavior; Piperazines; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Quinolones; Schizophrenia; Treatment Outcome	2008
D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole. Drug development and industrial pharmacy, 2008, Volume: 34, Issue:7 Topics: Antipsychotic Agents; Aripiprazole; Cholesterol; Delayed-Action Preparations; Lactic Acid; Microspheres; Particle Size; Piperazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Quinolones; Schizophrenia; Solubility; Solvents	2008
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia	2008
Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Therapeutic drug monitoring, 2008, Volume: 30, Issue:4 Topics: Adolescent; Adult; Aging; Antipsychotic Agents; Aripiprazole; Biotransformation; Body Mass Index; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Piperazines; Quinolones; Regression Analysis; Schizophrenia; Sex Characteristics; Young Adult	2008
New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life. The American journal of psychiatry, 2008, Volume: 165, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Corpus Striatum; Humans; Piperazines; Positron-Emission Tomography; Quality of Life; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Time Factors	2008
Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients. Current drug safety, 2008, Volume: 3, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Male; Mental Disorders; Middle Aged; Obsessive-Compulsive Disorder; Outcome Assessment, Health Care; Personality Disorders; Piperazines; Psychotropic Drugs; Quinolones; Retrospective Studies; Schizophrenia; Spain	2008
Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes & metabolism, 2008, Volume: 34, Issue:5 Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Dibenzothiazepines; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin-Secreting Cells; Male; Olanzapine; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia	2008
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole. Acta psychiatrica Scandinavica, 2008, Volume: 118, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Netherlands; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia	2008
Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Synapse (New York, N.Y.), 2008, Volume: 62, Issue:11 Topics: Animals; Aripiprazole; Dose-Response Relationship, Drug; Glutamic Acid; Humans; Male; Neuroprotective Agents; Piperazines; Prefrontal Cortex; Presynaptic Terminals; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia	2008
Aripiprazole-induced orthostatic hypotension and cardiac arrhythmia. Psychiatry and clinical neurosciences, 2008, Volume: 62, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Humans; Hypotension, Orthostatic; Middle Aged; Piperazines; Quinolones; Schizophrenia; Tachycardia, Supraventricular	2008
Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Libido; Piperazines; Quinolones; Schizophrenia; Sexual Dysfunction, Physiological	2008
Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Journal of psychiatric research, 2009, Volume: 43, Issue:6 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Genetic Predisposition to Disease; Hospitalization; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Protein Serine-Threonine Kinases; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Schizophrenia; Taiwan; Treatment Outcome; Young Adult	2009
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK . Current medical research and opinion, 2008, Volume: 24, Issue:11 Topics: Algorithms; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials, Phase I as Topic; Cost-Benefit Analysis; Decision Support Techniques; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Olanzapine; Patient Acceptance of Health Care; Piperazines; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; United Kingdom	2008
Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics. The American journal of psychiatry, 2009, Volume: 166, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Male; Myocardial Infarction; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Risperidone; Schizophrenia; Valproic Acid	2009
Successful switch from clozapine to aripiprazole: a case report. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Administration Schedule; Drug Resistance; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2009
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry and clinical neurosciences, 2009, Volume: 63, Issue:1 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Body Weight; Female; Humans; Korea; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Suicide; Young Adult	2009
Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Medical Records Systems, Computerized; Mental Health Services; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index	2009
Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy. Progress in neuro-psychopharmacology & biological psychiatry, 2009, Apr-30, Volume: 33, Issue:3 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Risperidone; Schizophrenia	2009
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. BMC psychiatry, 2009, Mar-31, Volume: 9 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome	2009
Influence of TAAR6 polymorphisms on response to aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry, 2009, Aug-01, Volume: 33, Issue:5 Topics: Adult; Aripiprazole; Cell Cycle Proteins; Female; Genetic Linkage; Genetic Markers; Haplotypes; Humans; Male; Middle Aged; Nuclear Proteins; Piperazines; Polymorphism, Single Nucleotide; Prospective Studies; Quinolones; Receptors, G-Protein-Coupled; Schizophrenia	2009
Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study. Pharmacopsychiatry, 2009, Volume: 42, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Germany; Health Status Indicators; Humans; Physicians' Offices; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychology; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome	2009
Aripiprazole in treatment-refractory schizophrenia. Journal of psychiatric practice, 2009, Volume: 15, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Consciousness Disorders; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Hospitalization; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology	2009
Use of aripiprazole in tardive dyskinesia: an open label study of six cases. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia	2009
Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry, 2009, Volume: 42, Issue:4 Topics: Adolescent; Age of Onset; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome; Young Adult	2009
Aripiprazole for the management of olanzapine-induced weight gain. Pharmacopsychiatry, 2009, Volume: 42, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Central Nervous System Agents; Cholesterol; Drug Therapy, Combination; Female; Glucose; Humans; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome; Triglycerides; Weight Gain	2009
Aripiprazole treatment of risperidone-induced hyperprolactinemia. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:7 Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia	2009
Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry, 2009, Nov-13, Volume: 33, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Young Adult	2009
Improvement in Pisa syndrome and tardive dyskinesia following aripiprazole treatment. The Journal of neuropsychiatry and clinical neurosciences, 2009,Summer, Volume: 21, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Schizophrenia; Syndrome; Treatment Outcome	2009
Therapy and quality of life of patients with psychosis. Psychiatria Danubina, 2009, Volume: 21 Suppl 1 Topics: Adult; Animal Assisted Therapy; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Family Therapy; Humans; Male; Object Attachment; Piperazines; Psychotherapy; Psychotherapy, Group; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Social Environment	2009
Clozapine-aripiprazole association in a 7-year-old girl with schizophrenia: clinical efficacy and successful management of neutropenia with lithium. Journal of child and adolescent psychopharmacology, 2009, Volume: 19, Issue:5 Topics: Antimanic Agents; Antipsychotic Agents; Aripiprazole; Child; Clozapine; Female; Humans; Lithium Carbonate; Neutropenia; Piperazines; Quinolones; Schizophrenia	2009
No influence of FAT polymorphisms in response to aripiprazole. Journal of human genetics, 2010, Volume: 55, Issue:1 Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cadherins; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Quinolones; Schizophrenia; Severity of Illness Index; Treatment Outcome	2010
Effectiveness of intramuscular aripiprazole injection in patients with catatonia: report on three cases. Pharmacopsychiatry, 2009, Volume: 42, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2009
Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. Psychiatry and clinical neurosciences, 2010, Volume: 64, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heart; Hormones; Humans; Japan; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Schizophrenia; Triglycerides	2010
Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents. Prescrire international, 2009, Volume: 18, Issue:104 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Approval; Europe; Humans; Piperazines; Quinolones; Schizophrenia	2009
[Aripiprazole-induced stuttering treated with risperidone]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2009, Volume: 31, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Risperidone; Schizophrenia; Stuttering	2009
Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. Psychopharmacology, 2010, Volume: 209, Issue:2 Topics: Acoustic Stimulation; Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Blinking; Female; Humans; Japan; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Reflex, Startle; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2010
Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature. Archives of women's mental health, 2010, Volume: 13, Issue:5 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Antagonists; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Secondary Prevention	2010
Pathological gambling and compulsive eating associated with aripiprazole. The Australian and New Zealand journal of psychiatry, 2010, Volume: 44, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Compulsive Behavior; Dose-Response Relationship, Drug; Eating; Female; Gambling; Humans; Middle Aged; Piperazines; Quinolones; Receptors, Dopamine D3; Schizophrenia; Weight Gain	2010
[Disappearance of paroxysmal perceptual alteration by switching to aripiprazole in a schizophrenic patient]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2010, Volume: 112, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Perceptual Distortion; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult	2010
Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophrenia research, 2010, Volume: 118, Issue:1-3 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Brain Mapping; Chlorpromazine; Female; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxygen; Photic Stimulation; Piperazines; Quinolones; Reaction Time; Schizophrenia; Schizophrenic Psychology; Time Factors; Visual Cortex; Young Adult	2010
Drug-induced Pisa syndrome associated with aripiprazole during clozapine treatment. Progress in neuro-psychopharmacology & biological psychiatry, 2010, May-30, Volume: 34, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Piperazines; Quinolones; Schizophrenia	2010
Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:2 Pt 2 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Female; Homovanillic Acid; Humans; Longitudinal Studies; Male; Methoxyhydroxyphenylglycol; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Young Adult	2010
Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:2 Pt 2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Treatment Failure; Young Adult	2010
[Difficulties in changing drugs--from clozapine to aripiprazole in ambulatory care]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2010, Volume: 12, Issue:1 Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Clozapine; Depressive Disorder, Major; Drug Administration Schedule; Humans; Interpersonal Relations; Male; Middle Aged; Obesity; Patient Education as Topic; Patient Satisfaction; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Spouses	2010
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost. American journal of therapeutics, 2011, Volume: 18, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Haloperidol; Humans; Injections, Intramuscular; Length of Stay; Male; Middle Aged; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles	2011
Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry, 2010, Aug-16, Volume: 34, Issue:6 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Schizophrenia	2010
Trial of aripiprazole in the treatment of first-episode schizophrenia. Psychiatry and clinical neurosciences, 2010, Volume: 64, Issue:1 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult	2010
Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. Psychiatry research, 2010, Jul-30, Volume: 178, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Carrier Proteins; Female; Humans; Intracellular Signaling Peptides and Proteins; Korea; Male; Neuropsychological Tests; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome	2010
Aripiprazole in pregnancy and lactation: a case report. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:2 Topics: Adult; Aripiprazole; Breast Feeding; Female; Humans; Infant, Newborn; Lactation; Male; Milk, Human; Piperazines; Pregnancy; Quinolones; Schizophrenia	2010
Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia. American family physician, 2010, Jun-01, Volume: 81, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia	2010
The use of aripiprazole in early onset schizophrenia: safety and efficacy. The Medical journal of Malaysia, 2009, Volume: 64, Issue:3 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia	2009
Changes in values of cholesterol and tryglicerides after weight loss during treatment with aripiprazole in a patient with schizophrenia - Case report. Psychiatria Danubina, 2010, Volume: 22, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Croatia; Dose-Response Relationship, Drug; Feeding Behavior; Humans; Life Style; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia; Triglycerides; Weight Loss	2010
Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility. Journal of forensic sciences, 2010, Volume: 55, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Crime; Forensic Psychiatry; Gambling; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Violence	2010
Diabetic ketoacidosis and elevated serum lipase in the setting of aripiprazole therapy. Diabetes care, 2010, Volume: 33, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Humans; Lipase; Male; Piperazines; Quinolones; Schizophrenia	2010
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity? Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain	2010
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 2010, Oct-01, Volume: 34, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia	2010
Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, Volume: 67, Issue:15 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Isoxazoles; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia	2010
Simultaneous determination of aripiprazole and its active metabolite, dehydroaripiprazole, in plasma by capillary electrophoresis combining on-column field-amplified sample injection and application in schizophrenia. Electrophoresis, 2010, Volume: 31, Issue:16 Topics: Adult; Amlodipine; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Electrophoresis, Capillary; Female; Humans; Hydrogen-Ion Concentration; Male; Piperazines; Quinolones; Reference Values; Schizophrenia; Solvents	2010
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:5 Topics: Adult; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Treatment Outcome	2010
No influence of DTNBP1 polymorphisms on the response to aripiprazole. Neuropsychobiology, 2010, Volume: 62, Issue:4 Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Carrier Proteins; Dysbindin; Dystrophin-Associated Proteins; Female; Haplotypes; Humans; Linkage Disequilibrium; Male; Piperazines; Polymorphism, Single Nucleotide; Quinolones; Schizophrenia	2010
Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents. Schizophrenia research, 2011, Volume: 125, Issue:1 Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; Behavioral Symptoms; Disease Models, Animal; Dizocilpine Maleate; Haloperidol; In Situ Nick-End Labeling; Inhibition, Psychological; Male; Methamphetamine; Microdialysis; Motor Activity; Neuroprotective Agents; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia	2011
A case of schizophrenia with Meige syndrome induced by long-term aripiprazole successfully treated with perospirone. Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jan-15, Volume: 35, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Meige Syndrome; Piperazines; Quinolones; Schizophrenia; Thiazoles; Young Adult	2011
Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Clinical schizophrenia & related psychoses, 2010, Volume: 4, Issue:3 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Japan; Male; Piperazines; Quinolones; Schizophrenia; Stupor; Treatment Outcome	2010
Epidemiologic study of aripiprazole use and the incidence of suicide events. Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:11 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Databases, Factual; Female; Humans; Incidence; Male; Middle Aged; Piperazines; Quinolones; Risk; Schizophrenia; Suicide; Suicide, Attempted; Young Adult	2010
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs. Schizophrenia research, 2011, Volume: 125, Issue:2-3 Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Body Mass Index; CLOCK Proteins; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Carrier Screening; Genotype; Humans; Long-Term Care; Male; Middle Aged; Mutation, Missense; Olanzapine; Period Circadian Proteins; Piperazines; Polymorphism, Single Nucleotide; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptor, Melanocortin, Type 3; Receptors, Glucocorticoid; Receptors, Leptin; Risperidone; Schizophrenia; Sex Factors; Sulpiride; Syndecan-3	2011
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex. Psychopharmacology, 2011, Volume: 214, Issue:3 Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors	2011
Neutropenia associated with quetiapine, olanzapine, and aripiprazole. The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Middle Aged; Neutropenia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia	2011
Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. The international journal of neuropsychopharmacology, 2011, Volume: 14, Issue:9 Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Immunohistochemistry; Locomotion; Male; Nerve Tissue Proteins; Neurons; Nucleus Accumbens; Piperazines; Proto-Oncogene Proteins c-fos; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia	2011
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current medical research and opinion, 2011, Volume: 27, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Treatment Outcome; United States; Young Adult	2011
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Progress in neuro-psychopharmacology & biological psychiatry, 2011, Mar-30, Volume: 35, Issue:2 Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Female; Humans; Inpatients; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain	2011
Effects of the CYP2D610 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic drug monitoring, 2011, Volume: 33, Issue:1* Topics: Alleles; Antipsychotic Agents; Aripiprazole; Asian People; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Genotype; Humans; Male; Piperazines; Quinolones; Schizophrenia	2011
Management of a patient with schizophrenia and underlying pituitary macroadenoma. Annals of the Academy of Medicine, Singapore, 2010, Volume: 39, Issue:11 Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromocriptine; Dopamine Antagonists; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Pituitary Neoplasms; Quinolones; Risperidone; Schizophrenia; Serotonin Antagonists; Trifluoperazine	2010
Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:1 Topics: Adult; Aripiprazole; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia	2011
Aripiprazole-induced pathological gambling: a report of 3 cases. Current drug safety, 2011, Feb-01, Volume: 6, Issue:1 Topics: Adolescent; Aripiprazole; Gambling; Humans; Male; Piperazines; Quinolones; Schizophrenia; Young Adult	2011
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophrenia bulletin, 2012, Volume: 38, Issue:4 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; Hospitalization; Hospitals, Psychiatric; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome	2012
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. BMC gastroenterology, 2011, Mar-08, Volume: 11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Clozapine; Constipation; Enema; Fecal Impaction; Female; Gastrointestinal Agents; Humans; Lactulose; Male; Middle Aged; Piperazines; Polyethylene Glycols; Prevalence; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Severity of Illness Index; Young Adult	2011
Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophrenia bulletin, 2012, Volume: 38, Issue:5 Topics: Animals; Antipsychotic Agents; Aripiprazole; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Long-Term Care; Male; Methamphetamine; Motor Activity; Piperazines; Psychoses, Substance-Induced; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia	2012
Placental transfer of aripiprazole. The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Maternal-Fetal Exchange; Piperazines; Pregnancy; Quinolones; Schizophrenia	2011
Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jun-01, Volume: 35, Issue:4 Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Linear Models; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Social Behavior; Treatment Outcome; Young Adult	2011
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychological medicine, 2011, Volume: 41, Issue:11 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Germany; Humans; Male; Matched-Pair Analysis; Obsessive-Compulsive Disorder; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia; Serotonin Antagonists; Severity of Illness Index; Sulpiride	2011
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jul-01, Volume: 35, Issue:5 Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Cohort Studies; Databases, Factual; Female; Hospitals, University; Humans; Male; Medical Records; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Quinolones; Republic of Korea; Retrospective Studies; Risperidone; Schizophrenia; Sex Factors; Young Adult	2011
Influence of prenatal undernutrition on the effects of clozapine and aripiprazole in the adult male rats: relevance to a neurodevelopmental origin of schizophrenia? European journal of pharmacology, 2011, Sep-30, Volume: 667, Issue:1-3 Topics: Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Clozapine; Disease Susceptibility; Eating; Female; Gene Expression Regulation; Hormones; Hypothalamus; Male; Malnutrition; Nervous System; Obesity; Piperazines; Pregnancy; Prenatal Nutritional Physiological Phenomena; Quinolones; Rats; Rats, Wistar; Schizophrenia	2011
Calculating occupancy when one does not have baseline: a comparison of different options. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2011, Volume: 31, Issue:8 Topics: Adult; Alkaloids; Antipsychotic Agents; Aripiprazole; Humans; Male; Methods; Piperazines; Positron-Emission Tomography; Protein Binding; Quinolones; Receptors, Dopamine D2; Reproducibility of Results; Schizophrenia; Young Adult	2011
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Crime; Delayed-Action Preparations; Dibenzothiazepines; Female; Florida; Humans; Isoxazoles; Male; Medicaid; Middle Aged; Olanzapine; Outpatients; Paliperidone Palmitate; Piperazines; Propensity Score; Pyrimidines; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Schizophrenia; Treatment Outcome; United States; Young Adult	2011
Perinatal use of aripiprazole: a case report. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Fetal Blood; Humans; Maternal-Fetal Exchange; Milk, Human; Piperazines; Postnatal Care; Pregnancy; Prenatal Care; Quinolones; Schizophrenia	2011
Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia". Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Risperidone; Schizophrenia	2011
High dosage of aripiprazole-induced dysphagia. The International journal of eating disorders, 2012, Volume: 45, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Deglutition Disorders; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2012
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta psychiatrica Scandinavica, 2011, Volume: 124, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Coronary Disease; Costs and Cost Analysis; Female; Humans; Male; Metabolic Diseases; Metabolism; Middle Aged; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quinolones; Risk Assessment; Schizophrenia; Sweden	2011
Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia. The Annals of pharmacotherapy, 2011, Volume: 45, Issue:7-8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Hallucinations; Humans; Loxapine; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2011
Aripiprazole-related body-weight gain and nutritional counseling. The Journal of neuropsychiatry and clinical neurosciences, 2011,Spring, Volume: 23, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain	2011
Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:4 Topics: Adolescent; Adult; Aripiprazole; Asian People; Benzodiazepines; Drug Substitution; Female; Heart Rate; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Young Adult	2011
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nordic journal of psychiatry, 2011, Volume: 65, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Models, Economic; National Health Programs; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sweden	2011
Pathological gambling and the treatment of psychosis with aripiprazole: case reports. The British journal of psychiatry : the journal of mental science, 2011, Volume: 199, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Male; Piperazines; Quinolones; Recurrence; Schizophrenia	2011
Aripiprazole induced transient myopia: a case report and review of literature. Cutaneous and ocular toxicology, 2012, Volume: 31, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Myopia; Piperazines; Quinolones; Schizophrenia	2012
Granulomatous cutaneous lesions associated with risperidone-induced hyperprolactinemia in an amputated upper limb. International journal of dermatology, 2012, Volume: 51, Issue:1 Topics: Amputation Stumps; Antipsychotic Agents; Aripiprazole; Forearm; Granuloma; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia; Skin Diseases; Treatment Outcome	2012
Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice. Acta pharmacologica Sinica, 2011, Volume: 32, Issue:10 Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Behavior, Animal; Brain; Comet Assay; Humans; Lipid Peroxidation; Male; Mice; Micronucleus Tests; Mutagens; Piperazines; Quinolones; Schizophrenia	2011
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2011, Volume: 13, Issue:3 Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hallucinations; Haloperidol; Humans; Hungary; Male; Marijuana Abuse; Olanzapine; Paranoid Disorders; Piperazines; Psychomotor Performance; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology	2011
Switching antipsychotic medications: not enough, too often, or just right? The American journal of psychiatry, 2011, Volume: 168, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia	2011
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress. Neuroscience research, 2011, Volume: 71, Issue:4 Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta Catenin; Blotting, Western; Brain-Derived Neurotrophic Factor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Hippocampus; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Restraint, Physical; Schizophrenia; Stress, Psychological	2011
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents. European child & adolescent psychiatry, 2011, Volume: 20, Issue:11-12 Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Child; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors	2011
Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report. The Journal of neuropsychiatry and clinical neurosciences, 2011,Summer, Volume: 23, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoxazoles; Movement Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia	2011
Aripiprazole-associated rhabdomyolysis in a patient with schizophrenia. The Journal of neuropsychiatry and clinical neurosciences, 2011,Summer, Volume: 23, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Rhabdomyolysis; Schizophrenia; Taiwan	2011
Manic induction with interferon alpha therapy. The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:11 Topics: Adult; Antipsychotic Agents; Antiviral Agents; Aripiprazole; Bipolar Disorder; Hepatitis C; Humans; Interferon-alpha; Male; Piperazines; Quinolones; Schizophrenia	2011
Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment. Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:6 Topics: Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Catatonia; Cerebrovascular Circulation; Female; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2011
Intermittent aripiprazole for schizophrenia. Schizophrenia research, 2012, Volume: 134, Issue:2-3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia	2012
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chi-Square Distribution; Clozapine; Dibenzothiazepines; Humans; Missouri; Olanzapine; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome	2012
Aripiprazole may be free from tachyphylaxis: preliminary findings. Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Tachyphylaxis; Treatment Outcome	2012
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis. Gender medicine, 2012, Volume: 9, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia	2012
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response. Physiology & behavior, 2012, May-15, Volume: 106, Issue:2 Topics: Acute-Phase Reaction; Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoxetine; Immune System; Male; Motor Activity; Piperazines; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Selective Serotonin Reuptake Inhibitors	2012
Tardive laryngeal dystonia associated with aripiprazole monotherapy. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Laryngeal Diseases; Movement Disorders; Piperazines; Quinolones; Schizophrenia; Young Adult	2012
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. International clinical psychopharmacology, 2012, Volume: 27, Issue:4 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Estradiol; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Olanzapine; Pilot Projects; Piperazines; Prolactin; Prospective Studies; Quinolones; Retreatment; Risperidone; Schizophrenia; Sex Hormone-Binding Globulin; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Sulpiride; Testosterone	2012
Hyperhidrosis under combination of zotepine and haloperidol alleviated by aripiprazole. Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Diabetes Complications; Dibenzothiepins; Dopamine; Drug Interactions; Female; Haloperidol; Humans; Hyperhidrosis; Middle Aged; Piperazines; Quinolones; Schizophrenia	2012
The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. Journal of psychiatric research, 2012, Volume: 46, Issue:6 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Statistics as Topic; Treatment Outcome; Young Adult	2012
Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. Acta psychiatrica Scandinavica, 2012, Volume: 126, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Dibenzothiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quetiapine Fumarate; Quinolones; Review Literature as Topic; Risperidone; Schizophrenia; Sulpiride	2012
Hyperprolactinaemia on depot risperidone treated with aripiprazole. The Australian and New Zealand journal of psychiatry, 2012, Volume: 46, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Monitoring; Drug Substitution; Female; Humans; Hyperprolactinemia; Medication Therapy Management; Pharmacovigilance; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome	2012
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients. Psychiatry research, 2012, Dec-30, Volume: 200, Issue:2-3 Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Auditory Cortex; Benzodiazepines; Dibenzothiazepines; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Reaction Time; Receptor, Adenosine A2A; Risperidone; Schizophrenia; Sensory Gating; Up-Regulation	2012
Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. BMC psychiatry, 2012, Aug-02, Volume: 12 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Databases, Factual; Dibenzothiazepines; Female; Humans; Male; Medication Adherence; Patient Discharge; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles	2012
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia; Weight Loss	2012
[Dysphagia or dysphagias during neuroleptic medication?]. L'Encephale, 2012, Volume: 38, Issue:4 Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Clonazepam; Deglutition Disorders; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Homicide; Humans; Ill-Housed Persons; Loxapine; Male; Mental Disorders; Piperazines; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology	2012
Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Diagnostic and Statistical Manual of Mental Disorders; DNA; Drug Interactions; Female; Genotype; Humans; Japan; Luminescence; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Postmenopause; Prolactin; Quinolones; Receptors, Dopamine D2; Regression Analysis; Schizophrenia; Sex Characteristics	2012
Daily dose of 105 mg aripiprazole because of delusional origin: a case report. Psychiatria Danubina, 2012, Volume: 24, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Drug Overdose; Female; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Self Medication	2012
Aripiprazole augmentation for clozapine-associated tardive torticollis. The Journal of neuropsychiatry and clinical neurosciences, 2012,Fall, Volume: 24, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia; Torticollis; Treatment Outcome	2012
Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:1 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Case-Control Studies; Cerebral Cortex; Drug Partial Agonism; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Positron-Emission Tomography; Pyridines; Quinolones; Radiopharmaceuticals; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult	2013
Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia. PloS one, 2013, Volume: 8, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brain; Cognition; Electroencephalography; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult	2013
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia. Current medical research and opinion, 2013, Volume: 29, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Tranquilizing Agents	2013
Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia. Preventive medicine, 2013, Volume: 57 Suppl Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Female; Flupenthixol; Humans; Malaysia; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quinolones; Schizophrenia; Trifluoperazine; Waist Circumference; Young Adult	2013
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. PloS one, 2013, Volume: 8, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; Evoked Potentials; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Young Adult	2013
Torsades de pointes after administration of low-dose aripiprazole. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Complications; Drug Monitoring; Heart Arrest; Humans; Hypertension; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Stroke; Torsades de Pointes; Treatment Outcome	2013
Aripiprazole (Abilify) for schizophrenia. The Medical letter on drugs and therapeutics, 2003, Feb-17, Volume: 45, Issue:1150 Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Dopamine Agonists; Drug Interactions; Fees, Pharmaceutical; Humans; Intestinal Absorption; Nausea; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Therapeutic Equivalency	2003
Aripiprazole. The newest antipsychotic agent for treatment of schizophrenia. Journal of psychosocial nursing and mental health services, 2003, Volume: 41, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia	2003
Aripiprazole: does partial dopaminergic agonism translate into clinical benefits? The Annals of pharmacotherapy, 2003, Volume: 37, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Schizophrenia	2003
Aripiprazole. Nature reviews. Drug discovery, 2003, Volume: 2, Issue:6 Topics: Animals; Aripiprazole; Clinical Trials as Topic; Humans; Patents as Topic; Piperazines; Quinolones; Schizophrenia	2003
Aripiprazole and extrapyramidal symptoms. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, Volume: 42, Issue:11 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Piperazines; Quinolones; Schizophrenia	2003
Similarities and differences among antipsychotics. The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 17 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles	2003
Aripiprazole. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Dec-01, Volume: 60, Issue:23 Topics: Antipsychotic Agents; Aripiprazole; Biological Availability; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; United States	2003
Medication developments in the treatment of mental illness. Behavioral healthcare tomorrow, 2003, Volume: 12, Issue:6 Topics: Adolescent; Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Blood Glucose; Child; Depressive Disorder; Humans; Mental Disorders; Piperazines; Primary Health Care; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors	2003
Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? The Journal of clinical psychiatry, 2004, Volume: 65, Issue:1 Topics: Anger; Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia	2004
Aripirazole-olanzapine combination for treatment of schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2004, Volume: 49, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2004
European College of Neuropsychopharmacology - 16th Congress. 20-24 September 2003, Prague, Czech Republic. IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:11 Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Anxiety; Aripiprazole; Dopamine Antagonists; Humans; Nicotinic Agonists; Piperazines; Psychotropic Drugs; Quinolones; Receptors, Metabotropic Glutamate; Receptors, Nicotinic; Schizophrenia	2003
[Expectations and developments in atypical antipsychotics]. Praxis, 2004, Aug-25, Volume: 93, Issue:35 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complications; Haloperidol; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Risk Factors; Schizophrenia; Weight Gain	2004
Aripiprazole: novelty, adherence and understatement. The international journal of neuropsychopharmacology, 2005, Volume: 8, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Haloperidol; Humans; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Therapeutic Equivalency	2005
Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS spectrums, 2004, Volume: 9, Issue:10 Suppl 1 Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cognition; Dibenzothiazepines; Dose-Response Relationship, Drug; Histamine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Muscarinic; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles	2004
Aripiprazole and neuroleptic malignant syndrome. International clinical psychopharmacology, 2004, Volume: 19, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Lorazepam; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia	2004
[Expectation and development of atypical antipsychotic drugs]. Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology	2004
Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment. Medical hypotheses, 2004, Volume: 63, Issue:6 Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Down-Regulation; Humans; Models, Neurological; Piperazines; Quinolones; Receptors, Dopamine; Schizophrenia; Treatment Outcome	2004
Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS spectrums, 2004, Volume: 9, Issue:11 Topics: Aged; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia	2004
Pharmacokinetics of aripiprazole and concomitant lithium and valproate. Journal of clinical pharmacology, 2005, Volume: 45, Issue:1 Topics: Adult; Aripiprazole; Drug Therapy, Combination; Humans; Lithium; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Valproic Acid	2005
Partial agonists in schizophrenia. The British journal of psychiatry : the journal of mental science, 2005, Volume: 186 Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Up-Regulation	2005
Aripiprazole in schizophrenia: consensus guidelines. International journal of clinical practice, 2005, Volume: 59, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Consensus; Drug Interactions; Heart Diseases; Humans; Hypertension; Mental Disorders; Metabolic Diseases; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2005
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain research, 2005, May-10, Volume: 1043, Issue:1-2 Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles	2005
[Combining effectiveness and tolerance]. Krankenpflege Journal, 2005, Volume: 43, Issue:1-3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Female; Humans; Long-Term Care; Patient Compliance; Physician-Patient Relations; Piperazines; Prognosis; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome	2005
An African patient with ziprasidone intolerance. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:6 Topics: Africa; Antipsychotic Agents; Aripiprazole; Dystonia; Ethnicity; Germany; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome	2005
[Aripiprazole in the treatment of schizophrenia]. Praxis, 2005, Jun-08, Volume: 94, Issue:23 Topics: Antipsychotic Agents; Aripiprazole; Brain; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2005
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. Journal of psychiatric practice, 2005, Volume: 11, Issue:4 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome	2005
Reversal of symptomatic hyperprolactinemia by aripiprazole. The American journal of psychiatry, 2005, Volume: 162, Issue:8 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Injections, Intramuscular; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome	2005
['Awakening': a confusing improvement during treatment with atypical antipsychotic agents]. Nederlands tijdschrift voor geneeskunde, 2005, Jul-30, Volume: 149, Issue:31 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Humans; Piperazines; Quality of Life; Quinolones; Risperidone; Schizophrenia; Treatment Outcome	2005
Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clinical chemistry, 2005, Volume: 51, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Piperazines; Quinolones; Schizophrenia; Spectrophotometry, Ultraviolet	2005
Diabetic ketoacidosis associated with aripiprazole. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:10 Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Female; Humans; Infusions, Intravenous; Insulin; Insulin, Isophane; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2005
Second generation antipsychotics--aripiprazole revisited. The Medical letter on drugs and therapeutics, 2005, Oct-10, Volume: 47, Issue:1219 Topics: Antipsychotic Agents; Aripiprazole; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain	2005
The patient with schizophrenia taking aripiprazole: case report. Psychiatria Danubina, 2005, Volume: 17, Issue:3-4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Approval; Humans; Male; Outcome Assessment, Health Care; Patient Participation; Piperazines; Quality of Life; Quinolones; Schizophrenia	2005
A case of Aripiprazole and extra pyramidal side effects. Journal of psychopharmacology (Oxford, England), 2006, Volume: 20, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia	2006
Aripiprazole as a dopamine partial agonist: positive and negative effects. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Female; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists	2006
Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin Agents; Treatment Outcome	2007
[No rebound psychosis in a case of switching from clozapine to quetiapine]. Psychiatrische Praxis, 2006, Volume: 33, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brief Psychiatric Rating Scale; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Schizophrenia; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome	2006
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry, 2006, Volume: 39 Suppl 1 Topics: Antipsychotic Agents; Aripiprazole; Cerebral Cortex; Corpus Striatum; Dopamine Agonists; Humans; Limbic System; Mesencephalon; Neural Pathways; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2006
Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report. Pharmacopsychiatry, 2006, Volume: 39, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Loss	2006
Three cases of risperidone-induced enuresis. Schizophrenia research, 2006, Volume: 84, Issue:1 Topics: Aripiprazole; Enuresis; Female; Humans; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia	2006
Clozapine augmentation with aripiprazole for negative symptoms. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Treatment Outcome	2006
High-dose aripiprazole in treatment-resistant schizophrenia. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2006
Aripiprazole and the neuroleptic malignant syndrome. Schizophrenia research, 2006, Volume: 85, Issue:1-3 Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia	2006
Elevated lipase and diabetic ketoacidosis associated with aripiprazole. JOP : Journal of the pancreas, 2006, May-09, Volume: 7, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Humans; Lipase; Male; Piperazines; Quinolones; Schizophrenia; Weight Gain	2006
[Pharmacology of antipsychotic drugs]]. L'Encephale, 2006, Volume: 32 Pt 2 Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Norepinephrine; Piperazines; Quinolones; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology	2006
Aripiprazole-associated seizure. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Schizophrenia; Seizures	2006
A case of dose-dependent aripiprazole-induced conduction disturbance. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bundle-Branch Block; Dose-Response Relationship, Drug; Female; Humans; Piperazines; Quinolones; Schizophrenia	2006
Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2006
Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series. Journal of psychopharmacology (Oxford, England), 2006, Volume: 20, Issue:6 Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Female; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid	2006
A model of anticholinergic activity of atypical antipsychotic medications. Schizophrenia research, 2006, Volume: 88, Issue:1-3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles	2006
A case series: evaluation of the metabolic safety of aripiprazole. Schizophrenia bulletin, 2007, Volume: 33, Issue:3 Topics: Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sex Factors; Treatment Outcome	2007
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sulpiride; Treatment Failure	2007
Aripiprazole in chronic schizophrenia: experiences in daily practice. Acta psychiatrica Scandinavica, 2006, Volume: 114, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors	2006
Atypical neuroleptic malignant syndrome associated with aripiprazole. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:5 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia	2006
Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes care, 2006, Volume: 29, Issue:10 Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Mellitus; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia	2006
Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? Journal of psychopharmacology (Oxford, England), 2007, Volume: 21, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Weight; Cholesterol; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Schizophrenic Psychology	2007
Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia research, 2007, Volume: 89, Issue:1-3 Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides	2007
[Endocrine side effects among psychiatric patients treated with antipsychotics]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2006, Volume: 8, Issue:2 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Breast; Dibenzothiazepines; Endocrine System; Female; Galactorrhea; Gynecomastia; Humans; Male; Olanzapine; Piperazines; Prolactin; Quetiapine Fumarate; Quinolones; Schizophrenia; Sulpiride	2006
In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. Journal of psychopharmacology (Oxford, England), 2007, Volume: 21, Issue:6 Topics: Animals; Antipsychotic Agents; Aripiprazole; Calcium Signaling; CHO Cells; Cloning, Molecular; Cricetinae; Cricetulus; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Immunoblotting; Lisuride; MAP Kinase Signaling System; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Phosphorylation; Piperazines; Piperidines; Quinolones; Raclopride; Receptors, Dopamine D2; Schizophrenia; Time Factors; Transfection	2007
Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:6 Topics: Aged; Antipsychotic Agents; Aripiprazole; Citalopram; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Urinary Retention	2006
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:12 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Humans; Male; Metabolic Diseases; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain	2006
Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clinical drug investigation, 2006, Volume: 26, Issue:3 Topics: Adult; Aripiprazole; Clozapine; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia	2006
Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clinical drug investigation, 2007, Volume: 27, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Italy; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2007
Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Hospitalization; Humans; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Retrospective Studies; Schizophrenia; Treatment Outcome	2006
Diagnostic and therapeutic challenges in narcolepsy-related psychosis. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:11 Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Female; Hallucinations; Humans; Narcolepsy; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia	2006
Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient. The American journal of psychiatry, 2007, Volume: 164, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Humans; Middle Aged; Mutation; Piperazines; Quinolones; Schizophrenia	2007
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology, 2007, Volume: 191, Issue:2 Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Male; Mice; Neural Inhibition; Olanzapine; Phencyclidine; Piperazines; Quinolones; Receptors, Dopamine D2; Reflex, Startle; Schizophrenia	2007
Aripiprazole-associated acute dystonia. The Journal of neuropsychiatry and clinical neurosciences, 2007,Winter, Volume: 19, Issue:1 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Drug Interactions; Dystonia; Female; Humans; Piperazines; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline	2007
Indexing of reports on aripiprazole augmentation of clozapine. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:2 Topics: Abstracting and Indexing; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Information Services; Information Storage and Retrieval; Piperazines; Quinolones; Schizophrenia	2007
Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Middle Aged; Outpatients; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Weight Loss	2007
Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. Journal of psychiatric practice, 2007, Volume: 13, Issue:2 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Clonazepam; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Patient Care Team; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Quinolones; Schizophrenia	2007
Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient. Pharmacopsychiatry, 2007, Volume: 40, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Male; Parkinsonian Disorders; Piperazines; Quinolones; Schizophrenia	2007
Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome? International clinical psychopharmacology, 2007, Volume: 22, Issue:4 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Lamotrigine; Piperazines; Quinolones; Schizophrenia; Stevens-Johnson Syndrome; Triazines	2007
Intramuscular aripiprazole in the control of agitation. Journal of psychiatric practice, 2007, Volume: 13, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Arousal; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2007
Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Current medical research and opinion, 2007, Volume: 23, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; United Kingdom	2007
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophrenia research, 2008, Volume: 98, Issue:1-3 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Readmission; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Risperidone; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Sensitivity and Specificity; Substance Withdrawal Syndrome; Survival Rate; Thiazoles	2008
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:4 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain	2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:4 Topics: Acute Disease; Acute Kidney Injury; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cocaine-Related Disorders; Diabetic Ketoacidosis; Humans; Male; Olanzapine; Pancreatitis; Piperazines; Quinolones; Schizophrenia	2007
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. European journal of pharmacology, 2007, Nov-28, Volume: 574, Issue:2-3 Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Schizophrenia	2007
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism? The American journal of psychiatry, 2007, Volume: 164, Issue:9 Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission	2007
Combined use of ECT with aripiprazole. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Electroconvulsive Therapy; Hospitalization; Humans; Male; Piperazines; Quinolones; Schizophrenia	2009
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2008, Volume: 9, Issue:3 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia	2008
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Diseases; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain	2007
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Remission Induction; Schizophrenia; Substance-Related Disorders	2007
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:10 Topics: Acute Disease; Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol, HDL; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Metabolic Syndrome; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia	2007
A prospective 6-month analysis of the naturalistic use of aripiprazole - factors predicting favourable outcome. Acta psychiatrica Scandinavica, 2007, Volume: 116, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Schizophrenia; Time Factors	2007
Effectiveness of aripiprazole in treating obsessive compulsive symptoms. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2008
Aripiprazole and perphenazine: no difference. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11 Topics: Antipsychotic Agents; Aripiprazole; Humans; Marketing; Perphenazine; Piperazines; Quality of Life; Quinolones; Schizophrenia; Surveys and Questionnaires	2007
A case of aripiprazole-related tardive akathisia and its treatment with ropinirole. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Female; Humans; Indoles; Middle Aged; Piperazines; Quinolones; Schizophrenia	2007
Tardive dystonic symptoms associated with aripiprazole treatment. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Dyskinesia, Drug-Induced; Dystonia; Humans; Intellectual Disability; Male; Ocular Motility Disorders; Piperazines; Quinolones; Schizophrenia	2008
Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole. The Journal of neuropsychiatry and clinical neurosciences, 2007,Fall, Volume: 19, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Humans; Male; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology	2007
Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Apr-01, Volume: 32, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Male; Piperazines; Quinolones; Schizophrenia; Sulpiride	2008
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:12 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Incidence; Male; Middle Aged; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Severity of Illness Index	2007
Aripiprazole treatment for risperidone-associated tic movement: a case report. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Apr-01, Volume: 32, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Risperidone; Schizophrenia; Tic Disorders	2008
Aripiprazole-induced rabbit syndrome in a drug-naive schizophrenic patient. Schizophrenia research, 2008, Volume: 103, Issue:1-3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Movement Disorders; Piperazines; Quinolones; Schizophrenia	2008
Aripiprazole diminishes cannabis use in schizophrenia. The Journal of neuropsychiatry and clinical neurosciences, 2008,Winter, Volume: 20, Issue:1 Topics: Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; Piperazines; Quinolones; Schizophrenia	2008
Partial agonists and suicide: the role of the mental health nurse. Journal of psychiatric and mental health nursing, 2008, Volume: 15, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Nurse's Role; Piperazines; Quinolones; Schizophrenia; Suicide Prevention	2008
Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient. Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guidelines as Topic; Humans; Male; Piperazines; Quinolones; Risk Assessment; Risperidone; Schizophrenia	2009
Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2008
Use of Aripiprazole in treatment resistant schizophrenia. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia	2008
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects. The American journal of psychiatry, 2008, Volume: 165, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Polypharmacy; Quinolones; Schizophrenia	2008
Aripiprazole's receptor pharmacology and extrapyramidal side effects. The American journal of psychiatry, 2008, Volume: 165, Issue:3 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Piperidines; Positron-Emission Tomography; Psychomotor Agitation; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Urea	2008
The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients. Basic & clinical pharmacology & toxicology, 2008, Volume: 103, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Prescriptions; Drug Therapy, Combination; Female; Hospital Bed Capacity, 300 to 499; Hospitals, Psychiatric; Hospitals, University; Humans; Inpatients; Male; Middle Aged; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quinolones; Retrospective Studies; Schizophrenia	2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:3 Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors	2008
Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:2 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Electrocardiography; Female; Haloperidol; Heart Conduction System; Humans; Long QT Syndrome; Piperazines; Quinolones; Schizophrenia	2008
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. The American journal of psychiatry, 2008, Volume: 165, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzamides; Binding Sites; Brain; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrrolidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia	2008
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:13 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzamides; Binding, Competitive; Brain; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Piperazines; Pituitary Gland; Positron-Emission Tomography; Pyrrolidines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult	2008
Severe hyperglycemic hyperosmolar nonketotic coma in a nondiabetic patient receiving aripiprazole. Annals of emergency medicine, 2009, Volume: 53, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemic Hyperosmolar Nonketotic Coma; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia	2009
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Comorbidity; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome	2008
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benztropine; Corpus Striatum; Dose-Response Relationship, Drug; Humans; Male; Piperazines; Prolactin; Quinolones; Receptors, Dopamine D2; Schizophrenia	2008
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:12 Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome	2001
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 27, Issue:2 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Brain; Cerebellum; Corpus Striatum; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Neurons; Piperazines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Tomography, Emission-Computed	2002